Untitled - Kenes Group

Transcription

1
新旧交汇
第十九届国际帕金森病及相关疾病学术会议
中国上海
2011.12.11~2011.12.14
最终方案
VENUE LAYOUT
7th floor
5th floor
3rd floor
1st floor
IV
SHANGHAI, CHINA, DECEMBER 11-14, 2011
FINAL PROGRAM
CONTENTS
Welcome Letters
VI
About APRD
VIII
Previous Congresses
IX
Committees
X
Acknowledgements
XI
General Information
XII
XVI
Additional Congress Activities
XVIII
Travel Awards
XX
Senator Burda Award
XXI
History of PD Exhibition
XXII
Instructions for Presenters
XXIV
Poster Presentations
XXV
Exhibition Information
XXVI
Company Profiles
Post-Congress Activities
XXXII
Scientific Program Overview
XXXIII
Information in Chinese
XXXV
SCIENTIFIC PROGRAM
1
Sunday, December 11
Monday, December 12
3
Tuesday, December 13
17
Wednesday, December 14
31
POSTER PRESENTATIONS:
Monday, December 12
43
67
93
119
Author Index
V
Dear Colleagues,
On behalf of the Association of Parkinsonism and Related Disorders, it is our
pleasure to welcome you to the XIX World Congress on Parkinson’s Disease and
Related Disorders taking place in Shanghai, China.
Under the motto “Old Meets New”, Congress highlights provide the latest
scientific developments in basic and clinical ‘western’ research as well as the
newest ideas in traditional, non-pharmacological ‘eastern’ clinical interventions,
comprising an overwhelming impression of the ultramodern lifestyle in a
metropolis with cherished traditional Chinese culture.
The Congress will deal in a most translational way with most recent research and
update on the etiology, pathogenesis, potential diagnostic markers and treatment
modalities of Parkinson’s Disease and related disorders, bringing together a large
faculty of distinguished scientists, clinicians and allied health experts with a wide
range of expertise in this field.
The Scientific Program is composed of Plenary Lectures, Parallel Sessions,
Interactive Forum Discussions, Video Supported Sessions, Educational Symposia,
Satellite Symposia, Chinese Parallel Sessions, Oral Platform Presentations and
Poster Presentations.
Shanghai, the largest and most dynamic city in China with an extremely
vibrant and cosmopolitan atmosphere, especially in Christmas time, combines
breathtaking modern architecture on one side of the immense Yangtze river, and
the richness of early nineteenth century’s architecture on the other side.
We hope that you will take enough time to enjoy the attractions of this metropolis
as part of your Congress experience, as well as the rest of China, with its rich
history.
Erik Ch. Wolters
Chairman
Association of Parkinsonism and Related Disorders
VI
FINAL PROGRAM
Dear Colleagues,
I am delighted to welcome you to the XIX World Congress on Parkinson ’s disease
and Related Disorders taking place in Shanghai 11-14 December, 2011.
Situated on the estuary of Yangtze River, Shanghai, Hu for short - China’s largest
and most dynamic city home to over 20 million inhabitants - is a renowned
international exciting metropolis, which serves as the most influential economic,
financial, international trade, cultural, science and technology center in East China.
Today, it is a thrilling cosmopolitan center of culture and design, with a vibrant
atmosphere where a perfect blend of cultures, the modern and the traditional,
the western and the oriental is found, where Western customs and Chinese
traditions intertwined, and old and new landmarks such as the Bund and City
God Temple, the modern Pudong skyline and the Oriental Pearl Tower join
together.
Shanghai’s exciting nightlife is among the best in Asia, with a great variety of
nightspots. The wide range of restaurants available in Shanghai will ensure that
the most discerning palates are catered to, and it provides a varied selection of
accommodation to suit all budgets. The new Pudong International Airport offers
optimal connections within China, Asia and to the rest of the world.
We hope you take the time to explore the city as a part of your Congress
experience, making your stay truly memorable.
Shengdi Chen
Congress Chairman
VII
ASSOCIATION OF PARKINSONISM AND
RELATED DISORDERS
Established over fifty years ago the Association of Parkinsonism and Related
Disorders (APRD) is an international, professional association of clinicians,
scientists and other healthcare professionals who are interested in neurodegenerative
disorders including Parkinson’s disease, secondary parkinsonisms, hyperkinetic and
hypokinetic movement disorders, and other disorders affecting muscle tone and
motor coordination.
The Association Parkinsonism and Related Disorders is a fully independent, charitable
institution under Dutch law aiming to conduct research into and advance knowledge
of Parkinson’s disease and other movement disorders, as well as to advise the World
Federation of Neurology in matters related to Parkinson’s disease and other movement
disorders. The Association’s registered seat is in the Municipality of Amsterdam, the
Netherlands, and is registered in the Trade Register of the Amsterdam Chamber of
Commerce and Industries.
Meetings
In addition to the biennial World Congress on Parkinson’s Disease and Related
Disorders to evaluate progress and identify promising areas for research in these
fields.The APRD regularly organizes meetings and educational activities. At various
intervals, workshops on current issues in Parkinson’s Disease, designed to produce
consensus reports, are also organized.
The Committee is especially committed to developing educational programs for
physicians in not fully westernized countries.
VIII
FINAL PROGRAM
Publications
In order to fulfil its mission statements, APRD not only develops educational activities
such as symposia and congresses, but also promotes different publications, among
them its official journal, Parkinsonism & Related Disorders, and various textbooks.
To optimally channel communication between basic research and clinical
communities, and in order to promote optimal diagnosis and treatment for the various
movement disorders, Parkinsonism & Related Disorders is supplied free of charge to
all APRD members, and listed books can be ordered by members at reduced prices
via the Amsterdam - Free University Press.
To learn more about APRD, please visit the association website: www.prdassociation.org
Previous Congresses
1959
Montreal, Canada (I Congress)
1963
Washington D.C., USA (II Congress)
1968
Edinburgh, Scotland (III Congress)
1972
Zurich, Switzerland (IV Congress)
1975
Vienna, Austria (V Congress)
1978
Quebec, QC, Canada (VI Congress)
1982
Frankfurt, Germany (VII Congress)
1985
New York, NY, USA (VIII Congress)
1988
Jerusalem, Israel (IX Congress)
1991
Tokyo, Japan (X Congress)
1994
Rome, Italy (XI Congress)
1997
London, UK (XII Congress)
1999
Vancouver, Canada (XIII Congress)
2001
Helsinki, Finland (XIV Congress)
2003
Beijing, China (XV Congress)
2005
Berlin, Germany (XVI Congress)
2007
Amsterdam, The Netherlands (XVII Congress)
2009
Miami, FL, USA (XVIII Congress)
IX
COMMITTEES
Executive Scientific Board
Local Consultant Committee
Erik Ch. Wolters, The Netherlands - Chair
Shengdi Chen, China
Ariel Y. Deutch, USA
Robert A. Hauser, USA
Peter Riederer, Germany
Moussa Youdim, Israel
Yu-Ping Jiang, Shanghai
Xiu-Ling Liang, Guangzhou
Dao-Kuan Liu, Shanghai
Zhuo-Lin Liu, Guangzhou
Yi Luo, Beijing
Xiang-Ru Sun, Beijing
Ming-Xun Tan, Beijing
Xiao-Fu Tang, Beijing
Ren-min Yang, Hefei
Zhen-Xin Zhang, Beijing
Abstract Committee
Erik Ch. Wolters, The Netherlands - Chair
Peter Riederer, Germany
Moussa Youdim, Israel
Local Scientific Committee
Shengdi Chen, Shanghai –Chair
Piu Chan, Beijing – Co-Chair
Hai-Bo Chen, Beijing
Yan Chen, Tianjin
Xiao-Chun Chen, Fuzhou
Li-Ying Cui, Beijing
Shu-Leong Ho, Hong Kong
Jian-Ping Jia, Beijing
Wei-Dong Le, Shanghai
Chun-Feng Liu, Suzhou
Yi-Ming Liu, Jinan
Chuan-Zhen Lv, Shanghai
Guo-Guang Peng, Chongqing
Hui-Fang Shang, Chengdou
Ming Shao, Guangzhou
Sheng-Gang Sun, Wuhan
Bei-Sha Tang, Changsha
Li-Juan Wang, Guangzhou
Ming-Wei Wang, Shijiazhuang
Xin-Hua Wan, Beijing
Han-Cheng Wang, Taibei
Xiao-Min Wang, Beijing
Zhen-Fu Wang, Beijing
Ruey-Mee Wu, Taibei
Ping-Yi Xu, Guangzhou
Bao-Rong Zhang, Hangzhou
Jia-Wei Zhou, Shanghai
Proceedings Committee
Zbigniew Wszolek, USA - Chair
Vincenzo Bonifati, The Netherlands
Susan Calne, Canada
Jonathan Carr, South Africa
Shengdi Chen, China Ronald F. Pfeiffer, USA
Robert Rodnitzky, USA
Eng Kin Tan, Singapore
Erik Ch. Wolters, The Netherlands
Local Organizing Committee
Shengdi Chen, Shanghai - Chair
Piu Chan, Beijing
Wei-Dong Le, Shanghai
Zhen-Guo Liu, Shanghai
Jian-Rong Liu, Shanghai
Sheng-Gang Sun, Wuhan
Jian Wang, Shanghai
Qin Xiao, Shanghai
X
FINAL PROGRAM
ACKNOWLEDGEMENTS
The XIX World Congress on Parkinson’s Disease and Related Disorders would
like to acknowledge the support of the following companies:
PLATINUM SPONSOR
GOLD SPONSORS
SILVER SPONSORS
SPONSORS
XI
GENERAL INFORMATION
Congress Venue
Shanghai International Convention Center
Oriental Riverside Hotel, 2727 Riverside Avenue
Pudong, Shanghai, 200120, China
Tel: + 86 21 50370000
www.shicc.net
Language
The official language of the Congress is English.
Parallel Chinese Sessions will be held in Chinese
Sessions marked 翻译 in the Final Program will be simultaneously translated
to Chinese.
Registration / Secretariat Desks
Registration Desks are situated on the first floor (ground floor) of the Shanghai
International Convention Center and will be open as follows:
Sunday, December 11
Monday, December 12
14:00-21:15
07:30-19:15
08:00-19:15
08:00-18:00
Badge
Upon registration you will receive your name badge. You are kindly requested
to wear your badge during all Congress sessions and events.
Exhibition Hours
The Exhibition will be open as follows:
Monday, December 12
09:30-16:30
09:30-16:30
09:30-16:00
XII
FINAL PROGRAM
WIFI
WIFI will be available in the exhibition area for the duration of the Congress.
Abstracts & Proceedings
Full Proceedings of the Plenary and Parallel Sessions are published in a supplement
of the journal Parkinsonism & Related Disorders, published by Elsevier. All accepted
abstracts are published both as an online supplement of the Parkinsonism and
Related Disorders Journal and in a CD-ROM.
Please approach the Elsevier booth located in the Exhibition Area to collect your
CD-Rom of abstracts and Journal supplement of full proceedings.
Parkinsonism and Related Disorders Journal
All registered Congress participants are entitled to be registered as non-voting,
associate members to the Association of Parkinsonism and Related Disorders. One
of the benefits of becoming a member is enjoying a 2-year long print and online
subscription to the journal Parkinsonism & Related Disorders.
Please make sure you have submitted your full individual address details and email
address to the Congress Secretariat at the time of registration.
Messages / Lost and Found
A notice board will be available in the registration area for messages and
notifications. For all other issues please approach the registration desk.
Congress Survey
We value your opinion!
Fill out a Participant Questionnaire
and stand to win a free registration for the
XX World Congress on Parkinson’s Disease and Related Disorders
in Geneva, 2013
XIII
Certificate of Attendance
Certificates of attendance will be available at the pre-paid registration stations
from Tuesday, December 13th at 14:30 until the end of sessions on Wednesday,
December 14th. Participants are requested to scan their barcode at the machine and
the certificate will automatically be printed with the participant’s name.
CME Accreditation
The XIX World Congress on Parkinson’s Disease and Related Disorders is accredited
by the European Accreditation Council for Continuing Medical Education (EACCME)
to provide the following CME activity for medical specialists.
The XIX World Conress on Parkinson’s Disease and Related Disorders is designated
for a maximum of 18 hours of European external CME credits.
Each medical specialist should claim only those hours of credit that he/she actually
spent in the educational activity.
The EACCME is an institution of the European Union of Medical Specialists (UEMS),
www.uems.net.
EACCME credits are recognized by the American Medical Association towards
the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA
category 1 credit, contact the AMA.
CME Attendance Tracking Report
Self scanning devices are placed in the registration area. You may approach the
scanners and self-scan your badge in order to record your attendance. Only
participants who have had recorded their attendance via the self-scanners will
receive a report tracking the timeframe of their daily attendance at the Congress
from the Secretariat after the Congress.
Smoking Policy
Smoking is prohibited at all times in halls, exhibition area and restrooms.Smoking
areas are available. Your compliance is appreciated.
Clothing
During the entire meeting, attire will be casual and informal.
XIV
FINAL PROGRAM
Mobile Phones
Mobile phones must be switched off or muted during all sessions.
Paperless Scientific Program Application
The WCPD 2011 Scientific Program is available on Smartphone and mobile
devices. Participants who access the mobile web site will have full access to
the scientific program, posters and abstracts. Choose, plan and maximize your
time at the congress.
Access the application via your browser: http://wcpd.kenesapp.com or scan
the barcode.
CME AccInsurance
The Congress Secretariat and Organizers cannot accept liability for personal accidents
or loss of or damage to private property of participants and accompanying persons.
Participants are advised to take out their own personal travel and health insurance
for their trip.
Caring for the Environment
It is our belief that by employing a Green Culture in the workplace we can duplicate
this culture, and the responsibilities it entails. Organizing green congresses all
over the world is a real challenge, as green is not only the onsite conduct but the
suppliers we are using, the source of the raw materials, the methods of production,
management of waste, shipping vs. using local products and fair management of
labor throughout the supply chain.
Congress Secretariat
1-3 Rue de Chantepoulet
P.O.Box 1726,CH-1211 Geneva 1, Switzerland
Tel: +41 22 908 0488,Fax: +41 22 906 9140
[email protected] , www.kenes.com/parkinson XV
ADDITIONAL CONGRESS
ACTIVITIES
SUNDAY, DECEMBER 11
OPENING CEREMONY
18:30
Hall A
Shanghai International Convention Center
(Congress Venue)
Followed by a
WELCOME RECEPTION
20:30
Hall A Foyer
(Congress Venue)
Supported by
MONDAY, DECEMBER 12
APRD FULL-MEMBERS ANNUAL GENERAL
BREAKFAST MEETING
07:00-08:30
Hall E
Congress Venue
APRD FULL-MEMBER’S DINNER
20:00-22:00
Peace Hotel
By Invitation Only
Buses will be leaving for the Dinner at 19:30 from the Oriental Riverside Hotel
XVI
FINAL PROGRAM
TUESDAY, DECEMBER 13
CONGRESS DINNER
20:30
The Lubolang Restaurant All Congress participants are welcome to join us for a traditional Chinese dinner
which will include Chinese Opera entertainment.
Tickets for the Dinner at $65 are available at the registration desk.
Buses will be leaving for the Dinner at 19:45 from the Oriental Riverside Hotel
WEDNESDAY, DECEMBER 14
CLOSING CEREMONY
17:30-18:00
Hall F
XVII
TRAVEL AWARDS
Congress Travel Awards are sponsored by the Melvin Yahr International
Parkinson’s Disease Foundation (Chaired by Dr. Alessandro Di Rocco) and the
Congress. The awards are aimed to promote participation at the Congress by
young researchers under the age of 35.
Congratulations to all awardees.
Khairul Anuar Abdul Manaf, Malaysia
Ziad Adwan, Syria
Souhad Al Faqih, Syria
Rahim Aliyev, Azerbaijan
Anam Anzak,UK
Ulugbek Askhonov, Uzbekistan
Roberta Biundo, Italy
Wannipat Buated, Thailand
Shuwen Cao, USA
Benoit Carignan, Canada
Papya Chatterjee, India
Wei Chen, China
Fu Bo Cheng, China
Alin Stelian Ciobica, Romania
Anna Czarnecka, Poland
Jean-Francois Daneault, Canada
K.M. Denny Joseph, India
Anke Dijkstra, The Netherlands
Mohammad Amin Edalatmanesh, Iran
Lou Fan, China
Salvatore Galati, Switzerland
Hardeep Gambhir, India
Han-ming Ge, China
Hugo Gonzalez, Chile
Rashmi Gupta, India
Zhen Hong, China
Arati Inamdar, USA
Elena Ivanova, Russia
Ji-Wan Jang, South Korea
Meenakshi Jayaraman, India
Luis Clemente Jimenez-Botello, Mexico
Juho Joutsa, Finland
Harikesh Kalonia, India
Zinovia-Maria Kefalopoulou, UK
Samson Khachatryan, Armenia
Hee Jin Kim, South Korea
Viktor Kokhan, Russia
Evgeniya Kozlova, Israel
Katarina Kracunova, Slovak Republic
Wei-Li Kuan, UK
Trase Kwok, China
Pardeep Kumar, India
Hou Le, China
Sheera Lerman, Israel
Huanmin Li, China
Hui Li, China
Hui Liang, China
Huifang Liu, Hong Kong S.A.R.
Jia Liu, Germany
Lin Liu, China
Ilya Logvinov, Russia
Yong Luo, China
Mihai-Dragos Maliia, Romania
Tafheem Malik, Pakistan
Torun Malmlöf, Sweden
Jana Martinková, Slovak Republic
Jarosław Marusiak, Poland
Jitendriya Mishra, India
Inder Singh Mudila, India
Ellen Murphy, UK
XVIII
Mohammad Naushahi, UK
Francisco Navarrete, Spain
Alexey Nepoklonov, Russia
Branimir Nevajda, Croatia
Martin Nevrly, Czech Republic
Jeremy Newman, Australia
Anwar Norazit, Malaysia
Kim Olde Dubbelink, The Netherlands
Manuela Padurariu, Romania
Artemi Papanastasiou, Greece
Gabriela Pavlic, Moldova
Santiago Perez-Lloret, France
Sitthi Petchrutchatachart, Thailand
Ilse Pienaar, UK
Dominik Pöltl, Germany
Korah Pushpamangalam Kuruvilla, India
Gail Melissa Ramiro, Philippines
Tania Ramo-Moreno, Spain
Judith Rath, The Netherlands
Prashanth Reddy, UK
Dong Dong Ren, China
Amy Ross Russell, UK
Richard Salazar Montero, USA
Neha Sharma, India
Nicola Simola, Italy
FINAL PROGRAM
Zaruhi Tavadyan, Armenia
Li-Peng Tian, China
Giorgia Tropini, Canada
Tatiana Usenko, Russia
Karin van Dijk, The Netherlands
Rohit Verma, India
Xiong Wang, China
Zhiquan Wang, China
Kristian Weegink, Australia
Lezanne Wynand, South Africa
Li Xie, Singapore
Rajesh Yadav, India
Xiaolan Yao, Belgium
Sooyeoun You, South Korea
Calvin Young, Norway
William Young, UK
Rong Zhang, China
Zhentao Zhang, China
Shi Zhang, China
Yu Zhang, China
Xiyao Zhao, China
Yan Zhi-Qiang, China
Lina Zhou, China
Yishu Zhou, China
XIX
SENATOR DR. FRANZ BURDA AWARD
12:00 – 12:30
Established in 1985, the Senator Burda Award is presented for outstanding
clinical and basic research in Parkinson’s Disease.
The Senator Burda Award for 2011 will be given to:
Prof. Dr. Erik Ch. Wolters, Amsterdam, The Netherlands, for his excellent
clinical research
&
Prof. Dr. Toshikazu Nagatsu, Aichi, Japan for his excellent basic research
achievements in Parkinson’s Disease
You are cordially invited to join the Senator Burda Award Ceremony and
Reception, held on Wednesday, December 14 at 12:00
Prof. Dr. Peter Riederer
Prof. Dr. Thomas Brücke
XX
FINAL PROGRAM
The History of Parkinson’s Disease Major Achievements in Research and
Therapy Exhibition
Following the successful exhibitions at the XVI World Congress in Berlin, 2005,
and the XVII World Congress in Amsterdam, 2007, we are delighted to re-launch
the medical exhibition on the History of Parkinson’s Disease.
The exhibition, located in the exhibition area and opened daily, presents a unique
collection of medical historical documents, highlighting decisive advances in
19th century research and honouring major therapeutical contributions in the
20th century in the field of Parkinson’s Disease.
Starting with the landmark essay of James Parkinson, medical milestones are
identified and wherever possible linked to the researchers and developers behind
these advances, featuring contributions from France, Germany and Austria,
alongside with the history of pharmaceutical substances and their significance
in today’s knowledge and treatment of Parkinson’s disease.
XXI
INFORMATION FOR PRESENTERS
All speakers, including the Oral Abstract Platform Presentation speakers, are requested
to submit their presentations to the Speakers’ Ready Room at least 1 hour before the
start of their session.
The Speakers’ Ready Room will be clearly sign posted at the Congress venue.
POWERPOINT PRESENTATIONS
If using a PowerPoint (or any other computer) presentation, please note that you need
to bring your presentation on a CD, a DVD or on a “disk on key” Memory stick (using
the USB port in the computer) and load it on one of the congress’ computers in the
Speakers’ Ready Room, at least 1 hour before the start of the session. You may supply
your own laptop computer as a back-up.
In case you combine video films with PowerPoint, please make sure to check these
films in the session hall where your lecture is taking place, during a coffee or lunch
break prior to your session, at least 30 minutes before the start of the session - even
after checking them in the Speakers’ Ready Room.
Please note that the congress’ computers in the session halls are being supplied with
Windows XP and Office 2007.
MACINTOSH PRESENTATIONS
In order to use MAC presentations on a PC compatible computer please note that
you need to prepare it according to the instructions below, before bringing it to the
Speakers’ Ready Room:
1.Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might be changed to a default font on a PowerPoint based PC).
2.Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be visible on a PowerPoint based PC).
XXII
FINAL PROGRAM
3.Use a common movie format, such as AVI, MPG and WMV (MOV files from QuickTime will not be visible on a PowerPoint based PC).
You may use your own Macintosh laptop computer as a back-up. In such a case please
confirm that it has a VGA socket for external signal and come to check it first in the
Speakers’ Ready Room as soon as you arrive and later on in the session hall where your
lecture is taking place during the coffee or lunch break prior to your session, at least 30
minutes before the start of the session.
Please note that VHS Video projection, 35 mm’ slide projection and Overhead projection
(projection of transparencies) will not be available. XXIII
POSTER PRESENTATIONS
Posters will be on display on three days: Monday, 12 December, Tuesday, 13
December, and Wednesday, 14 December, with a daily rotation.
Posters should be displayed as per the date and the poster board number in the Final
Program (see pages 43-117)
Posters are to be mounted starting 08:00 on your assigned day. Please remove your
poster at the conclusion of sessions on your assigned day. The Organizing Committee
will not be responsible for posters that are not removed on time.
Poster presenters are requested to be present at their designated poster board(s) to
answer questions during breaks.
POSTER SCHEDULE
MONDAY, 12 DECEMBER
PARKINSONISM
1 – 138
RELATED DISORDERS
139 – 264
TUESDAY, 13 DECEMBER
IMAGING
1 – 36
DIAGNOSTIC PROCEDURES
37 – 85
THERAPEUTICAL INTERVENTIONS
86 – 251
OTHERS
252 - 254
WEDNESDAY, 14 DECEMBER
GENETICS
1 – 78
ANIMAL MODELS
79 - 131
NEUROPROTECTION
132 -191
BASIC SCIENCE
192 – 249
XXIV
FINAL PROGRAM
EXHIBITION LAYOUT
COMPANY
BOOTH #
American Health & Medical Supply International
Corp. (AH Medical)
13
Boehringer Ingelheim GmbH
2
Britannia Pharmaceuticals Limited
14
Elsevier
5
Lundbeck / Teva
7
IOS Press
4A
Serono Symposia International Foundation (SSIF)
6
St. Jude Medical
4
TSE Systems
12
XXV
SPONSOR & EXHIBITOR PROFILES
Abbott Products Operations AG Hegenheimermattweg 127 4123 Allschwil Switzerland www.abbott.com Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the
discovery, development, manufacture and marketing of pharmaceuticals and medical
products, including nutritionals, devices and diagnostics. The company employs
approximately 90,000 people and markets its products in more than 130 countries.
American Health & Medical Supply International
Corp. (AH Medical)
35 Weaver Street
Scarsdale, NY10583
USA
www.ahmedical.com
AH Medical is a leading American company in the Medical research and Healthcare
Sectors of the Chinese marketplace, founded in 2001. It currently provides marketing,
logistical, and exclusive distribution services to: DURECT Corp. ALZET® Osmotic Pumps
are miniature, implantable pumps used for research in unrestrained laboratory animals as
small as mice and young rats. It provides researchers with a convenient, reliable, and costeffective method for controlled delivery of agents. Mini Mitter / Respironics;
For over 35 years, Mini Mitter has provided Actiwatch, Actical, PAM-RL and VitalSense
human monitoring products that are used in clinical trials, and in clinical sleep and
research applications. Mini Mitter also features implantable telemetry and noninvasive
products for animal physiological and behavioral monitoring.
XXVI
FINAL PROGRAM
Boehringer Ingelheim GmbH
Binger Strasse 173
Ingelheim, 55218
Germany
www.boehringer-ingelheim.com
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, it operates globally with 145
affiliates and more than 42,000 employees. Since it was founded in 1885, the familyowned company has been committed to researching, developing, manufacturing
and marketing novel products of high therapeutic value for human medicine, e.g.
the dopamine agonist for the treatment of Parkinson’s disease, Sifrol(R)/Mirapexin(R)
(Pramipexole). For more information please visit www.boehringer-ingelheim.com.
Britannia Pharmaceuticals Limited
Park View House, 65 London Road
Newbury, Berkshire, RG14 1JN
UK
www.britannia-pharm.co.uk
Britannia Pharmaceuticals Limited is a UK based pharmaceutical company specialising in
innovative products for niche medical conditions. We have a particular focus on treatment
of patients with complex Parkinson’s disease.
Active for nearly 30 years with UK neurologists and geriatricians, we identified the benefit
of and need for apomorphine as a treatment for Parkinson’s disease sufferers, leading to the
development of our APO-go products. These are now available in many countries through
the efforts of Distribution or Licensing Partners.
XXVII
Elsevier
32 Jamestown Road
NW1 7BY
UK www.elsevier.com
Elsevier Health advances medicine by delivering superior education, reference
information and decision support tools to doctors, nurses, health practitioners and
students. We have a wide selection of our leading journals on display including the
society affiliated title: Parkinsonism & Related Disorders
Please visit Elsevier stand # 5 to learn more about our products and take a look at our
information solutions to suit your needs. We offer great discounts on journals and
sample copies for you to take with you.
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
www.iospress.nl
IOS Press, headquartered in Amsterdam, publishes around 100 international
journals and approximately 130 book titles a year, in a broad range of subjects. IOS
Press has a strong neurosciences package, with one of the top journals being the
Journal of Alzheimer’s Disease. In 2010, the Journal of Parkinson’s Disease (www.
journalofparkinsonsdisease.com) is launched. The Journal of Parkinson’s Disease
publishes original research in basic science, translational research and clinical
medicine in Parkinson’s disease in cooperation with the Journal of Alzheimer’s Disease.
All journals are available in print and electronic format and an online book platform
has been launched in the first half of 2006.
XXVIII
FINAL PROGRAM
H. Lundbeck A/S
Ottiliavej 7-9
2500 Valby
Denmark
www.lundbeck.com
Lundbeck – The Specialist in Psychiatry – Pioneer in Neurology
H. Lundbeck A/S is an international pharmaceutical company dedicated in research
and development of new drugs for treatment of CNS disorders including depression,
schizophrenia, Alzheimer’s disease and Parkinson’s disease. Research has been the
foundation of Lundbeck activities for more than 50 years, and the company’s mission
is to improve the quality of life for people suffering from psychiatric and neurological
disorders. Lundbeck launched Ebixa® (memantine) for the treatment of Alzheimer’s disease in 2002
and Azilect® (rasagiline) for the treatment of Parkinson’s disease in 2005.
St. Jude Medical
6901 Preston Road
Plano, TX 75024
USA
www.sjm.com
St. Jude Medical develops medical technology designed to put more control into the
hands of those who treat neurological, cardiac and chronic pain patients worldwide.
SJM has provided leading neurostimulation therapy innovations for 30 years.
The company is dedicated to advancing the practice of medicine by reducing risk
wherever possible and contributing to successful patient outcomes.
XXIX
Serono Symposia International Foundation
14, Rue du Rhone
1208 Geneva, Switzerland
www.seronosymposia.org
Serono Symposia International Foundation (SSIF) is a non profit organization dedicated
to the Continuing Medical Education (CME) of scientists, physicians, nurses, pharmacists
and other healthcare professionals, providing state of the art educational activities
designed to enhance patient care and improve health outcomes. SSIF has a proud
tradition of encouraging excellence in medical education all over the world since the
early 1970s.
The Foundation was created to honour the memory of Cesare Serono, an Italian-born
scientist who dedicated his life to improving health and patient care. In its 40 year
history SSIF has organized more than 1500 international scientific congresses with more
than 500 proceedings appearing in leading international publications.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
5 Basel Street
Petah Tikva 49131
Israel
www.tevapharm.com
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company and
the world’s largest generic drug maker committed to increasing access to high-quality
healthcare.
Teva has a global product portfolio of nearly 1500 molecules and a direct presence in
about 60 countries. Teva’s branded businesses focus on neurological, respiratory and
women’s health therapeutic areas as well as biologics. AZILECT is indicated for the treatment of idiopathic Parkinson’s disease (PD) as
monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients
with end of dose fluctuations.
XXX
FINAL PROGRAM
TSE Systems
Rm. 1802, No.4 Building, Dayin Mingzuo
JiaoDaDongLu No.60, Haidian District
Beijing, 100044
China
www.TSE-Systems.com
TSE Systems is a leading supplier of sophisticated research instrumentation in
the global life science market. With now 125 years experience, we are able to
offer comprehensive, integrated hard- and software platforms for in-vivo studies in
neuroscience, phenotyping, drug screening and toxicology.
An interdisciplinary team of scientists and engineers collaborates closely with
customers for steady innovations and development of new approaches.
TSE MotoRater System, a novel set-up for standardized kinematic evaluation of animal
movement types. The unique modular design allows the investigation of rats and
mice during skilled walking on a ladder or beam, overground walking, wading and
swimming.
XXXI
POST-CONGRESS ACTIVITIES
PARKINSON’S DISEASE:
BIOMARKER DISCOVERY AND NEW TARGET THERAPY
POST WFN-PDRD Symposium
Chairs: Weidong Lei, MD, PhD
&
Moussa Youdim, PhD
15-16 December, 2011
No. 11 Building of Ruijin
Hospital Conference Hall, 197 Ruijin Er. Road
Shanghai, China
This Satellite Symposium is specially designed to honor Prof. Peter Riederer for his
life time research achievement and for world class experts in Parkinson’s Disease
to present the new developments in biomarker discovery and target therapy.
The one-day presentations and discussion will provide useful information
to better understand the pathogenesis of Parkinson’s Disease and Related
Disorders and stimulate the continuing search for promising treatment for
these diseases.
After the symposium a one-day tour will be arranged to the
beautiful garden city, Suzhou
For additional information and registration please contact:
Xiao Jie Zhang, [email protected]
XXXII
FINAL PROGRAM
PROGRAM OVERVIEW
The XIX World Congress on Parkinson’s Disease and Related Disorders contains
the following Sessions, highlighted in the program as follows:
Plenary Sessions - There will be six Plenary Sessions, covering the main topics
of the Congress, delivered by leading clinical experts, basic scientists and other
health care professionals. The Plenary Sessions will have a strong translational
focus, accommodating clinical specialists such as neurologists, neurosurgeons,
psychiatrists and other health care professionals as well as neuroscientists.
Parallel Sessions - will focus on specific topics, regarding clinical and basic science
aspects in the field of movement disorders, representing several points of view.
Video-Supported Sessions - There will be seven hour-and-a-half video-supported
lectures, dealing with various movement disorders.
Forum Discussions - During lunchtime, Forum Discussions will offer a lively and
fruitful discussion on controversial issues. A chairperson will moderate whilst
two-three speakers will offer and challenge opinions on ‘hot topics’.
Educational Symposia - will cover all aspects of Parkinson’s Disease and other
movement disorders, and will serve the educational mission of the APRD by
providing a 13.5 hours high-quality continuing Medical Education Program.
Chinese-Parallel Sessions - two 90-minutes Chinese-spoken (or simultaneously
translated) sessions, dealing with topics with high interest for the Chinese
community will be held each day. Sponsored Sessions - designed, produced and organized by pharmaceutical
industries in consultation with the Scientific Program Committee, these sessions
are fully integrated into the congress
Poster Presentations – with a daily rotation, authors have been invited to present
their new research finding or important ongoing research as posters.
Oral Platform Abstract Presentation - selected posters have been given the
opportunity to present their abstract in a short oral presentation, throughout the
Congress days.
XXXIII
WCPD 2011
SCIENTIFIC PROGRAM APP
The WCPD 2011 Scientific Program now
on your personal mobile device:
To access the WCPD 2011 Scientific Program App from the
browser of your device:
http://wcpd.kenesapp.com
Choose, plan and make the most of the Congress
XXXIV
FINAL PROGRAM
新旧交汇
第十九届国际帕金森病及相关疾病学术会议
中国上海
2011.12.11~2011.12.14
最终方案
目录
展览目录 ……………………………………………………………………………………………. XXV
展示资料…………………………………………………………………………………………….XXXIII
学术项目
12月11日，周日……………………………………………………………………………………………1
12月12日，周一……………………………………………………………………………………………3
12月13日，周二………………………………………………………………………………………..…17
12月14日，周三…………………………………………………………………………………………..31
海报展示
12月12日，周一…………………………………………………………………………………………43
12月13日，周二…………………………………………………………………………………………67
12月14日，周三…………………………………………………………………………………………93
著者索引…………………………………………………………………………………………………119
FINAL PROGRAM
欢迎信
亲爱的同仁，
我谨代表国际帕金森病及相关疾病研究委员会，非常荣幸欢迎您参加在中国上海举行的
第十九届国际帕金森病及相关疾病学术会议。
在“新旧交汇”的标语下，大会突出展示在基础及西方临床研究的最新科学进展，传统研
究的新观点，及非药理学的东方临床干预，当然中国珍贵的传统文化背景下大都市超现
代化的生活方式也将会给您留下难以磨灭的印象。
本次大会将通过多种翻译方式向您展示在帕金森病及相关疾病领域就病因、发病机理、
潜在诊断标记物和治疗措施方面进行的最新研究和所取得的最新进展，届时将汇集众多
知名科学家、临床医生和联合医疗保健专家就有关此领域的大量专业知识展开广泛的交
流。
科学计划将由大会报告会、平行会议、互动讨论论坛、视频会议、教育座谈会、卫星专
题讨论会、中国平行会议、口头平台介绍和海报介绍组成。
上海是中国最大最有活力的城市，有极具震撼力的国际化氛围，尤其是在圣诞节时候，
由壮阔的长江分隔两岸，将一岸惊人的现代建筑与对岸林立的十九世纪早期各式建筑结
合在一起。
我们希望您能花足够的时间欣赏这大都市及中国其它地方的名胜和丰富的历史，成为此
次会议历程的一部分。
国际帕金森病及相关疾病研究委员主席
Erik Ch. Wolters
亲爱的同仁们，
我很高兴欢迎您来 2011 年 12 月 11-14 日在上海举办的第十九届国际帕金森病及相关疾
病大会。
位于扬子江畔的上海，简称沪，居民超过 2 千万，是中国最大最有活力的城市，作为中
国东部最有影响力的经济、金融、国际贸易、文化、科学与技术中心，是著名的国际激
动人心的大都市。
今天，上海有着活力的气氛，是令人激动的国际文化和设计中心，这里可以发现现代及
传统、西方和东方文化完美交融，这里西方风俗和中华传统交织在一起，新旧标志像外
滩、城隍庙、现代浦东和东方明珠塔结合在一起。
上海刺激的夜生活在亚洲名列前茅，有各种各样的夜总会。上海汇集各式各样的餐厅确
保能迎合您最挑剔的口味，可以提供各种适合您预算的住宿。新浦东国际机场有连接国
内、亚洲及世界其它地区的最佳航程。
我们希望您在这次会程期间能花时间探索这座城市，一定会使您此程难忘。
大会主席
陈生弟
FINAL PROGRAM
鸣谢
非常感谢以下公司对第十九届国际帕金森病及相关疾病学术会议所提供的赞助支持：
通则
会议地点
上海国际会议中心
东方滨江大酒店，滨江大道 2727 号
中国上海浦东，200120
电话：+86 21 50370000
www.shicc.net
语言
会议正式语言是英语。
平行中国会议将用中文。
结束期间有标记
的会议将被同声翻译为中文。
注册/信息资料/秘书台
登记台设置在上海国际会议中心第一层（一楼）
，开放时间如下：
12 月 11 日，周日
14:00-21:00
12 月 12 日，周一
07:30-19:15
12 月 13 日，周二
08:00-18:00
12 月 14 日，周三
08:00-18:00
徽章
注册后您将收到一枚印有您姓名的徽章。请您在出席所有会议和活动期间都佩戴
您的徽章
FINAL PROGRAM
展示时间
展示在以下时间开放：
12 月 12 日，周一
09:30-16:30
12 月 13 日，周二
09:30-16:30
12 月 14 日，周三
09:30-16:00
WIFI
会议期间在展示区及登记区均可使用 WIFI 无线上网。
摘要和会议论文
主要会议及平行会议的全文发表在帕金森病及相关疾病杂志的增刊，由 Elsevier 出版。
所有接收的摘要发表在帕金森病及相关疾病杂志在线增刊和光盘上。
请到位于展示区的 Elsevier 点拿取您的文摘光盘和全文的杂志增刊。
帕金森病及相关疾病杂志
所有已注册的会议参加者有资格登记为帕金森病和相关疾病协会无投票权的准会员。作
为会员可以享有的权利之一是可以 2 年打印和在线订阅帕金森病及相关疾病杂志。
请确保您在注册时间内向大会秘书处提交完整的个人详细地址和电子邮件地址。
信息/医学补助/失物招领
在注册处区域的告示板上可获取此类信息和通知。所有其它问题请与注册处联系。
会议调查
我们非常珍视您的意见
填写与会者调查表将有机会免费注册 2013 年日内瓦第二十届国际帕金森病及相关疾病大会。
证书
从周二即 12 月 13 号 14:30 直到周三会议结束即 12 月 14 号，参会者的证书可在在预付
费登记处得到。参加者被要求在机器上浏览他们的条码，拥有参会者名字的证书将自动
打印
医学继续教育认证
第十九届国际帕金森病及相关疾病学术会议受欧洲继续医学教育认证委员会
（EACCME）许可，可以为医学专业人士提供以下的继续教育认证。
第十九届国际帕金森病及相关疾病学术会议最多可以提供 18 个小时的欧洲额外继续医
学教育学分。每位医学专家可根据自己实际参与教育活动的时间申请相应的学分。
欧洲继续医学教育认证委员会（EACCME）是欧洲医学专家联盟（UEMS）的一个下属
机构，www.uems.net。
美国医学会（AMA）同样认可 EACCME 学分，您可以联系美国医学会将您的 EACCME
学分换算成其 PRA 学分。
医学继续教育考勤办法
自助扫描设备将会放置在注册区。您需要通过扫描姓名徽章来记录您的出席，只有这样
您才能在会议结束时从秘书处领到一份追踪记录您会议出席情况的时间表。
交通补助
本次大会的交通补助由梅尔文亚尔国际帕金森病基金会（主席是 Dr.Alessandro）和帕
金森病及相关疾病协会共同赞助。补助是为了激励 35 岁以下年轻研究人员参与大会。
祝贺所有的受赞助者。
FINAL PROGRAM
有关吸烟
在所有会场、展区及洗手间均禁止吸烟，在不远处我们设有专门的吸烟区，感谢您的配
合。
着装要求
整个会议期间，休闲或非正式着装。
移动电话
所有会议期间请务必将您的手机关机或设为静音。
官方航空公司
第十九届国际帕金森病及相关疾病大会指定星空联盟各成员航空公司作为官方航空网
络。
责任以及保险
大会秘书处和组织者不承担参会者及随同人员人身事故、私人财产损失和损害赔偿责
任。建议与会者将此次行程加入到您个人的旅行及健康保险中。
爱护环境
相信通过在工作场所从事绿色文化，我们能够保持和继承下去。组织全世界的绿色大会
是一个真正的挑战，因为绿色不仅是所在地管理，还应该是整个供应链我们用品的供应，
原料的来源、生产方法、废物管理、运输和使用本地产品、公平劳动管理。
其它会议活动
周日，12 月 11 日
开幕式
18:30
A 礼堂
上海国际会议中心
会议地点）
随后是
欢迎酒会
20:30
A 礼堂大厅（会议地点）
周一，12 月 12 日
07:00-08:30
正式会员年度早餐会
E 礼堂，会议地址
20:00-22:00
正式会员晚餐
和平饭店
限受邀者
19:30 在东方滨江大酒店有大巴接往晚餐
FINAL PROGRAM
周二，12 月 13
会议晚餐
20:30
绿波廊酒楼
欢迎所有参会者和我们一起品味中国传统饭菜我们的中国传统的晚餐，其中包括中国戏
曲娱乐。
晚餐票价 65 美元可在前台办理。
周三，12 月 14 日
闭幕式
17:30-18:00
F 礼堂
参议员弗朗兹布尔达医学奖
12 月 14 日（星期三）
12:00 - 12:30
参议员布尔达奖成立于 1985 年，颁发给在帕金森病的临床和基础研究中贡献突出者。
2011 年参议员布尔达奖将授予：
Erik Ch. Wolters 教授: 博士，荷兰阿姆斯特丹，因其杰出的临床研究获奖；
Toshikazu Nagatsu 教授，博士，日本爱知县，因其在帕金森病基础研究中的突出贡献而
获奖。
我们诚挚邀请您参加于 12 月 14 日（星期三）12:00 - 12:30 在会议中心上层大厅举行的
参议员布尔达颁奖典礼。
雷尔教授/马斯布鲁科尔教授
FINAL PROGRAM
帕金森病的历史 - 主要研究成果及治疗展览
随着第 16 届（2005，in Berlin)及第 17 届（2007，Amsterdam)国际帕金森病及相关疾病
大会的成功举办，我们很高兴能再次举办关于帕金森病历史的医学展览。
该展览设在展览区并且日常开放，它代表着对医学历史文献的独特收集，突出了十九世
纪在帕金森病领域有决定性作用的研究并表彰了二十世纪治疗领域的主要贡献。
詹姆斯帕金森标志性的文章确立了其里程碑意义。尽可能联系在当今帕金森病理论及治
疗方面来自法国，德国及澳大利亚以及在药物历史及其意义上具有特殊贡献的研究者
演讲者须知
所有演讲者（包括口头简要平台演示者）务必在会议开始前至少 1 小时向演讲者准备室提交演讲稿。
我们将在会场清晰的指示出演讲人准备室的位置。
PowerPoint 演示文稿
如果您使用 PPT（或其他软件）演示文稿，请注意在会议开始前至少 1 小时将其从您随身携带的
CD,DVD 或移动硬盘（使用电脑上的 USB 接口）中加载到演讲准备室的会议电脑上。
如果您的 PPT 有视频文件，即使您在演讲者准备室已经检查过，也请务必在演讲开始前至少 30 分
钟的茶休及午休期间在演讲大厅检查您的视频文件。请注意：演讲大厅的电脑是 Windows XP 系统
和 Office 2007 版。
MAC 演示文稿
为了在个人兼容电脑上使用 MAC 演示文稿，请注意在提交给演讲者准备室演示文稿前，需要按以
下说明准备：
1.使用通用字体，如 Arial,Times New Roman,Verdana 等。（特殊字体在个人电脑的 PPT 上可
能会更改为错误字体）
2.插入 JPG 格式图片（而不是 TIF,PNG,或 PICT 格式，这些图片在个人电脑的 PPT 上将不可
用）。
3.使用视频通用格式，如 AVI,MPG 以及 WMV(QuickTime 的 MOV 格式在个人电脑的 PPT 上
将不可用）。
您若使用苹果电脑作为备份，请确保它有外界信号的 VGA 插座并且在演讲者准备室进行初次检查，
之后在演讲开始前至少 30 分钟的茶休及午休期间在演讲大厅再次检查。
请注意 VHS 视频投影，35 毫米的幻灯片投影及过大的投影（胶片投影）不可用。
FINAL PROGRAM
海报介绍
海报将轮流展示三天：12 月 12 日（周一),12 月 13 日（周二)，12 月 14 日（周三)，每
天更换。
海报将按照最终方案上的日期和版号顺序进行展览。
请与安排日期的早上 8 点悬挂海报，并在当天会议结束时摘下。大会组委不负责海报的
移除。在会议休息期间，海报介绍人需在指定的海报板下回答问题.
海报计划
12 月 12 日，周一
帕金森病
帕金森相关疾病
1-138
139-264
12 月 13 日，周二
影像学
1-36
诊断流程
37-85
治疗方案
86-251
252-254
其他
12 月 14 日，周三
遗传学
1-78
动物模型
79-131
神经保护
132-191
基础科学
192-249
2011 年 12 月 12 日星期一
08:30-10:00
B厅
中文分组会
研究进展
主席:
刘焯霖, 广州
程焱, 天津
Abstract No
08:30
遗传
唐北沙, 长沙
08:50
线粒体在帕金森病发病机制中的作用
刘军, 上海
09:10
10:00
1.5.4
讨论
茶休 , Poster 观展
12:30-14:00
卫星会
帕金森病治疗的卫星会
勃林格公司赞助
主席:
1.5.3
帕金森病早期诊断的生物标记物
徐评议, 广州
09:50
1.5.2
帕金森病不同 H-Y 分期的代谢分布
王坚, 上海
09:30
2.5.1
陈生弟, 中国上海
W. Oertel, 德国
12:35
DA 受体激动剂在早期和晚期帕金森病治疗中的作用
12:55
帕金森病的非运动症状:对生活质量的影响及治疗
13:15
帕金森病每日一次治疗
A. Schapira, 英国伦敦
P. Barone, 意大利纳普勒斯
N. Hattori, 日本东京
A厅
FINAL PROGRAM
2011 年 12 月 12 日星期一
16:00-17:30
B厅
中文视频会议: 帕金森综合征
主席:
张宝荣, 杭州
16:00
舞蹈病及相关疾病
Abstract No
张宝荣, 杭州
16:30
王丽娟, 广州
17:00
卫星会
帕金森病的未来
Serono Symposia 公司赞助
帕金森病进展: 前驱症状到恶化
A.H.V. Schapira,英国伦敦
18:20
多巴胺能和非多巴胺能通路对帕金森病病理生理的贡献
E.Ch. Wolters1,2, 1 阿姆斯特丹, 荷兰, 2Zurich, 瑞士
18:45
1.17.3
稍息换厅
17:45-19:15
17:55
1.17.2
多系统萎缩
邵明, 广州
17:30
1.17.1
肌张力障碍的诊断治疗
帕金森病的干细胞和基金治疗:未来方向
J.H. Kordower,美国芝加哥
F厅
2011 年 12 月 13 日星期二
08:30-10:00
B厅
中文分组会
帕金森病治疗
主席:
贾建平，北京
孙相如, 北京
Abstract No
08:30
中国帕金森病治疗指南
孙圣刚, 武汉
08:50
早期帕金森病的治疗
刘振国, 上海
09:10
10:00
茶休, 观展 Poster
卫星会
阻止帕金森病进展有何意义?
Lundbeck / Teva 公司赞助
12:30
张振馨, 中国北京
早期和晚期帕金森病中要关注的地方
E.Ch. Wolters, 荷兰阿姆斯特丹
13:00
我们能影响多少帕金森病的临床进展?
F. Stocchi, 意大利罗马
13:30
2.5.4
讨论
12:30-14:00
主席:
2.5.3
帕金森病的非运动症状治疗
王铭维, 石家庄
09:50
2.5.2
晚期帕金森病的治疗
肖勤, 上海
09:30
2.5.1
阻止帕金森病临床进展的价值：从临床、病人、社会观察
H. Reichmann, 德国德雷斯顿
F厅
FINAL PROGRAM
2011 年 12 月 13 日星期二
16:00-17:30
B厅
中文分组会
帕金森病危险因素
主席:
S.-L. Ho, 香港.
蒋雨平, 上海
Abstract No
16:00
职业性化学接触与帕金森病
C.M. Tanner, 美国加州桑尼维尔
16:20
流感病毒与帕金森病
S. Sadasivan, R.J. Smeyne, Memphis, TN, 美国
16:40
17:30
2.17.3
有机氯农药与帕金森病
A. Elbaz, 法国巴黎
17:20
2.17.2
接触三氟乙烯 (TCE) 与帕金森病
S.M. Goldman, 美国加州桑尼维尔
17:00
2.17.1
讨论
稍息换厅
2.17.4
2011 年 12 月 13 日星期二
17:45-19:15
卫星会
针对帕金森病未满足的需求: 持续的多巴胺能刺激治疗
Abbott 赞助
主席:
17:45
A. Antonini, 意大利威尼斯
针对帕金森病未满足的需求: 持续的多巴胺能刺激治疗
A. Antonini1,2, 1 意大利威尼斯, 2 帕多瓦,
17:50
对晚期帕金森病应用持续的多巴胺能刺激治疗的里程碑
M. Mouradian, 美国新泽西
18:15
应用左旋多巴卡比多巴肠内注入的持续的多巴胺能刺激: 最新证据
P. Odin1,2, 1 德国不来梅港, 2 瑞典
18:40
帕金森病的护理价值
B. Bloem, 荷兰奈梅根
19:05
主席总结
A. Antonini, 意大利威尼斯
F厅
FINAL PROGRAM
2011 年 12 月 14 日星期三
08:30-10:00
C厅
中文分组会议
替代治疗战略
主席:
彭国光, 重庆
杨任民, 合肥
Abstract No
08:30
帕金森病的针灸治疗
刘艺鸣,济南
08:50
帕金森病的中草药治疗
蔡定芳, 上海
09:10
3.5.3
神经培养中营养素的神经保护
W. Rausch, 澳地利维也纳
09:50
3.5.2
帕金森病与太极
王振福, 北京
09:30
3.5.1
3.5.4
讨论
16:00-17:30
C厅
中文分组会议
相关疾病
主席:
W. Rausch, 奥地利维也纳
汪汉澄，台北
Abstract No
16:00
肝豆状核变性病
梁秀玲, 广州
16:20
亨廷顿病
吴志英,上海
16:40
3.18.3
多系统萎缩
陈海波, 北京
17:20
4.18.2
发作性运动障碍
刘春风, 苏州
17:00
3.18.1
讨论
3.18.4
Scientific Program
Sunday, December 11
Sunday, December 11, 2011
18:30-20:30
Hall A
OPENING CEREMONY
Welcome Words:
S. Chen, China
Congress Chairman
Mayor of Shanghai, China
E.Ch. Wolters, Amsterdam, The Netherlands
Chairman, Association of Parkinsonism and Related Disorders
Keynote Lectures:
EASTERN BEANS, ROOTS AND LEAVES IN THE TREATMENT OF
MOVEMENT DISORDERS
S. Chen, China
WESTERN BEANS, ROOTS AND LEAVES IN THE TREATMENT OF
MOVEMENT DISORDERS
P. Foley, Australia
1
Scientific Program
Monday, December 12
Monday, December 12, 2011
08:30-10:00
Hall A
Parallel Session
GENOTYPES AND PHENOTYPES: FAMILIAL PARKINSONISM
Chairperson:
E.K. Tan, Singapore, Singapore
Abstract No
08:30
AUTOSOMAL DOMINANT PARKINSONISM
N. Hattori, Tokyo, Japan
1.1.1
08:50
AUTOSOMAL RECESSIVE PARKINSONISM
V. Bonifati, Rotterdam, The Netherlands
1.1.2
09:10
AUTOSOMAL DOMINANT PARKINSON´S DISEASE
Z.K. Wszolek, Jacksonville, FL, USA
1.1.3
09:30
AUTOSOMAL RECESSIVE PARKINSON'S DISEASE
R.-M. Wu, Taiwan
1.1.4
09:50
DISCUSSION
08:30-10:00
Hall B
Chinese Parallel Session
PROGRESS OF PD RESEARCH
Chairpersons:
Z. Liu, China
Y. Chen, Tianjin, China
Abstract No
08:30
GENETICS
B. Tang, Changsha, China
2.5.1
08:50
ERK PATHWAY IS INVOLVED IN SNCA INDUCED MITOCHONDRIAL
DYNAMIC DISORDERS BY REGULATING DLP1
J. Liu, Y. Gui, S. Chen, Shanghai, China
1.5.2
09:10
METABOLIC NETWORKING IN CHINESE PATIENTS WITH PARKINSON'S
DISEASE IN VARIOUS HOEHN & YAHR STAGES
J. Wang, C. Zuo, P. Wu, H. Zhang, Y. Guan, J. Wu, Z. Ding, Y. Jiang, Shanghai,
China
1.5.3
09:30
BIOMARKERS FOR EARLY DIAGNOSIS OF PD
P. Xu, Guangzhou, China
09:50
DISCUSSION
10:00
Coffee Break, Poster Viewing & Visit Exhibition
3
1.5.4
08:30-10:00
Hall C
Platform Abstract Presentations
PARKINSONISM AND RELATED DISORDERS
Chairperson:
B.S. Jeon, Seoul, Republic of Korea
Abstract No
08:30
INCREASED MEDIAL ORBITOFRONTAL DOPAMINE FUNCTION IN
PARKINSON´S DISEASE PATIENTS WITH IMPULSE CONTROL DISORDERS
J. Joutsa, K. Martikainen, S. Niemelä, S. Forsbacka, J.O. Rinne, V. Kaasinen,
Turku, Finland
1.112
08:36
A PROSPECTIVE STUDY OF STATIN USE AND RISK OF PARKINSON
DISEASE
X. Gao, K. Simon, M.A. Schwarzschild, A. Ascherio, Boston, MA, USA
1.120
08:42
ROLE OF SOMATODENDRITIC AND POSTSYNAPTIC SEROTONIN-1A
RECEPTORS IN THE ATTENUATION OF HALOPERIDOL-INDUCED
PARKINSONIAN LIKE EFFECTS
E. Shireen, D.J. Haleem, Karachi, Pakistan
3.353
08:48
TRACE METALS IN PATIENTS WITH PARKINSON'S DISEASE: A MULTICENTER CASE-CONTROL STUDY OF NIGERIAN PATIENTS
O.A. Ogunrin1, E.O. Sanya2, M.A. Komolafe3, C.C. Osubor1, 1Benin City, 2Ilorin,
3
Ile Ife, Nigeria
1.116
08:54
DEEP STUDY: A LARGE EPIDEMIOLOGICAL SURVEY ABOUT WEARING
OFF IN PARKINSON DISEASE
F. Stocchi1, G. Abbruzzese2, P. Barone3, V. Posocco4, D. Colombo4, A. Antonini5,
on behalf of DEEP Study Group, 1Rome, 2Genoa, 3Salerno, 4Varese, 5Venice,
Italy
1.108
09:00
DIFFERENTIAL MITOCHONDRIAL PROTEIN EXPRESSION WITHIN SINGLE
GLYCINERGIC NEURONS OF THE PEDUNCULOPONTINE NUCLEUS OF
PARKINSON'S DISEASE PATIENTS
I.S. Pienaar, C. Morris, D. Burn, C. Racca, G. Nelson, D. Turnbull, Newcastle
upon Tyne, UK
1.128
09:06
SLEEP REGULATORY CENTRES DYSFUNCTION IN PARKINSON'S DISEASE
PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS. AN IN VIVO PET
STUDY
N. Pavese, V. Metta, B.S. Simpson, T.A. Marphy, A. Ramlackhansingh, K.R.
Chaudhuri, D.J. Brooks, London, UK
1.060
09:12
SLEEP DESTRUCTURATION IN EARLY EXECUTIVE DYSFUNCTIONS: A
VIRTUAL AND NEUROPSYCHOLOGICAL STUDY IN PARKINSON'S DISEASE
G. Albani1, L. Priano1, P. Cipresso2, R. Pignatti1, G. Riva2, A. Mauro1, 1VerbaniaPiancavallo, 2Milan, Italy
1.056
09:18
THE 18[F] -FDG PET STUDY ON THE IDIOPATHIC PARKINSON'S DISEASE
AND SEVERAL PARKINSONIAN-PLUS SYNDROME
P. Zhao, B. Zhang, S. Gao, Tianjin, China
4
2.141
08:30-10:00
Hall C
PARKINSONISM AND RELATED DISORDERS (CONTD.)
Abstract No
09:24
BROAD-BAND DIRECTIONAL EEG CONNECTIVITY CHANGES DURING
MOTOR PREPARATION PREDICTS PARKINSON'S DISEASE SEVERITY
J. Chiang1, G. Tropini1,2, Z.J. Wang1, M.J. McKeown1, 1Vancouver, BC, 2Toronto,
ON, Canada
2.121
09:30
THE IMPACT OF EMOTIONAL DISORDERS AND COGNITIVE IMPAIRMENT
ON THE QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASE
X. Huang, Beijing, China
1.099
ASSOCIATION BETWEEN FATIGUE AND DEPRESSION IN PARKINSON'S
DISEASE
C.-J. Mao, D.-H. Li, L.-D. Cao, Q. Tang, C.-F. Liu, K.-P. Xiong, Suzhou, China
1.061
WILSON'S DISEASE: UPDATE ON INTEGRATED TRADITIONAL CHINESE
MEDICINAL HERBS AND WESTERN MEDICINE IN CHINA
X.-P. Wang, W. Li, Shanghai, China
1.278
QUANTITATIVE ASSESSMENT OF REST AND ACTION TREMOR AND THE
EFFECT OF CUEING IN PARKINSON'S PATIENTS TREATED WITH DEEP
BRAIN STIMULATION
T. Heida, E. Wentink, E. Marani, Enschede, The Netherlands
1.229
PSYCHOGENIC MOVEMENT DISORDER DURING THE FIRST GREAT WAR
C. Geny1, M. Wyart2, 1Montpellier, 2Nimes, France
1.300
09:36
09:42
09:48
09:54
08:30-10:00
Hall D
Educational Symposium
Chairperson:
08:30
PARKINSONISM AND PARKINSON'S DISEASE
09:00
PATHOLOGY IN PARKINSON'S DISEASE
W. Le, Shanghai, China
09:30
GENETICS IN PARKINSON'S DISEASE
N. Giladi, Israel
10:00
5
08:30-10:00
Hall F
Parallel Session
EMERGING NEW TREATMENTS IN PD
Chairperson:
P. Riederer, Wuerzburg, Germany
Abstract No
08:30
VACCINES
A. Schneeberger, Austria
1.2.1
08:50
USING STEM CELLS AND IPS CELLS TO DISCOVER NEW TREATMENTS
FOR PARKINSON'S DISEASE
O. Cooper, P. Hallett, O. Isacson, Belmont, MA, USA
1.2.2
09:10
MISFOLDED α-SYNUCLEIN AND NEUROINFLAMMATION AS THERAPEUTIC
TARGETS FOR PARKINSON´S DISEASE
K.A. Maguire-Zeiss, Washington, DC, USA
1.2.3
09:30
NEW TARGETS FOR DBS
A.L. Benabid, N. Torres, S. Chabardes, Grenoble, France
09:50
DISCUSSION
1.2.4
08:30-10:00
Hall G
Video-Supported Session
SYNUCLEINOPATHIES FROM BENCH TO BEDSIDE (PD, MSA, ADHD, RLS)
Chairperson:
A. Puschmann, Lund, Sweden
Abstract No
08:30
SYNUCLEINOPATHIES FROM BENCH TO BEDSIDE (PD, MSA, ADHD, RLS)
A. Puschmann1, R. Bhidayasiri2, W.J. Weiner3, 1Lund, Sweden, 2Bangkok,
Thailand, 3Baltimore, MD, USA
08:50
CLINICAL PRESENTATION
R. Bhidayasiri, Bangkok, Thailand
09:25
CLINICAL PRESENTATION
P.S. Fishman, USA
10:00
6
1.3.1
10:30-12:00
Hall A
Plenary Lecture
MELVIN YAHR SYMPOSIUM: PARKINSON’S DISEASE REVISITED
Chairpersons:
G. Deuschl, Kiel, Germany
Abstract No
10:30
NEUROPATHOLOGY IN THE PREMOTOR STAGES AND SUBTYPES OF
PARKINSON´S DISEASE
W.D.J. van de Berg, A.A. Dijkstra, D.H. Hebb, A.J.M. Rozemuller, Amsterdam,
The Netherlands
1.7.1
10:50
DIAGNOSIS OF PD
D.J. Brooks, London, UK
1.7.2
11:10
QUALITY TREATMENT OF PARKINSON´S DISEASE
R.J. Uitti, Jacksonville, FL, USA
1.7.3
11:30
UPCOMING TREATMENTS IN PARKINSON´S DISEASE, INCLUDING GENE
THERAPY
R. Rodnitzky, Iowa City, IA, USA
1.7.4
11:50
DISCUSSION
12:00
Lunch Break, Poster Viewing & Visit Exhibition
7
12:30-14:00
翻译
Hall A
Satellite Symposium
STATE OF THE ART IN PD TREATMENT SATELLITE SYMPOSIUM
Sponsored by Boehringer Ingelheim
Chairpersons:
S. Chen, China
W. Oertel, Germany
12:35
THE ROLE OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY AND
ADVANCED PD
A. Schapira, London, UK
12:55
NON MOTOR SYMPTOMS IN PD: IMPACT ON QUALITY OF LIFE AND
MEDICAL TREATMENT
P. Barone, Naples, Italy
13:15
ONCE DAILY TREATMENTS IN PD: AN UPDATE
N. Hattori, Tokyo, Japan
12:30-14:00
Hall C
Forum
WHAT ABOUT BRAAK
Moderator:
[1.10.1]
I. Alafuzoff, Uppsala, Sweden
Discussants:
D.W. Dickson, USA
H. Reichmann, Dresden, Germany
H. Chen, USA
8
12:30-14:00
Hall D
Chairperson:
J. Zhang, Seattle, WA, USA
12:30
PRE-MOTOR BIOCHEMICAL MARKERS FOR PARKINSON DISEASE
J. Zhang, Seattle, WA, USA
13:00
IMAGING (SONOGRAPHY, MRI)
T. Brücke, Austria
13:30
IMAGING (PET, SPET)
T. Brücke, Austria
12:30-14:00
Hall G
Forum
PD-MCI & PDD, DLB and AD
Moderator:
J. Leverenz, USA
Discussants:
A.D. Korczyn, Tel Aviv, Israel
B. Boeve, USA
Y. Shen, USA
9
14:00-15:30
Hall A
Plenary Lecture
HIROTARO NARABAYASHI SYMPOSIUM: FROM PATHOLOGY TO DIAGNOSIS
Chairpersons:
S. Chen, China
R.F. Pfeiffer, USA
Abstract No
14:00
PARKINSON´S DISEASE: MOLECULAR RISK FACTORS
E. Grünblatt, Zurich, Switzerland
1.12.1
14:20
ADVANCES IN CSF BIOMARKERS OF PARKINSON´S DISEASE
P. LeWitt, West Bloomfield, MI, USA
1.12.2
14:40
NEURONAL VULNERABILITY IN PARKINSON'S DISEASE
K. Double, Sydney, NSW, Australia
1.12.3
15:00
NEUROIMAGING
A.J. Stoessl, Canada
15:20
DISCUSSION
15:30
10
16:00-17:30
Hall A
Parallel Session
GENOTYPES AND PHENOTYPES: SPORADIC PARKINSON’S DISEASE
Chairperson:
Z. Wszolek, Jacksonville, FL, USA
Abstract No
16:00
THE GWAS PERSPECTIVE AND BEYOND
T. Gasser, Germany
1.13.1
16:20
SNP VARIANTS IN PD: EAST VS WEST
E.K. Tan, Singapore, Singapore
1.13.2
16:40
ROLE OF MENDELIAN GENES IN SPORADIC PD
A. Brice, Paris, France
1.13.3
17:00
MOLECULAR PATHWAYS IN SPORADIC PD
E.M. Valente, Rome, Italy
1.13.4
17:20
DISCUSSION
16:00-17:30
Hall B
CHINESE VIDEO SESSION: PARKINSONISM
Chairperson:
B. Zhang, Hangzhou, China
Abstract No
16:00
CHOREA AND RELATED DISORDER
B. Zhang, Hangzhou, China
1.17.1
16:30
THE DIAGNOSIS AND TREATMENT OF DYSTONIA
W.L. Wanglijuan, Guangzhou, China
1.17.2
17:00
MULTIPLE SYSTEM ATROPHY
M. Shao, Guangzhou, China
1.17.3
17:30
Short break to change halls
11
16:00-17:30
Hall C
IMAGING AND DIAGNOSTICS
Chairperson:
Abstract No
16:00
CASE CONTROL DIFFUSION TENSOR IMAGING TRACTOGRAPHY STUDIES
IN POSTURAL INSTABILITY GAIT DISORDER PARKINSONISM
L.-L. Chan, K.-M. Ng, H. Rumpel, E.-K. Tan, Singapore, Singapore
2.010
16:06
NEUROPHYSIOLOGICAL CORRELATES OF COGNITIVE DECLINE IN
PARKINSON'S DISEASE: A LONGITUDINAL
MAGNETOENCEPHALOGRAPHIC STUDY
K.T.E. Olde Dubbelink, J.W.R. Twisk, C.J. Stam, H.W. Berendse, Amsterdam,
The Netherlands
16:12
DEFAULT MODE NETWORK AND EXTRASTRIATE VISUAL RESTING STATE
NETWORK IN PATIENTS WITH PARKINSON'S DISEASE DEMENTIA
I. Rektorova, L. Krajcovicova, R. Marecek, M. Mikl, Brno, Czech Republic
2.033
16:18
INCREASED MICROGLIAL ACTIVATION AND AMYLOID DEPOSITION IN
PARKINSON´S DISEASE SUBJECTS AT HIGH RISK OF DEMENTIA: A PET
STUDY
B.S. Simpson1, A.F. Ramlackhansingh1, N. Pavese1, R.A. Barker2, D.P. Breen2,
D.J. Brooks1, 1London, 2Cambridge, UK
2.026
16:24
THE MESENCEPHALIC AREA MEASURED BY BRAIN SONOGRAPHY IN THE
DIFFERENTIAL DIAGNOSIS OF PARKINSONISMS
J.F. Vazquez, I. Sastre, J.I. Tembl, I. Martinez, P. Sahuquillo, V. Parkhutik, A.
Lago, J.A. Burguera, Valencia, Spain
2.143
16:30
LONGITUDINAL PET STUDIES OF MICROGLIAL ACTIVATION IN
HUNTINGTON'S DISEASE
Y.F. Tai, N. Pavese, S.J. Tabrizi, R.A. Barker, D.J. Brooks, P. Piccini, London, UK 2.039
16:36
CSF CLUSTERIN IS ASSOCIATED WITH COGNITIVE IMPAIRMENT AND
ALZHEIMER'S DISEASE BIOMARKERS IN PARKINSON'S DISEASE
PATIENTS
K.D. van Dijk, W. Jongbloed, C.E. Teunissen, T. Koene, H.J. Groenewegen,
H.W. Berendse, W.D. van de Berg, R. Veerhuis, Amsterdam, The Netherlands
2.031
2.131
16:42
CSF BIOMARKERS OF CENTRAL CATECHOLAMINE DEFICIENCY IN THE
DIAGNOSIS OF PARKINSON DISEASE AND OTHER SYNUCLEINOPATHIES
D.S. Goldstein, C. Holmes, Y. Sharabi, Bethesda, MD, USA
2.144
16:48
CHANGE IN GLUTATHIONE-S-TRANSFERASE-PI EXPRESSION IN BLOOD
OF PARKINSON'S DISEASE PATIENTS FOLLOWING EXPOSURE TO
OXIDATIVE STRESS: POTENTIAL USE AS A BIOMARKER
A. Korff, B. Pfeiffer, M. Smeyne, M. Kocak, R. Pfeiffer, R. Smeyne, Memphis, TN,
USA
2.130
16:54
NIGRAL IRON DEPOSITION OCCURS ACROSS MOTOR PHENOTYPIC
EXPRESSIONS OF PARKINSON'S DISEASE
L. Jin, J. Wang, H. Jin, G. Fei, Y. Zhang, W. Chen, L. Zhao, N. Zhao, X. Sun, M.
Zeng, C. Zhong, Shanghai, China
1.009
12
16:00-17:30
Hall C
IMAGING AND DIAGNOSTICS (CONTD.)
Abstract No
17:00
GENE EXPRESSION PROFILING OF PERIPHERAL BLOOD FOR DETECTION
OF PARKINSON´S DISEASE
M.K. Karlsson1,2, H.-M. Andersen1, S. Sæbø2, A. Lönneborg1, 1Oslo, 2Ås, Norway 3.010
17:06
CLINICAL RESEARCH OF [11C]CFT DOPAMINE TRANSPORTER PET
IMAGING IN PARKINSON'S DISEASE
W. Xian, X. Shi, X. Fu, Y. Liu, J. Chen, Y. Zheng, H. Zhou, Y. He, J. Li, Z. Liu, Z.
Pei, L. Chen, Guang Zhou, China
2.028
17:12
CEREBRAL PATHOLOGIES STUDY BY MEANS OF MAGNETIC
ENCEPHALOGRAPHY DATA
S.A. Makhortykh, Pushshino, Russia
2.126
17:18
DECREASED NURR1 AND PITX3 GENE EXPRESSION IN CHINESE
PATIENTS WITH PARKINSON'S DISEASE
H.-M. Liu, Q.-Q. Tao, W. Le, Shanghai, China
2.132
17:24
IDENTIFICATION OF PLASMA GLYCOPROTEINS AS BIOMARKERS OF
PATIENTS WITH PARKINSON´S DISEASE
C. Pan, S. Lu, M. Shi, J. Zhang, Seattle, WA, USA
2.145
16:00-17:30
Hall D
Chairperson:
D.W. Dickson, USA
16:00
TAU
D.W. Dickson, USA
16:30
α-SYNUCLEIN AND MOVEMENT DISORDERS
G.M. Halliday, Randwick, NSW, Australia
17:00
HIPPOCAMPAL NEUROGENESIS IN PARKINSON'S DISEASE
K. Double, J. Zhang, A. Gysbers, F. Carew-Jones, C. Shannon Weickert, G.
Halliday, Sydney, NSW, Australia
17:30
13
16:00-17:30
Hall F
Parallel Session
BEHAVIOURAL DISORDERS IN PD
Chairperson:
K. Kompoliti, Chicago, IL, USA
Abstract No
16:00
MOOD DISORDERS
L. Tan, Singapore, Singapore
1.14.1
16:20
COGNITIVE DEFICITS IN PARKINSON´S DISEASE: VARIABILITY,
EVOLUTION, AND EFFECT OF DOPAMINERGIC MEDIATION
O. Monchi, Montreal, QC, Canada
1.14.2
16:40
DOPAMINE DEPENDENCY AND PUNDING
M. Rabey, Tel Aviv, Israel
2.14.3
17:00
IMPULSE CONTROL DISORDERS
E. Tolosa, Barcelona, Spain
1.14.4
17:20
DISCUSSION
16:00-17:30
Hall G
TAUOPATHIES FROM BENCH TO BEDSIDE
Chairperson:
A. Albanese, Milano, Italy
Abstract No
16:00
CHAIR INTRODUCTION
16:20
CLINICAL CASE PRESENTATION
D. Waldvogel, Switzerland
16:55
Y. Pijnenburg1, D. Waldvogel2, 1Amsterdam, The Netherlands, 2Luzern,
Switzerland
17:30
2.15.1
14
17:45-19:15
Hall D
Sponsored Roundtable Discussion
ENHANCING SUCCESS IN IDENTIFYING TREATMENTS FOR PARKINSON'S DISEASE
Sponsored by GSK R&D China
Moderators:
X. Guan, GSK R & D Shanghai, China
D. Tattersall, GSK R & D Shanghai, China
17:45-19:15
翻译
Satellite Symposium
THE FUTURE OF PARKINSON’S DISEASE
Sponsored by Serono Symposia
17:55
PD IN EVOLUTION: PRODROME TO DEGENERATION
A.H.V. Schapira, London, UK
18:20
THE CONTRIBUTION OF DOPAMINERGIC AND NON-DOPAMINERGIC
PATHWAYS TO THE PATHOPHYSIOLOGY OF PD
E.Ch. Wolters1,2, 1Amsterdam, The Netherlands, 2Zurich, Switzerland
18:45
STEM CELLS AND GENE THERAPY IN PD: FUTURE DIRECTIONS
J.H. Kordower, Chicago, IL, USA
15
Hall F
Scientific Program
Tuesday, December 13, 2011
08:30-10:00
Hall A
Parallel Session
TREMOR REVISITED: PD TREMOR
Chairperson:
E. Louis, New York, NY, USA
Abstract No
08:30
PATHOPHYSIOLOGY OF PARKINSON'S DISEASE TREMOR
M. Hallett, Bethesda, MD, USA
2.1.1
08:50
PHENOTYPES OF PARKINSON'S DISEASE TREMOR
2.1.2
09:10
EPIDEMIOLOGY, DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS IN
PARKINON'S DISEASE TREMOR
C.R. Baumann, Zurich, Switzerland
2.1.3
09:30
TREATMENT OF PARKINSON'S DISEASE TREMOR
M. Castro Jiménez, F.J. Vingerhoets, Lausanne, Switzerland
2.1.4
09:50
DISCUSSION
08:30-10:00
Hall B
TREATMENT OF PD
Chairpersons:
J. Jia, China
X. Sun, China
Abstract No
08:30
GUIDELINES FOR PD TREATMENT IN CHINA
S. Sun, China
2.5.1
08:50
MEDICAL MANAGEMENT OF EARLY PARKINSON'S DISEASE
Z. Liu, M. Zhou, Shanghai, China
2.5.2
09:10
MEDICAL MANAGEMENT OF LATE STAGE OF PD
Q. Xiao, China
2.5.3
09:30
MEDICAL MANAGEMENT OF NON-MOTOR SYMPTOMS IN PD
M.-W. Wang, L. Meng, P. Gu, Y.-M. Li, Y. Geng, Shijiazhuang, China
2.5.4
09:50
DISCUSSION
10:00
17
08:30-10:00
Hall C
THERAPEUTIC STRATEGIES
Chairperson:
T. Nagatsu, Japan
Abstract No
08:30
08:36
USING ECOLOGICAL EVENT-BASED ACOUSTIC GUIDES TO CUE GAIT IN
W. Young, M. Rodger, C. Craig, Belfast, Ireland
2.357
EFFECT OF TETRAHYDROBIOPTERIN AND PHARMACOLOGICAL
CHAPERONES ON TYROSINE HYDROXYLASE; CORRECTION OF
NEUROTRANSMITTER DEFICIENCIES
M. Ying1, C.N. Sarkissian2, T. Scherer3, B. Thöny3, A. Martinez1, 1Bergen,
Norway, 2Montreal, QC, Canada, 3Zürich, Switzerland
2.237
08:42
EPIGALLOCAETECHIN GALLATE (EGCG) INHIBITS α-SYNUCLEIN
AGGREGATION: A POTENTIAL AGENT FOR PARKINSON DISEASE
Y. Zhang1, Y. Xu1, Y. Deng1, W. Wong2, P.L. McGeer2, H. Qing1, 1Beijing, China,
2
Vancouver, BC, Canada
2.206
08:48
CHEMICALLY MODIFIED PEPTIDES FOR INHIBITING α-SYNUCLEIN
AGGREGATION
F.M. Zhou, L. Zhang, Y. Peng, Y.-N. Liu, Changsha, China
2.210
08:54
SEROTONERGIC DRUGS IN THE TREATMENT OF PARKINSONISM:
STUDIES ON RAT MODEL
D.J. Haleem, F. Batool, E. Shireen, H. Ikram, A. Hasnat, M.A. Haleem, Karachi,
Pakistan
1.135
09:00
DEVELOPMENT OF INHALED APOMORPHINE FOR PATIENTS WITH
FLUCTUATING PARKINSON'S DISEASE: DOSE-FINDING RESULTS
D. Grosset1, K. Grosset1, F. Morgan2, Inhaled Apomorphine Study Group,
1
Glasgow, 2Chippenham, UK
2.271
09:06
ONE OUT OF TEN PATIENTS DISCONTINUE ANTI-PARKINSON TREATMENT
DUE TO NOCEBO ADVERSE EVENTS: A META-ANALYSIS OF 47
RANDOMIZED TRIALS
P. Stathis, M. Smpiliris, D.D. Mitsikostas, Athens, Greece
2.226
09:12
IMPULSE-CONTROL DISORDERS IN PARKINSON'S DISEASE PATIENTS
S. Perez-Lloret1, M.V. Rey1, N. Fabre1, F. Ory1, U. Spampinato2, J.-L.
Montastruc1, O. Rascol1, 1Toulouse, 2Bordeaux, France
09:18
LONG-TERM EXPOSURE TO TETRABENAZINE (TBZ) HAS NO ADVERSE OR
FAVORABLE IMPACT ON CHOREA AFTER IT IS WITHDRAWN
F.J. Marshall1, S. Eberly1, P. Auinger1, I. Shoulson2, S. Frank3, K. Biglan1, K.
Clarence-Smith2, E.R. Dorsey4, 1Rochester, NY, 2Washington, DC, 3Boston, MA,
4
Baltimore, MD, USA
1.255
09:24
A NEW TREATMENT ALGORITHM FOR TARDIVE DYSKINESIA OR
DYSTONIA
P.N. van Harten1,2, D.E. Tenback1,3, 1Amersfoort, 2Maastricht, 3Utrecht, The
Netherlands
18
2.284
2.289
08:30-10:00
Hall C
THERAPEUTIC STRATEGIES (CONTD.)
Abstract No
09:30
RELATIONSHIP BETWEEN POLYPHARMACY AND FREQUENCY OF ADVERSE
EVENTS TO ANTIPARKINSONIAN DRUGS: A PRELIMINARY STUDY
M.V. Rey1, S. Perez-Lloret1, U. Spampinato2, J.-L. Montastruc1, O. Rascol1, 1Toulouse,
2
Bordeaux, France
2.280
09:36
RELIEF OF PARKINSON´S DISEASE WITH AN ENDOSCOPIC SYMPATHETIC
BLOCK, 3 CASE REPORTS WITH A LONG-TERM FOLLOW-UP
T. Telaranta1,2, R. Oikarinen3, 1Oulu, 2Helsinki, 3Tampere, Finland
1.144
09:42
ADX48621, A MGLUR5 NEGATIVE ALLOSTERIC MODULATOR ALLEVIATES
L-DOPA-INDUCED CHOREA AND DYSTONIA IN THE MPTP MACAQUE
MODEL OF PARKINSON´S DISEASE
C. Keywood1, E. Bezard2, M. Hill2, Q. Li2, F. Girard1, S. Poli1, V. Mutel1, 1Plan les
Ouates, Switzerland, 2Manchester, UK
2.231
09:48
REMISSION OF L-DOPA RESPONSIVE PAIN IN PARKINSON'S DISEASE
AFTER SUBTHALAMIC DEEP BRAIN STIMULATION
O. Sueruecue, H. Vogel, M. Uhl, C.R. Baumann, Zurich, Switzerland
2.333
THE PUZZLE OF BOTULINUM TOXIN AND PAIN
Z. Lackovic, I. Matak, L. Bach-Rojecky, B. Filipovic, Z. Gagula, N. Durovic, I.
Stracenski, Zagreb, Croatia
3.310
09:54
08:30-10:00
Hall D
Chairperson:
R.F. Pfeiffer, USA
08:30
NON-MOTOR SIGNS AND SYMPTOMS
R.F. Pfeiffer, USA
09:00
PREMOTOR DIAGNOSIS
H. Kaufmann, USA
09:30
PREMOTOR (DISEASE MODIFYING) TREATMENT
F. Stocchi, Rome, Italy
10:00
19
08:30-10:00
Hall F
Parallel Session
CORTICAL DYSFUNCTION IN PD
Chairperson:
I. Bodis-Wollner, Brooklyn, NY, USA
Abstract No
08:30
PET STUDIES IN PARKINSON'S DISEASE MOTOR AND COGNITIVE
DYSFUNCTION
N. Pavese, London, UK
2.2.1
09:00
FRONTO-PARIETAL COHERENCE AND IMPAIRED VOLUNTARY SACCADES
IN PARKINSON'S DISEASE
I. Bodis-Wollner, M.A. Javaid, S. Glazman, Brooklyn, NY, USA
2.2.2
09:30
THE FRONTOSTRIATAL CIRCUITRY AND BEHAVIORAL COMPLICATIONS
IN PARKINSON'S DISEASE
A.P. Strafella, Toronto, ON, Canada
08:30-10:00
2.2.3
Hall G
HUNTINGTON’S DISEASE
Chairperson:
J.-M. Burgunder, Bern, Switzerland
Abstract No
08:30
NEW VIEWS ON HUNTINGTON'S DISEASE PHENOTYPE
J.-M. Burgunder, Bern, Switzerland
2.3.1
08:50
HUNTINGTON'S DISEASE IN CHINA
H. Shang, Chengdu, China
2.3.2
09:10
A GENOME-WIDE ANALYSIS IN THE EUROPEAN HD POPULATION
G.B. Landwehrmeyer, Germany
09:30
NEUROACANTHOCYTOSIS SYNDROMES AND OTHER HD-PHENOCOPIES
A. Danek, Munich, Germany
09:50
DISCUSSION
10:00
20
3.3.4
10:30-12:00
Hall A
Plenary Lecture
MARGARET HOEHN SYMPOSIUM: INITIATING TREATMENTS IN EARLY PD PATIENTS
Chairpersons:
W. Oertel, Germany
Abstract No
THERAPEUTIC STRATEGIES FOR NON-MOTOR SYMPTOMS IN EARLY
PARKINSON'S DISEASE
R. Bhidayasiri1,2, 1Bangkok, Thailand, 2Los Angeles, CA, USA
2.7.1
10:50
ALLIED HEALTH STRATEGIES (EXERCISE, CUES)
E. van Wegen, The Netherlands
2.7.2
11:10
PULSATILE OR CONTINUOUS DOPAMINOMIMETIC STRATEGIES
A. Antonini1, D. Calandrella2, 1Venice, 2Milan, Italy
2.7.3
11:30
ADULT AUTOLOGOUS STEM CELLS: POTENTIAL DISEASE-MODIFYING
STRATEGY FOR PARKINSON`S DISEASE
E. Melamed, Tel Aviv, Israel
2.7.4
10:30
11:50
12:00
DISCUSSION
Lunch Break, Poster Viewing & Visit Exhibition
21
12:30-14:00
Hall C
Forum
THE IRON STORY
Moderator:
[2.10.1]
P. Riederer, Wuerzburg, Germany
Discussants:
D. Berg, Tübingen, German
A. Friedman, Warszawa, Poland
H. Mochizuki, Japan
12:30-14:00
Hall D
Educational Symposium:
Chairperson:
12:30
NON-PHARMACOLOGICAL TREATMENT (MOTOR SYMPTOMS)
13:00
CONVENTIONAL PHARMACOLOGICAL TREATMENT (MOTOR SYMPTOMS)
W. Oertel, Germany
13:30
PHARMACOLOGICAL TREATMENT (NON-MOTOR SYMPTOMS)
22
12:30-14:00
翻译
Hall F
Satellite Symposium
WHAT IS THE VALUE OF DELAYING PROGRESSION IN PARKINSON’S DISEASE?
Sponsored by Lundbeck / Teva
Chairperson:
Z. Zhang, China
12:30
WHAT REALLY MATTERS IN EARLY AND ADVANCED PARKINSON'S
DISEASE
13:00
HOW MUCH CAN WE INFLUENCE CLINICAL PROGRESSION OF
PARKINSON'S DISEASE?
13:30
THE VALUE OF DELAYING CLINICAL PROGRESSION OF PARKINSON'S
DISEASE FROM A CLINICIAN, PATIENT, AND SOCIETAL PERSPECTIVE
12:30-14:00
Hall G
Forum
NEURO-REHABILITATION IN PD
Moderator:
[2.11.1]
S. Calne, Kamloops, BC, Canada
Discussants:
B. Bloem; Nijmegen, The Netherlands
N. Giladi, Israel
M.A. Hirsch, Charlotte, NC, USA
23
14:00-15:30
Hall A
Plenary Lecture
ANDRE BARBEAU SYMPOSIUM: STRIATAL PLASTICITY
Chairpersons:
Z. Yue, New York, NY, USA
J. Zhou, Shanghai, China
Abstract No
14:00
STRIATAL PLASTICITY IN PARKINSON´S DISEASE AND L-DOPA INDUCED
DYSKINESIA
P.G. Jenner, M. Iravani, A. McCreary, London, UK
2.12.1
14:20
THE SEROTONIN SYSTEM: A POTENTIAL TARGET FOR ANTI-DYSKINETIC
TREATMENTS AND BIOMARKER DISCOVERY
D. Rylander, Lund, Sweden
2.12.2
14:40
SEROTONERGIC MECHANISMS OF STRIATAL SYNAPTIC PLASTICITY
B.N. Mathur, D.M. Lovinger, Rockville, MD, USA
2.12.3
15:00
ENDOCANNABINOIDS IN STRIATAL PLASTICITY
D. Lovinger, C. Gremel, B. Mathur, Rockville, MD, USA
2.12.4
15:20
DISCUSSION
15:30
24
16:00-17:30
Hall A
Parallel Session
TREMOR REVISITED: ESSENTIAL TREMOR
Chairperson:
F.J. Vingerhoets, Lausanne, Switzerland
Abstract No
16:00
PATHOLOGY IN ESSENTIAL TREMOR
H. Shill1, C. Adler2, T. Beach1, 1Sun City, 2Scottsdale, AZ, USA
2.13.1
16:20
GENETICS OF ESSENTIAL TREMOR
B. Jasinska-Myga1, C. Wider2, 1Katowice, Poland, 2Lausanne, Switzerland
2.13.2
16:40
PHENOTYPES OF ESSENTIAL TREMOR
H.A.G. Teive, Curitiba, Brazil
2.13.3
17:00
TREATMENT OF ESSENTIAL TREMOR
E.D. Louis, New York, NY, USA
2.13.4
17:20
DISCUSSION
16:00-17:30
Hall B
RISK FACTORS FOR PD
Chairpersons:
S.-L. Ho, Hong Kong S.A.R.
Y.-P. Jiang, Shanghai, China
Abstract No
16:00
OCCUPATIONAL CHEMICAL EXPOSURES AND PARKINSON´S DISEASE
C.M. Tanner, Sunnyvale, CA, USA
2.17.1
16:20
INFLUENZA VIRUS AND PARKINSON´S DISEASE
S. Sadasivan, R.J. Smeyne, Memphis, TN, USA
2.17.2
16:40
TRICHLOROETHYLENE (TCE) EXPOSURE AND PARKINSON´S DISEASE
S.M. Goldman, Sunnyvale, CA, USA
2.17.3
17:00
ORGANOCHLORINE INSECTICIDES AND PARKINSON´S DISEASE
A. Elbaz, Paris, France
2.17.4
17:20
DISCUSSION
17:30
Short Break to Change Halls
25
16:00-17:30
Hall C
Parallel Session
NEURORESTORATION
Chairperson:
P. Jenner, London, UK
Abstract No
16:00
NEUROPROTECTIVE AND NEUROREGENERATIVE TROPHIC PROTEINS IN
PARKINSON'S DISEASE
B. Hoffer1, M. Airavaara2, M. Voutilainen2, 1Baltimore, MD, USA, 2Helsinki,
Finland
2.14.1
16:20
NEURORESTORATION BY PHYSICAL EXERCISE
M. Zigmond, USA
16:40
NEURORESTORATIVE, NEUROPROTECTIVE AND CELL CYCLE ARREST
ACTIVITY OF NOVEL MULTI TARGET DRUGS IN ANIMAL MODELS OF
PARKINSON’S DISEASE
M.B.H. Youdim1,2,3, 1Haifa, Israel, 2Seoul, Republic of Korea, 3Delaware, PA, USA2.14.3
17:00
TRADITIONAL CHINESE HERBAL MEDICINE AND ELECTROACUPUNCTURE
X. Wang, Beijing, China
17:20
2.14.2
2.14.4
DISCUSSION
16:00-17:30
Hall D
Chairperson:
P. Odin, Lund, Sweden
16:00
IATROGENIC COMPLICATIONS (DYSKINESIA, PUNDING)
16:30
IATROGENIC COMPLICATIONS (IMPULSE CONTROL DISORDERS)
R. Chaudhuri, UK
17:00
IATROGENIC COMPLICATIONS - RESTLESS LEGS, EXCESSIVE DAYTIME
SLEEPINESS, PSYCHOSIS
A. Friedman, Warszawa, Poland
26
16:00-17:30
Hall E
GENETICS AND ANIMAL MODELS
Chairperson:
P. Chan, Beijing, China
Abstract No
CANNABINOID CB2 RECEPTOR GENE EXPRESSION DIFFERENCES IN
PARKINSON'S DISEASE POST-MORTEM BRAIN SAMPLES AND
LYMPHOCYTES FROM RECENTLY DIAGNOSED AND NON-TREATED
PATIENTS
F. Navarrete1, J.A. Molina2, C. Leiva3, J. Manzanares1, 1San Juan de Alicante,
2
Madrid, 3Alicante, Spain
3.045
16:07
POLYGENIC DETERMINANTS OF PARKINSON'S DISEASE
J. Guo, L. Wang, X. Yan, B. Tang, Changsha, China
3.012
16:14
ANALYSIS OF SERUM MICRORNAS IN SCA3/MJD PATIENTS
Y.T. Shi, B. Tang, H. Jiang, ChangSha, China
3.061
16:21
THE ASSOCIATION BETWEEN LRRK2 S1647T POLYMORPHISM AND
COGNITIVE FUNCTION IN PARKINSON´S DISEASE
Y. Zheng, Q. Wu, Y. Fang, Y. He, H. Zhou, Y. Liu, J. Chen, W. Xian, X. Fu, C.
Shen, C. Guo, L. Chen, Z. Pei, Guangzhou, China
3.050
16:28
SEARCHING FOR MODIFIER GENES IN A GENOME-WIDE ASSOCIATION
STUDY OF LRRK2 G2019S CARRIERS
K. Nicodemus, Oxford, UK
3.046
16:35
ASSOCIATIONS BETWEEN GCH1 POLYMORPHISMS AND PRIMARY
DYSTONIA AND PARKINSON'S DISEASE IN AN AUSTRALIAN CASECONTROL SERIES
J.R.B. Newman1, G.T. Sutherland1, R. Boyle2, N. Limberg2, S. Blum2, J.
O'Sullivan2, P. Silburn2, G.D. Mellick1,2, 1Nathan, 2Brisbane, QLD, Australia
3.056
16:42
OXIDATIVE STRESS, α-SYNUCLEIN, AND EPIGENETIC AFFECTS IN THE
PARKINSONIAN BRAIN
A. Siddiqui, S. Chinta, I. Hansen, A. Rane, J. Andersen, Novato, CA, USA
3.137
EVALUATION OF TWO EXPERIMENTAL DESIGNS FOR LEVODOPAINDUCED DYSKINESIA IN A RAT MODEL OF PARKINSON'S DISEASE
E. Ivanova, I. Kapitsa, A. Nepoklonov, I. Kokshenev, Moscow, Russia
3.151
16:00
16:49
16:56
NURR1 DETERMINES THE PREFERENTIAL DEGENERATION OF MIDBRAIN
DOPAMINERGIC NEURONS IN A PARKINSON'S DISEASE MOUSE MODEL
X. Lin1,2, L. Parisiadou2, G. Liu2, J. Yu2, H. Cai2, 1Guangzhou, China, 2Bethesda,
MD, USA
3.141
27
16:00-17:30
Hall E
GENETICS AND ANIMAL MODELS (Contd.)
Abstract No
17:03
STRIATAL LONG-TERM DEPRESSION AND DOPAMINE SIGNALING
IMPAIRMENT IN A53T- α-SYNUCLEIN OVEREXPRESSING MICE
G. Auburger1, A. Kurz1, K.L. Double2, I. Lastres-Becker1, A. Tozzi3,4, M.
Tantucci3, V. Bockhart5, M. Bonin6, M. Garcia-Arencibia7, S. Nuber8, F.
Schlaudraff9, B. Liss9, J. Fernandez-Ruiz10, M. Gerlach11, U. Wuellner12, H.
Lueddens5, P. Calabresi3,13, S. Gispert1, 1Frankfurt/Main, Germany, 2Sydney,
NSW, Australia, 3Perugia, 4Roma, Italy, 5Mainz, 6Tübingen, Germany, 7Madrid,
Spain, 8Tuebingen, 9Ulm, 10Madrid, 11Wuerzburg, 12Bonn, Germany, 13Rome, Italy 3.119
17:10
INTRACELLULAR TRAFFICKING OF A53T MUTANT α-SYNUCLEIN
INVOLVED IN MICROGLIAL PERSISTENT ACTIVATION
Y.-W. Wu, Q. Yang, J.-Q. Ding, J. Liu, Shanghai, China
3.034
PRIMATE AND RODENT MODELS OF PARKINSON'S DISEASE BASED ON
VIRAL VECTOR MEDIATED OVEREXPRESSION OF α-SYNUCLEIN
J.B. Koprich, T. Johnston, P. Huot, J.M. Brotchie, Toronto, ON, Canada
3.118
17:17
16:00-17:30
Hall G
PSYCHOGENIC MOVEMENT DISORDERS
Chairperson:
Abstract No
16:00
CHAIR INTRODUCTION
16:20
K. Kompoliti, Chicago, IL, USA
16:55
P.S. Fishman, USA
17:30
2.15.1
Short Break to Change Halls
28
17:45-19:15
翻译
Hall F
Satellite Symposium
TARGETING UNMET NEEDS IN PARKINSON’S DISEASE: CONTINUOUS DOPAMINERGIC
STIMULATION (CDS) THERAPY
Sponsored by Abbott
Chairperson:
A. Antonini, Venice, Italy
17:45
TARGETING UNMET NEEDS IN PARKINSON'S DISEASE: CONTINUOUS
DOPAMINERGIC STIMULATION THERAPY
A. Antonini1,2, 1Venice, 2Padua, Italy
17:50
MILESTONES IN THE INTRODUCTION OF CONTINUOUS DOPAMINERGIC
STIMULATION THERAPY FOR ADVANCED PARKINSON'S DISEASE
M. Mouradian, Piscataway, NJ, USA
18:15
CONTINUOUS DOPAMINERGIC STIMULATION THERAPY WITH LEVODOPA
CARBIDOPA INTESTINAL GEL INFUSION: THE LATEST EVIDENCE
P. Odin1,2, 1Bremerhaven, Germany, 2Sweden, Sweden
18:40
THE VALUE OF CARE IN PARKINSON'S DISEASE
B. Bloem, Nijmegen, The Netherlands
19:05
CHAIR'S SUMMARY
29
Scientific Program
Wednesday, December 14, 2011
08:30-10:00
Hall C
ALTERNATIVE THERAPEUTICAL STRATEGIES
Chairpersons:
G. Peng, Chongqing, China
R. Yang, China
Abstract No
08:30
ACUPUNCTURE AND PARKINSON'S DISEASE
A. Liu, Jinan, China
3.5.1
08:50
HERBAL MEDICINE
D. Cai, China
3.5.2
09:10
TAI CHI AND PARKINSON´S DISEASE
Z.-F. Wang, Beijing, China
3.5.3
09:30
NEUROPROTECTION FROM NUTRIENTS IN NEURAL CULTURE
W. Rausch1, R. Moldzio1, K. Radad2, 1Vienna, Austria, 2Abha, Saudi Arabia
3.5.4
09:50
DISCUSSION
08:30-10:00
Hall D
Chairperson:
J. Volkmann, Germany
08:30
DEEP BRAIN STIMULATION
J. Volkmann, Germany
09:00
CONTINUOUS DOPAMINERGIC STIMULATION (APOMORPHINE, PATCHES)
09:30
CONTINUOUS DOPAMINERGIC STIMULATION (DUODOPA)
10:00
31
08:30-10:00
Hall E
NEUROPROTECTION AND BASIC NEUROSCIENCE
Chairperson:
B.S. Jeon, Seoul, Republic of Korea
Abstract No
08:30
FURTHER EVIDENCES OF EXERCISE-INDUCED NEUROPROTECTION IN 6OHDA-HEMIPARKINSONIAN MICE
A.S. Aguiar Jr1,2, G. Boemer1, M. Duzzioni1, R. Raisman-Vozari2, R.D. Prediger1,
1
Florianópolis, Brazil, 2Paris, France
3.264
08:36
SIMVASTATIN PREVENTS DOPAMINERGIC NEURODEGENERATION IN
EXPERIMENTAL PARKINSONIAN MODELS: THE ASSOCIATION WITH ANTIINFLAMMATORY RESPONSES
Q. Wang, J. Yan, Y. Xu, Guangzhou, China
3.201
08:42
NEUROPROTECTIVE ROLE OF 17Β-ESTRADIOL ADMINISTRATION ON
ALTERED AGE RELATED NEURONAL PARAMETERS IN FEMALE RATS
P. Kumar, R.K. Kale, N.Z. Baquer, New Delhi, India
08:48
INCREASING ENDOGENOUS NEUROGENESIS USING NEUROSTEROIDS: A
NOVEL THERAPEUTIC STRATEGY TO TREAT PARKINSON´S DISEASE
S. Adeosun1, X. Hou1, Y. Jiao2, B. Zheng1, P. Kyle1, I. Paul1, J. Farley1, C.
Stockmeier1, S. Bigler1, R. Smeyne2, J. Wang1, 1Jackson, MS, 2Memphis, TN,
USA
3.243
08:54
EFFECTS OF URATE OXIDASE TRANSGENE OR KNOCKOUT IN A MOUSE
MODEL OF PARKINSON'S DISEASE
X. Chen, T. Burdett, C. Desjardins, Y. Xu, M.A. Schwarzschild, Boston, MA, USA 3.245
09:00
BLOCKING DRP-1 FUNCTION IS NEUROPROTECTIVE IN ANIMAL MODELS
OF PARKINSON'S DISEASE
P. Rappold1, S. Lim1, M. Cui1, L. Chen2, W. Bowers1, X. Zhuang2, K. Tieu1,
1
Rochester, NY, 2Chicago, IL, USA
3.246
09:06
PLASTICITY INDUCTION BY PAIRING SUBTHALAMIC NUCLEUS DEEP
BRAIN STIMULATION AND MOTOR CORTICAL TRANSCRANIAL MAGNETIC
STIMULATION IN PARKINSON'S DISEASE
K. Udupa, N. Bahl, C. Gunraj, F. Mazzella, E. Moro, M. Hodaie, A. Lozano, A.
Lang, R. Chen, Toronto, ON, Canada
2.297
09:12
G. Yaxing, J. Liu, S.D. Chen, Shanghai, China
1.131
09:18
A NOVEL SUBSTRATE OF PINK1 IMPLICATED IN THE AUTOPHAGY AND
APOPTOSIS PATHWAYS
G. Arena, V. Gelmetti, L. Torosantucci, D. Vignone, E.M. Valente, Rome, Italy
3.024
09:24
ACTIVATED MICROGLIAL FACILITATE IRON-INDUCED SELECTIVE AND
PROGRESSIVE DOPAMINERGIC NEURODEGENERATION
Z. Yan, J. Gao, L. Sun, Z. Liu, X. Huang, C. Cao, B. Li, L. Zhang, W. Zhang, X.
Wang, Beijing, China
3.347
32
3.250
08:30-10:00
Hall E
NEUROPROTECTION AND BASIC NEUROSCIENCE (CONTD.)
Abstract No
09:30
CYTOKINES ASSOCIATED WITH PARKINSON'S DISEASE
Y. Huang, G. Halliday, Sydney, NSW, Australia
3.301
09:36
CHEMICALS POSSESSING A NEUROTROPHIN-LIKE ACTIVITY ON
DOPAMINERGIC NEURONS IN PRIMARY CULTURE
R. Raisman-Vozari1, F. Schmidt2, P. Champy2, B. Seon-Meniel2, X. Franck2, G.
Le Douaron2, B. Figadère2, 1Paris, 2Châtenay-Malabry, France
3.231
09:42
α-SYNUCLEIN NEUROPATHOLOGY IS CONTROLLED BY NUCLEAR
RECEPTORS AND ENHANCED BY DOCOSAHEXANOIC ACID IN A MOUSE
MODEL FOR PARKINSON'S DISEASE
E. Yakunin, V. Loeb, H. Kisos, R. Sharon, Jerusalem, Israel
3.305
09:48
DIFFERENTIAL REGULATION OF NMDA RECEPTOR FUNCTION BY DJ-1
AND PINK1
Q. Wan, N. Chang, Reno, NV, USA
3.032
09:54
MICROGLIAL NOX2: A POTENTIAL TARGET OF IRON-INDUCED
DOPAMINERGIC NEURODEGENERATION
J. Gao1, Z. Yan1, Z. Liu1, L. Sun1, C. Cao1, X. Huang1, L. Zhang1, B. Li1,
W. Zhang1, X. Wang1, J.-S. Hong2, 1Beijing, China, 2Research Triangle Park,
NC, USA
3.355
08:30-10:00
Hall F
Parallel Session
DYSTONIA
Chairperson:
D. Dressler, Germany
Abstract No
08:30
OVERVIEW OF PRIMARY MONOGENIC DYSTONIA
M. Spatola, C. Wider, Lausanne, Switzerland
3.1.1
08:50
DYSTONIA: PHENOMENOLOGY
M.S. LeDoux, Memphis, TN, USA
3.1.2
09:10
PHARMACOLOGICAL TREATMENT FOR DYSTONIA
Y. Baba, Fukuoka, Japan
3.1.3
09:30
SUBTHALAMIC NUCLEUS STIMULATION FOR PRIMARY DYSTONIA AND
TARDIVE DYSKINESIA: LONG-TERM FOLLOW UP RESULTS
B. Sun, D. Li, S. Zhan, J. Zhang, Shanghai, China
3.1.4
09:50
10:00
DISCUSSION
33
08:30-10:00
Hall G
MYOCLONUS
Chairperson:
J. Carr, Cape Town, South Africa
Abstract No
08:30
CHAIR INTRODUCTION
J. Carr, Cape Town, South Africa
08:50
J.N. Caviness, Scottsdale, AZ, USA
09:25
E. Roze, Paris, France
3.3.1
08:30-10:00
Hall H
Parallel Session
HOT TOPICS IN DBS
Chairperson:
A.L. Benabid, Grenoble, France
Abstract No
08:30
WHICH DBS TARGET: GPI, STN, OR PPN?
K. Follett, D. Torres-Russotto, Omaha, NE, USA
3.2.1
08:50
DBS: COGNITIVE AND BEHAVIOURAL SIDE EFFECTS
K. Witt, Kiel, Germany
3.2.2
09:10
DBS: CHALLENGING NEW STRUCTURAL TARGETS
3.2.3
09:30
CHALLENGING NEW CLINICAL APPLICATIONS
L. Chen, Shanghai, China
3.2.4
09:50
DISCUSSION
10:00
34
10:30-12:00
Hall F
Plenary Lecture
DAVID MARSDEN SYMPOSIUM: THE QUEST FOR THE IDEAL PD ANIMAL MODEL
Chairpersons:
M.B.H. Youdim, Haifa, Israel
P. Chan, Beijing, China
Abstract No
GENETIC REDUCTION OF THE E3 UBIQUITIN LIGASE ELEMENT, SKP1A
AND ENVIRONMENTAL MANIPULATION TO EMULATE CARDINAL
FEATURES OF PARKINSON´S DISEASE
S.A. Mandel, T. Fishman-Jacob, M.B.H. Youdim, Haifa, Israel
3.7.1
GENETIC LRRK2 MODELS: DISSECTING PATHOGENIC PATHWAY AND
EXPLORING CLINICAL APPLICATIONS IN PD
Z. Yue, New York, NY, USA
3.7.2
11:10
ANIMAL MODELS OF PD
S. Przedborski, New York, NY, USA
3.7.3
11:30
ANIMAL MODELS FOR LRRK2 PATHOGENESIS
C. Li, New York, NY, USA
3.7.4
11:50
DISCUSSION
10:30
10:50
12:00
Lunch Break, Poster Viewing, Visit the Exhibition
35
12:30-14:00
Hall C
Forum
NEW TARGETS IN DBS
Moderator:
[1.2.4]
A.L. Benabid, Grenoble, France
Discussants:
J. Zhang, Beijing, China
H. Sharma, Uppsala, Sweden
12:30-14:00
Hall D
Chairperson:
12:30
MULTIPLE SYSTEM ATROPHY
H. Reichmann, Fetscherstraße, Germany
13:00
PSP
B. Boeve, USA
13:30
TREMOR
12:30-14:00
Hall F
Forum
WHAT ARE THE PITFALLS IN CLINICAL TRIALS
Moderator:
A.D. Korczyn, Tel Aviv, Israel
Discussants:
M. Rabey, Tel Aviv, Israel
R. Rodnitzky, Iowa City, IA, USA
36
[3.12.1]
12:30-14:00
Hall G
ASIAN MOVEMENT DISORDERS
Chairperson:
R. Kaji, Tokushima, Japan
Abstract No
THE NEURODEGENERATIONS: GENOMICS FROM A PERPLEXED
CLINICIAN
G. Stern, London, UK
3.9.1
12:50
ALS-PARKINSONISM-DEMENTIA COMPLEX OF KII AND OTHER RELATED
DISEASES IN JAPAN
R. Kaji, Tokushima, Jordan
3.9.2
13:10
HUNTINGTON´S DISEASE AND NEUROACANTHOCYTOSIS SYNDROMES
H. Shang, Chengdu, China
3.9.3
13:30
DYSTONIA, WILSON'S DISEASE
M. Bhatt, India
3.9.4
13:50
DISCUSSION
12:30
37
14:00-15:30
Hall F
Plenary Lecture
XIN-DE WANG SYMPOSIUM: IS PRE-MOTOR DIAGNOSIS POSSIBLE?
Chairpersons:
H. Kaufmann, USA
Abstract No
14:00
THE EUROPEAN EXPERIENCE
D. Berg, Tübingen, Germany
3.13.1
14:20
THE HONOLULU-ASIA EXPERIENCE
W. Ross, Honolulu, HI, USA
3.13.2
14:40
THE CHINA EXPERIENCE
P. Chan, Parkinson Study Group of China, Beijing, China
3.13.3
15:00
THE ARIZONA EXPERIENCE
3.13.4
15:20
DISCUSSION
15:30
38
16:00-17:30
Hall C
RELATED DISORDERS
Chairpersons:
W. Rausch, Vienna, Austria
H. Wang, China
Abstract No
16:00
WILSON'S DISEASE
X.-L. Liang1, X.-H. Li1, R. Chen2, 1Guangzhou, China, 2Urbana, IL, USA
3.18.1
16:20
HUNTINGTON DISEASE
Y. Dong1, Y.M. Sun1, Z.-Y. Wu2, 1Shanghai, 2Shaghai, China
4.18.2
16:40
PAROXYSMAL MOVEMENT DISORDERS
C.-F. Liu, Suzhou, China
3.18.3
17:00
MULTIPLE SYSTEM ATROPHY - ADVANCES IN IMAGES
H. Chen, Beijing, China
3.18.4
17:20
DISCUSSION
16:00-17:30
Hall D
Chairperson:
J. Caviness, Scottsdale, AZ, USA
16:00
MYOCLONUS, CHOREA, BALLISMUS, TICS
16:30
DYSTONIA
R.L. Rosales, Manila, Philippines
17:00
PSYCHOGENIC MOVEMENT DISORDERS
B. Bloem, Nijmegen, The Netherlands
39
16:00-17:30
Hall E
BREAKING NEWS & HOT TOPICS
Chairperson:
S. Chen, China
Abstract No
OLFACTION AND PROFILE OF WEIGHT CHANGE IN PARKINSON'S
DISEASE: IDENTIFYING A PHENOTYPE
J.C. Sharma1, J. Turton2, 1Lincoln, 2Newark, UK
1.037
16:05
SIGNIFICANCE OF BODY WEIGHT IN PARKINSON'S DISEASE RELATIONSHIP WITH DYSKINESIA
J.C. Sharma, Lincoln, UK
1.042
16:10
LEWY PATHOLOGY IS NOT THE FIRST SIGN OF DEGENERATION IN
SELECTIVELY VULNERABLE NEURONS IN PARKINSON´S DISEASE
J.M. Milber1, J.V. Noorigan1, J.F. Morley1, H. Petrovitch2, L. White2, G.W. Ross2,
J.E. Duda1, 1Philadelphia, PA, 2Honolulu, HI, USA
3.348
16:20
STAGE-DEPENDENT DOPAMINERGIC CELL LOSS IN THE SUBSTANTIA
NIGRA DURING PARKINSON'S DISEASE
A. Dijkstra, P. Voorn, H.J. Groenewegen, P. Heutink, A.J. Rozemuller, W.D.J.
van de Berg, Amsterdam, The Netherlands
3.356
16:30
ASSESSMENT OF FINE MOTOR CONTROL IN PARKINSON´S DISEASE
WITH THE NEUROSKILLTM ANALYSIS OF HANDWRITING DYNAMICS
R. Shrairman1, C.F. O'Brien2, A. Landau1, 1Boulder, CO, 2San Diego, CA, USA
2.109
16:00
16:40
HUMAN α-SYNUCLEIN FIBRILS INDUCE α-SYNUCLEIN AGGREGATION IN
VITRO AND BEHAVIORAL ALTERATIONS IN VIVO UPON INOCULATION IN
WILDTYPE MICE
A.H.N. Tran1, N.T.T. Le1, F. Moda2, Z. Paolo1, F. Tagliavini2, S. Gustincich1, G.
Legname1, 1Trieste, 2Milan, Italy
3.361
16:50
M1 MACHRS IN BASAL GANGLIA AND IMPLICATIONS FOR TREATMENT
Z. Xiang, A.D. Thompson, C.K. Jones, C.W. Lindsley, P.J. Conn, Nashville, TN,
USA
3.362
17:00
STUDY OF GLYCOSAMINOGLYCANS IN PARKINSON´S DISEASE AND
THEIR IMPLICATIONS IN GDNF INDUCED PLASTICITY IN VITRO
M.O. Ouidja1, M.B. Huynh1, S. Lehri-Boufala1, C. Morin1, G. Zhang1,2, E.C.
Hirsch3, R. Raisman-Vozari3, D. Papy-Garcia1, 1Créteil, France, 2Beijing, China,
3
Paris, France
3.227
40
16:00-17:30
Hall E
Platform Abstract Presentations:
BREAKING NEWS & HOT TOPICS (CONTD.)
Abstract No
17:10
A LARGE RANDOMISED TRIAL ASSESSING QUALITY OF LIFE IN PATIENTS
WITH EARLY PD: RESULTS FROM PD MED EARLY
R. Gray1, S. Patel1, N. Ives1, C. Rick1, C. Jenkinson2, K. Wheatley1, A. Williams1,
C.E. Clarke1, PD MED Collaborators, 1Birmingham, 2Oxford, UK
1.091
17:20
WITH LATER PD: RESULTS FROM PD MED LATER
C.E. Clarke1, S. Patel1, N. Ives1, C. Rick1, C. Jenkinson2, K. Wheatley1, A.
Williams1, R. Gray1, PD MED Collaborators, 1Birmingham, 2Oxford, UK
1.092
16:00-17:30
Hall F
Parallel Session
ROLE OF NEUROINFLAMMATION IN THE PATHOGENESIS OF PD
Chairperson:
J. Ding, China
Abstract No
16:00
MICROGLIA AND NEUROINFLAMMATION IN PD
S. Przedborski, New York, NY, USA
3.14.1
16:20
NEURO-INFLAMMATION AND PD
E.C. Hirsch, Paris, France
3.14.2
16:40
EPIDEMIOLOGICAL EVIDENCE ON INFLAMMATION, NSAIDS USE, AND
PARKINSON'S DISEASE
H. Chen, RTP, USA
17:00
IMMUNIZATION STRATEGIES IN PD
H. Gendelman, R.L. Mosley, Omaha, NE, USA
17:20
DISCUSSION
41
3.14.4
16:00-17:30
Hall G
DYSTONIA
Chairperson:
D.D. Truong, USA
16:00
CHAIR INTRODUCTION
D.D. Truong, USA
16:20
D. Dressler, Germany
16:55
X.H. Wan, Beijing, China
16:00-17:30
Hall H
Parallel Session
PAIN AND FATIGUE IN PD
Chairperson:
C.R. Baumann, Zurich, Switzerland
Abstract No
16:00
EPIDEMIOLOGY AND PHENOMENOLOGY
Z. Zhang, China
3.15.1
16:20
PATHOPHYSIOLOGY OF PARKINSON'S DISEASE
A. Berardelli, Roma, Italy
3.15.2
16:40
CLINICAL RATING SCALES
M. Relja, Zagreb, Croatia
3.15.3
17:00
CLINICAL MANAGEMENT
3.15.4
17:20
DISCUSSION
42
Posters
Key:
All presentations marked with this symbol are Platform Abstract
Presentations
Abstract No. – Numbers indicated are abstract numbers which appear
in the Abstract CD-Rom and Online Supplement of the
Journal Parkinsonism and Related Disorders
08:00-18:00
Poster Area
Poster session
Parkinsonism
Board No
Abstract No
1
MEDICO LEGAL ASPECTS OF PARKINSON'S DISEASE
R.Y.P. Babu, K. Kishan, S. Raghavendra, Mangalore, India
2
FACILITATING CLINICAL RESEARCH: THE NATIONAL INSTITUTE OF
NEUROLOGICAL DISORDERS AND STROKE PARKINSON'S DISEASE
COMMON DATA ELEMENTS PROJECT
C.M. Tanner1, K. Kieburtz2, W. Galpern3, M. Delong4, D. Dickson5, J.J. Elm6,
T. Faroud7, C. Kamp2, A.E. Lang8, K. Marder9, K. Marek10, R. Pfeiffer11,
G.W. Ross12, A. Siderowf13, D. Weintraub13, NINDS PD CDE Working Group,
1
Sunnyvale, CA, 2Rochester, NY, 3Bethesda, MD, 4Atlanta, GA, 5Jacksonville, FL,
6
Charleston, SC, 7Indianapolis, IN, USA, 8Toronto, ON, Canada, 9New York, NY,
10
New Haven, CT, 11Memphis, TN, 12Honolulu, HI, 13Philadelphia, PA, USA
1.003
3
HETEROGENEITY OF PARKINSON´S DISEASE
K. Kracunova, P. Valkovic, J. Benetin, Bratislava, Slovak Republic
1.004
4
CLINICAL HETEROGENEITY IN PATIENTS WITH EARLY-STAGE
PARKINSON'S DISEASE: A CLUSTER ANALYSIS T. Feng, P. Liu, Y. Wang,
X. Zhang, B. Chen, Beijing, China
1.005
ANALYSIS OF AGE OF ONSET AND EPIDEMIOLOGICAL FACTORS IN
PARKINSONS DISEASE
A.A. Ravan, C.S. Sankhla, M. Gadhari, Mumbai, India
1.007
6
NIGRAL IRON DEPOSITION OCCURS ACROSS MOTOR PHENOTYPIC
EXPRESSIONS OF PARKINSON'S DISEASE
L. Jin, J. Wang, H. Jin, G. Fei, Y. Zhang, W. Chen, L. Zhao, N. Zhao, X. Sun,
M. Zeng, C. Zhong, Shanghai, China
1.009
7
THE RELATIONSHIP BETWEEN SIDE OF MOTOR SYMPTOM ONSET AND
CLINICAL SEVERITY OF DISEASE IN PARKINSON'S DISEASE
D. Aygun, M. Onar, Samsun, Turkey
1.010
8
CIRCULATING VITAMIN D LEVELS, VITAMIN D BINDING PROTEIN GENE
POLYMORPHISMS, AND SEVERITY OF PARKINSON'S DISEASE
M. Noya, M. Suzuki, M. Yoshioka, M. Hashimoto, M. Murakami, K. Kawasaki,
D. Takahashi, M. Urashima, Tokyo, Japan
1.011
9
CLINICAL SCENARIO OF PATIENTS WITH PARKINSONISM: A MONGOLIAN
STUDY
T. Sosorburam1, B. Baterdene2, 1Wuhan, China, 2Ulan Bator, Mongolia
1.012
10
PARKINSONISM IN GHANA: OBJECTIVES, CLINICAL AND GENETICS
FINDINGS FROM A 3-YEAR INTERNATIONAL PROJECT
R. Cilia1, A. Akpalu2, M. Cham3, F.S. Sarfo4, A. Bonetti1, M. Fabbri5, M. Amboni6,7,
G. Pezzoli1, 1Milan, Italy, 2Accra, 3Sogakofe, 4Kumasi, Ghana, 5Bologna, 6Salerno,
7
Napoli, Italy
1.013
5
43
1.002
08:00-18:00
Poster Area
Monday,
December
Poster
Session
Parkinsonism (Contd.)
08:00-18:00
Board No
11
12
12, 2011
Poster Area
Abstract No
Poster
SessionPRESENTING WITH PARKINSON´S DISEASE: CLINICAL
PATIENTS
Parkinsonism
SCENARIO (Contd.)
IN PAKISTAN AND SOUTH EAST ASIAN COUNTRIES
1
T. Hussain
, A. Ali1, M.A. Awan2, 1Islamabad, 2Rawalpindi, Pakistan
Board
No
DISEASE
IN THE WITH
YOUNG:
A REPORT OF
FOUR CASES
IN A
11 PARKINSON
PATIENTS
PRESENTING
PARKINSON´S
DISEASE:
CLINICAL
TEACHING
HOSPITAL
IN SOUTHERN
NIGERIA
SCENARIO
IN PAKISTAN
AND SOUTH
EAST ASIAN COUNTRIES
B.C. Ekeh,
Uyo, 1Nigeria
T. Hussain
, A. Ali1, M.A. Awan2, 1Islamabad, 2Rawalpindi, Pakistan
1.014 No
Abstract
1.0151.014
13
ANALYSIS
OF SPEECH
DYSRHYTHMIA
IN PARKINSON
DISEASE
12 ACOUSTIC
PARKINSON
DISEASE
IN THE YOUNG:
A REPORT
OF FOUR CASES
IN A
PATIENTS
TEACHING HOSPITAL IN SOUTHERN NIGERIA
R. Podemski,
S. Uyo,
Budrewicz,
1.0161.015
B.C. Ekeh,
NigeriaK. Slotwinski, M. Koszewicz, Wroclaw, Poland
14
ABILITY
AFFECTED
AND RELATED
TO MOTOR
SKILLS IN DISEASE
13 LANGUAGE
ACOUSTIC
ANALYSIS
OF SPEECH
DYSRHYTHMIA
IN PARKINSON
PARKINSON'S
PATIENTSDISEASE - A PRELIMINARY REPORT
L. Liu,
Luo, Y.S.
Ren,
Z.-X. Ren,
Z.-Y. He, Shenyang,
ChinaWroclaw, Poland 1.0171.016
R.X.-G.
Podemski,
Budrewicz,
K. Slotwinski,
M. Koszewicz,
15
IN ELBOW JOINT
IS MOST PRONOUNCED
IN DISTAL
14 PARKINSONIAN
LANGUAGERIGIDITY
ABILITY AFFECTED
AND RELATED
TO MOTOR SKILLS
IN
PHASE
OF EXTENSION
PARKINSON'S
DISEASE
- A3 PRELIMINARY
REPORT
1
2
2
1
4
T. Endo
, T. X.-G.
Hamasaki
, R.Ren,
Okuno
Yokoe
H. Fujimura
, K.China
Akazawa ,
L. Liu,
Luo, Y.
Z.-X., M.
Ren,
Z.-Y., He,
Shenyang,
1.017
S. Sakoda1, 1Toyonaka, 2Suita, 3Neyagawa, 4Osaka, Japan
1.018
15
PARKINSONIAN RIGIDITY IN ELBOW JOINT IS MOST PRONOUNCED IN DISTAL
DOPAMINE
AND NON-RESPONSIVE GAIT PARAMETERS IN
PHASERESPONSIVE
OF EXTENSION
PARKINSON´S
DISEASE
T. Endo1, T.
Hamasaki2, R. Okuno3, M. Yokoe2, H. Fujimura1, K. Akazawa4,
1 1
2
3
4
W. Martin,
M. Wieler,
C. Cooke,
Edmonton,
AB, Canada
1.0191.018
S. Sakoda
, Toyonaka,
Suita,
Neyagawa,
Osaka, Japan
16
17
18
ABNORMALITIES
PARKINSON´S
DISEASE:
A DESCRIPTIVE
16 POSTURAL
DOPAMINE
RESPONSIVEIN
AND
NON-RESPONSIVE
GAIT
PARAMETERS IN
STUDY
M. Peralta,
D.
Barzola,
M.
Perez
Akly,
R.
Diaz,
F.
Alvarez,
M.M.
Esnaola,
Caba,
W. Martin, M. Wieler, C. Cooke, Edmonton, AB, Canada
1.019
Argentina
1.020
17
POSTURAL ABNORMALITIES IN PARKINSON´S DISEASE: A DESCRIPTIVE
POSTURAL
STUDY ABNORMALITY IN PARKINSON'S DISEASE IS A RISK FACTOR
FOR M.
LEG
DEEP D.
VEIN
THROMBOSIS
Peralta,
Barzola,
M. Perez Akly, R. Diaz, F. Alvarez, M.M. Esnaola, Caba,
K. Yamane,
F. Kimura, Osaka, Japan
1.0211.020
Argentina
19
AMBULATORY
PROFILE
(FAP) GAIT DISEASE
CHANGESISDURING
18 FUNCTIONAL
POSTURAL
ABNORMALITY
IN PARKINSON'S
A RISK FACTOR
INCREASED
COGNITIVE
IN PARKINSON DISEASE
FOR LEG
DEEP VEINLOAD
THROMBOSIS
L.L. LaPointe,
C.G.
Maitland,Osaka,
J.A.G. Japan
Stierwalt, Tallahassee, FL, USA
1.0221.021
K. Yamane,
F. Kimura,
20
STEPPING
RESPONSES
ON A (FAP)
MOVING
PLATFORM
19 PROTECTIVE
FUNCTIONAL
AMBULATORY
PROFILE
GAIT
CHANGESINDURING
PARKINSON'S
DISEASE
(PD) LOAD IN PARKINSON DISEASE
INCREASED
COGNITIVE
P.-Y. L.L.
Lee,LaPointe,
M.J. Naushahi,
N. Pavese,
P.G.Stierwalt,
Bain, D. Tallahassee,
Nandi, A.M. Bronstein,
C.G. Maitland,
J.A.G.
FL, USA
1.022
London, UK
1.023
20
PROTECTIVE STEPPING RESPONSES ON A MOVING PLATFORM IN
A COMPARISON
OFDISEASE
CLINICAL(PD)
AND OBJECTIVE MEASURES OF
PARKINSON'S
FREEZING
OF GAIT
P.-Y.1 Lee,
M.J. 1Naushahi,2 N. Pavese,
P.G. Bain, D. Nandi, A.M. Bronstein,
S. Moore
, T. UK
Morris , J. Shine , S. Lewis2, 1New York, NY, USA,
London,
1.023
2
Sydney, NSW, Australia
1.024
21
A COMPARISON OF CLINICAL AND OBJECTIVE MEASURES OF
QUANTATIVE
OF GAIT USING PORTABLE GAIT
FREEZINGASSESSMENT
OF GAIT
1 ON MUSIC
1 THERAPY
2
2 1
RHYMOGRAM
FOR PARKINSON'S
DISEASE
S. Moore
, T. Morris
1
2 1, J. Shine 2, S. Lewis , New York, NY, USA,
2
A. Hayashi
, H.NSW,
Mitoma
, Urayasu, Tokyo, Japan
1.0251.024
Sydney,
Australia
21
22
22
QUANTATIVE ASSESSMENT OF GAIT USING PORTABLE GAIT
44
RHYMOGRAM ON MUSIC THERAPY
FOR PARKINSON'S DISEASE
A. Hayashi1, H. Mitoma2, 1Urayasu, 2Tokyo, Japan
44
1.025
08:00-18:00
Poster Area
Poster Session
Board No
23
VESTIBULAR EVOKED MYOGENIC POTENTIALS IN OLDER PEOPLE WITH
G.-H. Lee, Cheon-An, Republic of Korea
1.027
24
CLINICAL STUDY OF NON-MOTOR SYMPTOMS IN PARKINSON DISEASE
M. Ye, W.G. Liu, Nanjing, China
25
ANALYSIS OF NON-MOTOR SYMPTOMS OF PARKINSON´S DISEASE
L. Meng, Y.M. Li, W.G. Liu, J.H. Guo, P. Gu, M.W. Wang, Shi JIa Zhuang, China 1.029
26
EVALUATION OF NON MOTOR SYMPTOMS IN PARKINSON'S PATIENTS IN
A TERTIARY CARE CENTRE
A.A. Ravan, C.S. Sankhla, S. Chhabria, M. Gadhari, Mumbai, India
1.030
27
THE IMPACT OF NON-MOTOR SYMPTOMS ON QUALITY OF LIFE OF
H.S. Kim, J.W. Seo, H.J. Ryu, S.M. Cheon, J.W. Kim, Busan, Republic of Korea 1.031
28
NON-MOTOR SYMPTOMS AND QUALITY OF LIFE IN PATIENTS WITH
PARKINSON'S DISEASE
D. Joshi, P. Chatterjee, B. Kumar, A.Z. Ansari, V.N. Mishra, R.N. Chaurasia,
B. Kumar, T. Desai, Varanasi, India
1.028
1.032
29
THE IMPACT OF NON-MOTOR SYMPTOMS ON HEALTH-RELATED QUALITY
OF LIFE IN PATIENTS WITH ATYPICAL PARKINSONISM
C.-N. Lee, S.-B. Koh, B.-J. Kim, K.-W. Park, M.J. Kim, Seoul, Republic of Korea 1.033
30
NON MOTOR SYMPTOMS IN TURKISH PATIENTS WITH PARKINSON'S
DISEASE
A. Koksal, D.H. Ertem, A. Sen, S. Baybas, Istanbul, Turkey
1.034
AUTONOMIC SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE: A
CLINICAL INVESTIGATION
C. Cao, Beijing, China
1.035
31
32
HEART RATE VARIABILITY IN PATIENTS WITH IDIOPATHIC PARKINSON'S
DISEASE WITH AND WITHOUT OBSTRUCTIVE SLEEP APNEA SYNDROME
P.O. Valko, S. Hauser, E. Werth, D. Waldvogel, C.R. Baumann, Zurich,
Switzerland
1.036
33
OLFACTION AND PROFILE OF WEIGHT CHANGE IN PARKINSON'S
DISEASE: IDENTIFYING A PHENOTYPE
J.C. Sharma1, J. Turton2, 1Lincoln, 2Newark, UK
1.037
ANALYSIS OF FACTORS CORRELATED TO CONSTIPATION IN PATIENTS
WITH PARKINSON'S DISEASE
H. Tan, C. Chen, Z. Wu, M. Shao, Guangzhou, China
1.038
GASTROINTESTINAL DYSFUNCTION IN PARKINSON'S DISEASE:
ASSOCIATION WITH SEVERITY AND DISABILITY
K.S. Anand, K. Singh, A. Rajoria, R. Verma, Delhi, India
1.039
34
35
45
08:00-18:00
Poster Area
Poster Session
Board No
36
Abstract No
DIETARY HABITS AND ANTHROPOMETRIC PARAMETERS IN AFRICAN
M. Barichella, G. Privitera, E. Cassani, L. Iorio, E. Cereda, R. Cilia, A. Bonetti,
G. Pezzoli, Milan, Italy
1.040
37
A PATIENT PRESENTING WITH ACUTE COLONIC PSEUDO-OBSTRUCTION
AS A COMPLICATION OF PARKINSON'S DISEASE
N. Nikhil Sharma, A.R. Pinto, West Bromwich, UK
1.041
38
SIGNIFICANCE OF BODY WEIGHT IN PARKINSON'S DISEASE RELATIONSHIP WITH DYSKINESIA
J.C. Sharma, Lincoln, UK
1.042
ANALYSIS OF SAWLOWING SOUNDS THROUGH SONAR DOPPLER IN
PATIENTS WITH PARKINSONS DISEASE
R.S. Santos, E.M. Abdulmasshi, B.S. Zeigeilboim, H. Teive, Curitiba, Brazil
1.043
40
PRIMARY PAIN SYNDROMES IN PATIENTS WITH PARKINSON'S DISEASE
A.V. Alekseev, M.R. Nodel, N.N. Yakhno, E.V. Podchufarova, Moscow, Russia
1.044
41
EVALUATION OF REACTION TIME IN PARKINSON DISEASE
A. Herranz, M. Losada, S. Bellido, M.A. Aranda, P.J. García, Madrid, Spain
1.045
42
CLINICAL CORRELATES OF APATHY IN EARLY PARKINSON DISEASE:
THE ANIMO STUDY
E. Cubo1, J. Benito-León2, C. Coronell3, D. Armesto1, Animo Study Group,
1
Burgos, 2Madrid, 3Barcelona, Spain
1.046
NEW OBJECTIVE APATHY SCALE FOR PARKINSON'S DISEASE
A. Kumon1, E. Kaneko1, F. Saito2, M. Kato2, S. Matsunaga3, N. Kawashima3,
K. Hasegawa1, 1Sagamihara, 2Tokyo, 3Fujisawa, Japan
1.047
FATIGUE IS NOT AN INDEPENDENT PREDICTOR OF MORTALITY IN
PARKINSON'S DISEASE
M. Skorvanek1, J. Rosenberger1, I. Rajnicova1, J. van Dijk2, J. Groothoff2,
Z. Gdovinova1, 1Kosice, Slovak Republic, 2Groningen, The Netherlands
1.048
CORRELATION BETWEEN CLINICAL CHARACTERISTICS AND SLEEP
DISTURBANCES IN PARKINSON'S DISEASE
Y.-H. Sung, D.J. Shin, Y.-B. Lee, H.-M. Park, Incheon, Republic of Korea
1.049
46
SLEEP DISORDERS IN PATIENTS WITH PARKINSON'S DISEASE
I. Krasakov, I.V. Litvinenko, O.V. Tichomirova, Saint-Petersburg, Russia
1.050
47
INSOMNIA IS LINKED MORE TO AFFECTIVE THAN MOTOR SYMPTOMS IN
Z. Tavadyan, Yerevan, Armenia
1.051
48
SLEEP DISORDERS IN DIFFERENT CLINICAL SUBGROUPS OF
PARKINSON'S DISEASE
L. Fan, C. Dan, L.X. Guang, R. Yan, Shenyang, China
39
43
44
45
46
1.052
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
49
STUDY ON OBJECTIVE SLEEP DISTURBANCE IN PARKINSON'S DISEASE
K.-P. Xiong, J. Li, C.-J. Mao, S.-S. Shen, Q. Tang, J.-Y. Huang, M.-Y. Zhao,
F. Han, R. Chen, C.-F. Liu, Suzhou, China
1.053
50
SLEEP, SLEEPINESS AND VIGILANCE IN DOPAMINE- AND HYPOCRETIN
DEFICIENT DISORDERSV
M. Wienecke1, E. Werth2, M. Weller2, R. Poryazova2, H. Vogel2, C.L. Bassetti2,
D. Waldvogel2, A. Storch1, C.R. Baumann2, 1Dresden, Germany, 2Zurich,
Switzerland
1.054
51
A STUDY OF CLINICAL VARIABLES IN PARKINSON'S DISEASE AFFECTING
SLEEP QUALITY
R. Verma, K.S. Anand, S. Mina, Delhi, India
1.055
52
SLEEP DESTRUCTURATION IN EARLY EXECUTIVE DYSFUNCTIONS: A
VIRTUAL AND NEUROPSYCHOLOGICAL STUDY IN PARKINSON'S DISEASE
G. Albani1, L. Priano1, P. Cipresso2, R. Pignatti1, G. Riva2, A. Mauro1,
1
Verbania-Piancavallo, 2Milan, Italy
1.056
53
NOCTURNAL DISTURBANCES IN PARKINSON'S DISEASE: A VALIDATION
STUDY OF PARKINSON'S DISEASE SLEEP SCALE-2 JAPANESE VERSION
K. Suzuki1, M. Miyamoto1, M. Tatsumoto1, T. Miyamoto2, Y. Watanabe1,
S. Suzuki1, M. Iwanami2, T. Sada1, T. Kadowaki1, C. Trenkwalder3, K. Hirata1,
1
Tochigi, 2Saitama, Japan, 3Kassel, Germany
1.057
54
THE RELATIONSHIP BETWEEN FATIGUE AND SLEEP DISORDERS IN
X. Zhang, T. Feng, P. Liu, Beijing, China
1.058
55
THE RELATIONSHIP BETWEEN DISRUPTED SLEEP AND COGNITIVE
DYSFUNCTION IN PARKINSON´S DISEASE: A SYSTEMATIC REVIEW
M. Kroczek, A.M. Loftus, R.S. Bucks, Perth, WA, Australia
1.059
56
SLEEP REGULATORY CENTRES DYSFUNCTION IN PARKINSON'S DISEASE
PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS. AN IN VIVO PET
STUDY
N. Pavese, V. Metta, B.S. Simpson, T.A. Marphy, A. Ramlackhansingh,
K.R. Chaudhuri, D.J. Brooks, London, UK
1.060
57
ASSOCIATION BETWEEN FATIGUE AND DEPRESSION IN PARKINSON'S
DISEASE
C.-J. Mao, D.-H. Li, L.-D. Cao, Q. Tang, C.-F. Liu, K.-P. Xiong, Suzhou, China
1.061
MOOD AND BEHAVIOURAL EVALUATION IN PARKINSON´S
DISEASE - VALIDATION OF A NEW SCALE
I. Rieu1, I. Chéreau1, C. Ardouin2, B. Pereira1, I. De Chazeron1, F. Tison3,
O. Rascol4, L. Defebvre5, M. Schüpbach6, J.L. Houeto7, P. Krack2, F. Durif1,
1
Clermont-Ferrand, 2Grenoble, 3Bordeaux, 4Toulouse, 5Lille, 6Paris, 7Poitiers,
France
1.062
58
47
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
59
FEATURES OF EXPRESSIVE - AND - IMPRESSIVE ASPECT OF EMOTIONAL
SPHERE AMONG PATIENTS WITH PARKINSONISM IN ARAL SEA REGION,
UZBEKISTAN
D. Izyumov1, G. Izyumova2, 1Tashkent, 2Urgench, Uzbekistan
1.063
60
THE ROLE OF THE OLFACTORY BULB DA NEURONS ON DEPRESSION IN
PARKINSON'S DISEASE
C.-H. Wang, J. Chao, X.-R. Zhu, H.-H. Yuan, D.-S. Gao, Xuzhou, China
1.064
61
PREVALENCE AND CLINICAL CORRELATES OF ANXIETY IN PARKINSON'S
DISEASE
T. Yamanishi, H. Tachibana, M. Oguru, K. Kawabata, D. Danno, T. Oku,
M. Hashimoto, K. Matsui, K. Matsubara, N. Murata, Nishinomiya, Japan
1.065
62
INVESTIGATION ON THE RELATIONSHIP BETWEEN ANXIETY AND THE MOTOR
SYMPTOMS OR NON-MOTOR SYMPTOMS IN PATIENTS WITH PARKINSON'S
DISEASE
Z. Liu, X. Huang, L. Sun, C. Cao, S. Yu, L. Zuo, W. Zhang, Beijing, China
1.066
63
NEUROPSYCHOLOGICAL PROFILE OF PATIENTS WITH IDIOPATHIC
PARKINSON'S DISEASE
P. Chatterjee, D. Joshi, B. Kumar, A.Z. Ansari, V.N. Mishra, R.N. Chaurasia,
B. Kumar, T. Desai, Varanasi, India
1.067
64
BEHAVIORAL CHANGES IN PARKINSON´S DISEASE
M. Petrovic1, E. Stefanova2, V. Kostic2, 1Kragujevac, 2Belgrade, Serbia
1.068
65
SELF ASSESSMENT SCALE FOR DOPAMINE DEPENDENT BEHAVIOURS IN
PARKINSON'S DISEASE
E. Schmitt1, I. Rieu2, I. Chéreau2, A. Juphard1, B. Pereira2, I. De Chazeron2,
F. Tison3, O. Rascol4, L. Defebvre5, M. Schüpbach6, J.L. Houeto7, F. Durif2,
P. Krack1, 1Grenoble, 2Clermont-Ferrand, 3Bordeaux, 4Toulouse, 5Lille,
6
Paris, 7Poitiers, France
1.069
66
INCIDENCE AND CHARACTERISTICS OF DEPRESSION IN PARKINSON´S
DISEASE
S. Telarovic, I. Telarovic, Zagreb, Croatia
67
1.071
THE SLOVAKIA ASSISTED LIVING STUDY: PREVALENCE, RECOGNITION AND
TREATMENT OF DEMENTIA, PARKINSONISM AND DEPRESSION IN THE
ASSISTED LIVING POPULATION
S. Sutovsky, K. Klobucnikova, V. Volarikova, P. Turcani, Bratislava, Slovak Republic
1.072
68
ACUTE DOPAMINERGIC DEPLETION IN HEALTHY SUBJECTS IMPAIRS
EXECUTIVE CONTROL
C. Ramdani-Beauvir, F. Vidal, L. Carbonnell, T. Hasbroucq, Marseille, France
48
1.073
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
69
THE PATTERN OF CORTICAL ATROPHY IN PARKINSON'S DISEASE WITH MILD
COGNITIVE IMPAIRMENT ACCORDING TO THE TIMING OF COGNITIVE
DYSFUNCTION
P.H. Lee, Y.H. Sohn, J.E. Lee, K.H. Cho, M. Kim, Seoul, Republic of Korea
1.074
70
DOES NEUROINFLAMMATION AFFECT THE DEVELOPMENT OF DEMENTIA IN
PATIENTS WITH PARKINSON´S DISEASE?
I.-U. Song1, Y.-D. Kim1, K.-S. Lee2, 1Incheon, 2Seoul, Republic of Korea
1.075
71
PREDISPOSING FACTORS FOR COGNITIVE IMPAIRMENT IN PARKINSON'S
DISEASE: ASSESSMENT OF 67 PATIENTS
G.S. Dahani1, M. Al-Hakami1, A. Dahani2, Z. Waheed1, B. Hameed1,
1
Khamis Mushayt, Saudi Arabia, 2Karachi, Pakistan
1.076
72
CORRELATION RESEARCH ON THE MEMORY MONITORING AND
EPISODIC MEMORY IN PARKINSON'S PATIENTS
X. Lv, Hefei, China
73
THE CLINICAL CHARACTER OF COGNITIVE DYSFUNCTION IN PARKINSON'
DISEASE PATIENTS
C. Chen, M. Shao, H. Tan, Guangzhou, China
1.078
74
PREDICTORS FOR COGNITIVE DECLINE IN CHINESE PATIENTS WITH
PARKINSON'S DISEASE
V. Mok1, Y. Wong2, A. Chan1, J. Yeung1, M. Au-Yeung1, N. Cheung1, J. Chan1,
K.K. Lau1, P.W. Ng1, C. Lau1, L.K.S. Wong1, 1Hong Kong, China, 2Nijmegen,
Netherlands Antilles
1.079
OCCIPITAL LOBE AND POSTERIOR CINGULATE METABOLIC CHANGES
OCCUR IN PARKINSON'S DISEASE WITH THE MILD COGNITIVE
IMPAIRMENT
K. Nie, Y.H. Zhang, B. Huang, L. Wang, J. Zhao, Z. Huang, R. Gan, L.J. Wang,
Guangzhou, China
1.080
75
1.077
76
CORRELATION BETWEEN SEVERITY OF COGNITIVE DEFICIT AND MOTOR
SYMPTOMS IN PATIENTS WITH PARKINSON`S DISEASE
S. Butkovic-Soldo, S. Tomic, M. Vladetic, K. Solic, S. Misevic,
T. Mirosevic-Zubonja, Osijek, Croatia
1.081
77
CLINICAL FEATURES OF PARKINSON´S DISEASE DEMENTIA
Z. Adwan, Homs, Syria
1.082
78
VALIDATION OF THE MONTREAL COGNITIVE ASSESSMENT (MOCA) IN
DETECTING COGNITIVE IMPAIRMENT IN SINGAPOREAN PARKINSON
DISEASE PATIENTS - PILOT DATA
E.C.H. Lim1, L. Yeo1, W.I. Koay1, W.Y. Lee1, J.A. Catindig1, S. Collinson1,
Y. Dong1,2, 1Singapore, Singapore, 2Sydney, NSW, Australia
1.083
49
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
79
VALIDATION OF THE BEIJING VERSION OF THE MONTREAL COGNITIVE
ASSESSMENT (BJ-MOCA) FOR PARKINSON´S DISEASE: RESULTS FROM
A CHINESE PILOT STUDY
K. Nie, Y. Zhang, R. Gan, L. Wang, J. Zhao, Z. Huang, L. Wang, Guangzhou,
China
1.084
80
THE COGNITIVE FUNCTION OF DEMENTIA WITH LEWY BODIES,
ACCOMPANIED WITH VISUAL HALLUCINATION
H. Le, N. Yuping, S. Haishan, L. Xinni, Z. Xiaomei, Guangzhou, China
1.085
81
PATTERN OF PSYCHOSIS IN PARKINSON'S DISEASE
R. Yadav, B.R. Amar, Y.C.J. Reddy, P.K. Pal, Bangalore, India
1.086
82
A COMMON NON MOTOR SYMPTOMS OF PARKINSON´S DISEASE PSYCHOSIS
L. Meng, N. Liu, Y.M. Li, X.Z. Kong, M.W. Wang, Shi JIa Zhuang, China
1.087
83
PREVALENCE AND RISK FACTORS OF HALLUCINATION IN PATIENTS
WITH PARKINSON´S DISEASE
R. Zhang, T. Feng, Beijing, China
1.088
84
VISUAL INFORMATION PROCESSINGS ARE SELECTIVELY IMPAIRED
FROM THE EARLY STAGE OF COGNITIVE DECLINE IN HALLUCINATORY
PATIENTS WITH LEWY BODY DISEASE
A. Kurita1, M. Suzuki2, M. Murakami2, S. Takagi2, 1Kashiwa, 2Tokyo, Japan
1.089
85
HALLUCINATIONS IN DRUG-NAÏVE, NEWLY-DIAGNOSED PARKINSON'S
DISEASE
J. Pagonabarraga, S. Martinez-Horta, R. Fernández-Bobadilla, C. Villa,
R. Ribosa, B. Pascual-Sedano, J. Kulisevsky, Barcelona, Spain
1.090
86
WITH EARLY PD: RESULTS FROM PD MED EARLY
R. Gray1, S. Patel1, N. Ives1, C. Rick1, C. Jenkinson2, K. Wheatley1, A. Williams1,
1.091
C.E. Clarke1, PD MED Collaborators, 1Birmingham, 2Oxford, UK
87
WITH LATER PD: RESULTS FROM PD MED LATER
C.E. Clarke1, S. Patel1, N. Ives1, C. Rick1, C. Jenkinson2, K. Wheatley1,
A. Williams1, R. Gray1, PD MED Collaborators, 1Birmingham, 2Oxford, UK
1.092
88
CORRELATION BETWEEN NON MOTOR SYMPTOMS, UNIFIED
PARKINSON´S DISEASE RATING SCALE SCORE AND QUALITY OF LIFE
V. Vuletic, B. Nevajda, A. Havelka Mestrovic, S. Basic, Zagreb, Croatia
89
1.093
THE PREVALENCE OF NON MOTOR SYMPTOMS AND RESTLESS LEGS
SYNDROME IN PARKINSON'S DISEASE: CORRELATION WITH QUALITY OF
LIFE
K.A. Abdul Manaf, W.N.N. Wan Yahya, H.J. Tan, R. Azman Ali, H. Othman,
S. Azhar, N. Mohd Ibrahim, Cheras, Malaysia
1.094
50
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
90
METABOLIC CHANGES INDUCED BY THETA BURST STIMULATION OF THE
CEREBELLUM IN DYSKINETIC PARKINSON´S DISEASE PATIENTS
G. Koch1, L. Brusa1, R. Ceravolo2, L. Kiferle2, O. Schillaci1, P. Stanzione1,
1
Rome, 2Pisa, Italy
1.095
91
THE RELATIONSHIP BETWEEN JOINT CONFIGURATION AND HAPTIC
SENSITIVITY IN PATIENTS WITH PARKINSON'S DISEASE
P.-Y. Chu1, K.-Y. Li1, K. Pickett2, 1Taoyuan County, Taiwan, 2St. Louis, MO, USA 1.096
92
NEUROPSYCHOGICAL AND NEUROANATOMIC BASES DIFFER BETWEEN
PARKINSON'S DISEASE WITH STABLE MCI AND MCI TO DEMENTIA
CONVERTER
J.E. Lee, J.-S. Kim, H.J. Kim, Y.H. Sohn, P.H. Lee, Seoul, Republic of Korea
1.097
93
WELLBEING OF SPOUSES OF PATIENTS WITH PARKINSON´S DISEASE
EXHIBITING IMPULSE CONTROL DISORDERS
S.F. Lerman1, E. Kozlova1, M. Soffer2, H. Strauss1, F. Wertenauer3,
O.S. Cohen1,4, S. Hassin-Baer1,4, 1Tel Hashomer, 2Haifa, Israel,
3
Berlin, Germany, 4Tel Aviv, Israel
1.098
THE IMPACT OF EMOTIONAL DISORDERS AND COGNITIVE IMPAIRMENT
ON THE QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASE
X. Huang, Beijing, China
1.099
94
95
DEMENTIA, NONMOTOR SYMPTOMS AND HEALTH-RELATED QUALITY OF
LIFE IN PATIENTS WITH PARKINSON'S DISEASE
M.-Y. Eun, M.J. Kim, H.M. Lee, J.-W. Jang, J. Kim, C.N. Lee, D.Y. Kwon,
S.-B. Koh, Seoul, Republic of Korea
1.100
96
FACTORS ASSOCIATED WITH FUNCTIONAL PERFORMANCE IN ELDERLY
PEOPLE WITH PARKINSON´S DISEASE
L.A. Leandro, R.P. Munhoz, H.A.G. Teive, Curitiba, Brazil
1.102
97
THE COMBINATION OF HOMOCYSTEINE AND C-REACTIVE PROTEIN
PREDICTS THE OUTCOMES OF CHINESE PATIENTS WITH PARKINSON'S
DISEASE AND VASCULAR PARKINSONISM
Q. Wang, Guangzhou, China
1.103
98
ANTIBODIES AGAINST GM1, GD1B AND GQ1B IN PATIENTS WITH
PARKINSON'S DISEASE
E. Hatzifilippou, M. Arnaoutoglou, E. Koutsouraki, V. Costa, S. Baloyannis,
Thessaloníki, Greece
1.104
SUSCEPTIBILITY TO COMPRESSION NEUROPATHY IN PARKINSON'S
DISEASE
S. Yilmaz, A.B. Tokcaer, Ankara, Turkey
1.105
ASSOCIATION OF ESSENTIAL TREMOR AND PARKINSON'S DISEASE IN
FAMILIES: A CLINICAL INVESTIGATION LINKING THE TWO
R. Hanna AL-Shaikh, S. Fujioka, A. Strongosky, O. Ross, Z. Wszolek,
Jacksonville, FL, USA
1.106
99
100
51
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
101
PARKINSON`S DISEASE AND MYASTHENIA GRAVIS
J. Martinkova, P. Špalek, J. Benetin, Bratislava, Slovak Republic
102
DEEP STUDY: A LARGE EPIDEMIOLOGICAL SURVEY ABOUT WEARING
OFF IN PARKINSON DISEASE
F. Stocchi1, G. Abbruzzese2, P. Barone3, V. Posocco4, D. Colombo4, A. Antonini5,
on behalf of DEEP Study Group, 1Rome, 2Genoa, 3Salerno, 4Varese, 5Venice,
Italy
1.108
103
MYOTONOMETRY REVEALED MEDICATION-INDUCED DECREASE IN
RESTING MUSCLE STIFFNESS IN PARKINSON'S DISEASE
J. Marusiak, A. Jaskólska, M. Koszewicz, S. Budrewicz, A. Jaskólski, Wroclaw,
Poland
1.109
104
ASSESSING HYPERSEXUALITY IN PARKINSON'S DISEASE: VALIDATION
OF A SCREENING INSTRUMENT
I. de Chazeron, B. Pereira, P.-M. Llorca, P. Derost, F. Durif, Clermont-Ferrand,
France
1.110
105
CLINICAL AND NEUROPSYCHOLOGICAL CHARACTERIZATION OF
PATIENTS WITH PARKINSON'S DISEASE AND DOPAMINE
DYSREGULATION SYNDROME
R. Cilia, C. Siri, M. Canesi, D. De Gaspari, A.L. Zecchinelli, N. Meucci, M. Zini,
C. Ruffmann, I.U. Isaias, C.B. Mariani, S. Tesei, G. Sacilotto, G. Pezzoli, Milan,
Italy
1.111
1.107
106
INCREASED MEDIAL ORBITOFRONTAL DOPAMINE FUNCTION IN
PARKINSON´S DISEASE PATIENTS WITH IMPULSE CONTROL DISORDERS
J. Joutsa, K. Martikainen, S. Niemelä, S. Forsbacka, J.O. Rinne, V. Kaasinen,
Turku, Finland
1.112
107
PATHOLOGICAL GAMBLING AND RISK FOR IMPULSE CONTROL
DISORDERS IN PARKINSON'S DISEASE: A COMMUNITY BASED STUDY
J. Joutsa1, K.K. Martikainen1, T. Vahlberg1, V. Voon2, V. Kaasinen1, 1Turku,
Finland, 2Cambridge, UK
1.113
108
VISUALLY-DEPENDENT, DIRECTIONAL EEG CONNECTIVITY CHANGES IN
PARKINSON'S DISEASE AT REST
G. Tropini1,2, J. Chiang1, Z.J. Wang1, M.J. McKeown1, 1Vancouver, BC, 2Toronto,
ON, Canada
1.114
109
DECREASED MOTOR CORTICAL INHIBITION AND INCREASED
FACILITATION IN PARKINSON´S DISEASE
Z. Ni, N. Bahl, C. Gunraj, F. Mazzella, R. Chen, Toronto, ON, Canada
110
TRACE METALS IN PATIENTS WITH PARKINSON'S DISEASE: A
MULTI-CENTER CASE-CONTROL STUDY IN NIGERIAN PATIENTS
O.A. Ogunrin1, E.O. Sanya2, M.A. Komolafe3, C.C. Osubor1, 1Benin City, 2Ilorin,
3
Ile Ife, Nigeria
1.116
52
1.115
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
111
ENDOTOXIN AND RISK OF PARKINSONISM AMONG WOMEN TEXTILE
WORKERS IN SHANGHAI, CHINA: STUDY DESIGN AND ENROLLMENT
PROGRESS
X. Wang1, W. Fan1, J. Ding1, L.R. Jin1, J. Hu1, W. Li2, S.-C. Hu2, C. Tanner3,
J. Zhang2, S.A. Lipton4, D.L. Gao1, R.M. Ray2, D.B. Thomas2, H. Checkoway2,
1
Shanghai, China, 2Seattle, WA, 3Sunnyvale, 4La Jolla, CA, USA
112
RISKS OF PARKINSON DISEASE IN PATIENTS WITH AUTOIMMUNE
DISORDERS: A NATION-WIDE EPIDEMIOLOGICAL STUDY FROM SWEDEN
X. Li1, J. Sundquist1,2, K. Sundquist1, 1Malmo, Sweden, 2San Francisco, CA, USA 1.118
113
THE ASSOCIATION BETWEEN PARKINSON DISEASE AND FACTORS
REFLECTING ENDOGENOUS ESTROGEN ACTIVITY IN WOMEN
R. Chen1, B. Zhang1, B. Ouyang2, S. Wang1, 1Tianjin, China, 2Chicago, IL, USA
1.119
A PROSPECTIVE STUDY OF STATIN USE AND RISK OF PARKINSON
DISEASE
X. Gao, K. Simon, M.A. Schwarzschild, A. Ascherio, Boston, MA, USA
1.120
CNS INFECTIONS, SEPSIS, AND RISK OF PARKINSON DISEASE
H. Chen1, F. Fang2, K. Wirdefeldt2, A. Jacks3, F. Kamel1, W. Ye2,
1
RTP, NC, USA, 2Stockholm, Sweden, 3Helsinki, Finland
1.121
116
GSK-3B EXPRESSION IN CEREBROSPINAL FLUID IN PARKINSON´S
DISEASE
J.A. Molina-Arjona, A. Sanchez-Ferro, D. Antequera, F. Bermejo-Pareja,
E. Carro, Madrid, Spain
1.122
117
NEUROTRANSMITTERS-MEDIATING ENZYME - DOPAMINE-βHYDROXYLASE AND ITS COFACTORS IN THE SERUM OF BANGLADESHI
PATIENTS WITH PARKINSON´S DISEASE, MENTAL RETARDATION AND
ARSENICOSIS
M.K. Rahman, Dhaka, Bangladesh
1.123
DISTRIBUTION OF MICROGLIA IN THE POSTNATAL MURINE
NIGROSTRIATAL SYSTEM
A. Sharaf, K. Krieglstein, B. Spittau, Freiburg, Germany
1.124
114
115
118
1.117
119
STOCHASTIC RESONANCE IN THE FIRING PATTERNS OF SUBTHALAMIC
NUCLEUS NEURONS
Y. Wang, W.-N. Xue, Z.-Q. Yan, S.-M. He, J.-L. Zhu, G.-D. Gao, Xi'an, China
1.125
120
MEMBRANE RESONANCE IN SUBTHALAMIC NUCLEUS NEURONS
Y. Zhi-qiang, G. Guo-Dong, Z. Jun-Ling, X. Wei-ning, W. Yuan, Xi'an, China
1.126
121
THE DYNAMIC OF FUNCTIONAL INTERHEMISPHERIC ASYMMETRY IN
M. Bykanova, N. Pizova, Yaroslavl, Russia
1.127
53
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
122
DIFFERENTIAL MITOCHONDRIAL PROTEIN EXPRESSION WITHIN SINGLE
GLYCINERGIC NEURONS OF THE PEDUNCULOPONTINE NUCLEUS OF
I.S. Pienaar, C. Morris, D. Burn, C. Racca, G. Nelson, D. Turnbull, Newcastle
upon Tyne, UK
1.128
123
THE MECHANISM OF SYNERGISTIC ACTIVATION OF PI3K/AKT SIGNAL
PATHWAY IN INJURED DOPAMINERGIC NEURONS
M. Wang, Z. Shi, H. Chen, F. Chen, L. Wang, L. Li, Y. Liu, D. Qi, D. Gao,
Xuzhou, China
124
INVERSE RELATIONSHIP BETWEEN THE CONTENTS OF NEUROMELANIN
PIGMENT AND THE VESICULAR MONOAMINE TRANSPORTER-2 AMONG
SUBSTANTIA NIGRA AND VENTERAL TEGMENTAL AREA
P. Pasbakhsh1, D.C. German2, N. Omidi1, 1Tehran, Iran, 2Dallas, TX, USA
1.130
125
G. Yaxing, J. Liu, S.D. Chen, Shanghai, China
1.131
126
TYROSINE HYDROXYLASE INTERACTING WITH PHOSPHOLIPID
MEMBRANES: A MOLECULAR DYNAMICS STUDY
Å.A. Skjevik, Ø. Halskau, Jr., M. Ying, A. Martinez, K. Teigen, Bergen, Norway
1.132
127
INVESTIGATING THE ROLE OF OLIGODENDROCYTE PRECURSOR CELLS
IN MULTIPLE SYSTEM ATROPHY AND RELATED DISORDERS
Y. Asi, Z. Ahmed, A.J. Lees, T. Revesz, J.L. Holton, London, UK
1.133
128
THE EFFECTS OF URIC ACID ON NEURONAL DIFFERENTIATED PC12
CELLS AGAINST THE TOXICITY INDUCED BY ROTENONE
L. Zheng, W. Luo, Q. Zhang, J. Liu, Suzhou, China
1.134
129
THE TREATMENT EFFECTS OF HUMAN α-SYNUCLEIN DNA VACCINE IN
CHRONIC ROTENONE MOUSE OF PARKINSON'S DISEASE
Y. Xu, Chongqing, China
1.135
130
THE RESEARCH OF POTENTIAL ROLE OF KIR6.2 ON MECHANISM AND
TREATMENT OF PARKINSON'S DISEASE
X.K. Liu, G. Wang, S.D. Chen, Shanghai, China
1.136
131
COMPARISON OF ENDOTHELIAL PROGENITOR CELLS IN PARKINSON´S
DISEASE PATIENTS TREATED WITH LEVODOPA AND LEVODOPA/COMT
INHIBITOR
P.H. Lee, J.E. Lee, Y.H. Sohn, H.-S. Kim, Y. Choi, H.O. Kim, J.Y. Hong,
H.S. Nam, Seoul, Republic of Korea
1.137
PRO-INFLAMMATORY CYTOKINES INCREASE IRON INFLUX AND
DECREASE IRON EFFLUX OF VENTRAL MESENCEPHALIC NEURONS
J. Wang, J. Wang, N. Song, J.X. Xie, Qingdao, China
1.138
132
54
1.129
08:00-18:00
Poster Area
Poster Session
Board No
133
ANTI-PARKINSONIAN EFFECTS OF ADX48621 A MGLUR5 NEGATIVE
ALLOSTERIC MODULATOR (NAM), IN THE RAT HALOPERIDOL INDUCED
CATALEPSY MODEL
C. Keywood, F. Girard, S. Poli, V. Mutel, Plan les Ouates, Switzerland
1.139
134
ANTI OXIDANT AND ANTI CATALEPTIC ACTIVITY OF SMILAX ZEYLANICA
LINN
R.A. Shaik, R. Ahemad, S. Venkataraman, K.N. Jayaveera, Hyderabad, India
1.140
135
SEROTONERGIC DRUGS IN THE TREATMENT OF PARKINSONISM:
STUDIES ON RAT MODEL
D.J. Haleem, F. Batool, E. Shireen, H. Ikram, A. Hasnat, M.A. Haleem, Karachi,
Pakistan
1.141
136
COST ANALYSIS OF THE TREATMENTS FOR PATIENTS WITH
COMPLICATED PARKINSON´S DISEASE: SCOPE STUDY
F. Valldeoriola1, J. Puig-Junoy1, R. Puig-Peiró1,2, P. González3, Workgroup of the
SCOPE Study, 1Barcelona, Spain, 2London, UK, 3Madrid, Spain
1.142
137
DEVELOPMENT OF A TIME-RESOLVED FRET IMMUNOASSAY FOR αSYNUCLEIN QUANTIFICATION SUITABLE FOR CLINICAL SAMPLE
ANALYSIS AND HIGH-THROUGHPUT TRANSLATIONAL RESEARCH
M. Bidinosti1, D. Shimshek1, M. Schlossmacher2, A. Weiss1, 1Basel,
Switzerland, 2Ottawa, ON, Canada
1.143
PARKINSON SUMMER SCHOOL III, WARSAW JULY 2011
M. Maliia1, P.D. Roos2, 1Bucharest, Romania, 2Jönköping, Sweden
1.144
138
55
08:00-18:00
Poster Area
Poster Session
Related Disorders
Board No
Abstract No
CLINICAL FEATURES AND DIFFERENTIATION OF ATYPICAL
PARKINSONIAN SYNDROMES
L. Chen, B. Zhang, Tianjin, China
1.201
COGNITIVE IMPAIRMENT IN CEREBELLAR TYPE MULTIPLE SYSTEM
ATROPHY
M.-S. Lee1, J.H. Kim2, 1Seoul, 2Gwangju, Republic of Korea
1.202
141
CORRELATION OF MIDBRAIN ATROPHY WITH QUANTITATIVE BALANCE
IMPAIRMENT IN PROGRESSIVE SUPRANUCLEAR PALSY
P. Pal, S.A. Pasha, M. Sandhya, R. Yadav, J. Saini, B.S. Bagepally, A. Gupta,
Bangalore, India
1.203
142
PILOT COMPARATIVE STUDY IN PSP AND FTD OF THE EFFECTS OF
NEUROFEEDBACK IN COGNITIVE SYMPTOMS
T. Hergueta, N. Gunther-Cohen, A. Guignebert, A.M. Bonnet, F. Bloch,
I. Wargon, I. Leber, Paris, France
1.204
143
COEXISTENCE OF ALS/ET/PD AND ALS/ET/MSA IN TWO DIFFERENT
FAMILIES
X. He1, Y. Xu2, 1Nanning, 2Chengdu, China
1.205
144
UPDATE IN THE CLINICAL PRESENTATION AND NATURAL HISTORY OF
DCB AND PSP PATIENTS
F. Bloch, A.M. Bonnet, C. Chamayou, T. Hergueta, C. Pointon, V. Mourlon,
I. Leber, B. Dubois, Paris, France
1.206
139
140
145
CLINICAL PAIN AND EXPERIMENTAL PAIN SENSITIVITY IN PROGRESSIVE
SUPRANUCLEAR PALSY
M. Stamelou1,2, H. Dohmann2, J. Brebemann2, G. Hoeglinger2, W. Oertel2,
C. Moeller2, V. Mylius2, 1London, UK, 2Marburg, Germany
1.208
146
MOOD DISORDERS AND SEXUAL DYSFUNCTION IN RESTLESS LEGS
SYNDROME
N. Cinar, T. Okluoglu, S. Sahin, S. Karsidag, Istanbul, Turkey
1.209
THE SHARE OF VASCULAR PARKINSONISM (VP) IN PATIENTS WITH
STROKE
R. Aliyev, Baku, Azerbaijan
1.210
DEPRESSION IN THE ELDERLY ASSOCIATED TO VASCULAR
PARKINSONISM: A CASE REPORT
C. Soler1, S. Arques1, A. Zafra1, T. Rubio1, A. Gonzalez2, 1Valencia,
2
Alzira, Spain
1.211
RISK INDEX OF INFARCT STROKE BASED ON MODIFIABLE RISK
FACTORS
S. Martini, K. Kuntoro, Surabaya, Indonesia
1.212
DELAYED APPEARANCE OF VASCULAR PARKINSONISM SIX YEARS
AFTER A PUTAMINAL INFARCTION
T.-B. Ahn, Seoul, Republic of Korea
1.213
147
148
149
150
56
08:00-18:00
Poster Area
Poster Session
Related Disorders (Contd.)
Board No
Abstract No
THROMBOEMBOLIC RISK AND THERAPY IN A PATIENT WITH
L. Thomas, Scranton, PA, USA
1.214
FREEZING OF GAIT IN PATIENTS WITH WHITE MATTER CHANGES IS
RELATED WITH WIDE DISRUPTION OF WHITE MATTER
J. Youn, J.W. Cho, H. Shin, J. Kim, Seoul, Republic of Korea
1.215
MOYAMOYA DISEASE INITIALLY MANIFESTING AS VASCULAR
PARKINSONISM
H.J. Cho, J.H. Choi, K.D. Choi, S.H. Kim, Busan, Republic of Korea
1.216
154
HEMIPARKINSONISM-HEMIATROPHY SYNDROME: NEUROIMAGING AND
GENETICS
E.S. Oh1, J.-M. Kim1, S.-S. Park1, Y.K. Kim1, S.E. Kim1, S.-H. Oh2, Z.-H. Cho2,
1
Seoul, 2Icheon, Republic of Korea
1.217
155
TWO CASES OF DURAL ARTERIOVENOUS FISTULA (DAVF) PRESENTING
WITH PARKINSONISM AND PROGRESSIVE COGNITIVE DYSFUNCTION
Y. Luo1,2, J. Qi1, W. Luo1, H.T. Hu1, B.R. Zhang1, 1Hangzhou, 2Qingtian, China
1.218
156
NEUROSYPHILIS PRESENTING WITH PARKINSONISM
L. Fan, R. Yan, Shenyang, China
1.219
157
A PATIENT WITH SJÖGREN SYNDROME WITH SYSTEMIC LUPUS
ERYTHEMATOSUS AND TRIGEMINAL SENSORY NEUROPATHY AND
PARKINSONISM (CASE REPORT)
S. Nazarbaghi, Urmia, Iran
1.220
158
HASHIMOTO ENCEPHALOPATHY WITH PARKINSONISM
F.N. Mercan, M.C. Akbostanci, Ankara, Turkey
1.221
159
NEUROLEPTIC MALIGNANT SYNDROME WITH ATYPICAL NEUROLEPTICS
AND DOPAMINE MODULATING DRUGS: SEVEN CASE REPORTS
J.B. Sharms, S.K. Saxena, A. Singh, Noida, India
1.222
160
THE INFLUENCE OF DRUG CLASS ON THE MOTOR FEATURES OF
DRUG−INDUCED PARKINSONISM
R.P. Munhoz, M. Farah, C.S. Ikuta, H. Teive, Curitiba, Brazil
151
152
153
1.223
161
THE IMPACT OF NONMOTOR SYMPTOMS ON HEALTH-RELATED QUALITY
OF LIFE IN DRUG-INDUCED PARKINSONISM: COMPARISON TO
PARKINSON'S DISEASE
J.-W. Jang, M.J. Kim, H.M. Lee, J. Kim, M.-Y. Eun, C.N. Lee, D.Y. Kwon,
S.-B. Koh, Seoul, Republic of Korea
1.224
162
MOVEMENT DISORDERS: PRIMARY WRITING TREMOR ABOUT TWO
CASES
C.E. Cavalcanti, A.C. Ribeiro, São Luis, Brazil
1.225
163
IMPACT OF APOE GENOTYPE ON COGNITION OF ESSENTIAL TREMOR
Y.-S. Oh, K.-S. Lee, J.-S. Kim, Seoul, Republic of Korea
1.226
57
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
164
CEREBELLAR GABA-B RECEPTORS IN ESSENTIAL TREMOR
C. Luo, A.H. Rajput, A. Rajput, Saskatoon, SK, Canada
1.227
165
RECORDING PATHOLOGICAL TREMOR WITH A SMARTPHONE
B. Carignan, J.-F. Daneault, C.É. Codère, A.F. Sadikot, C. Duval,
Montréal, QC, Canada
1.228
QUANTITATIVE ASSESSMENT OF REST AND ACTION TREMOR AND THE
EFFECT OF CUEING IN PARKINSON'S PATIENTS TREATED WITH DEEP
BRAIN STIMULATION
T. Heida, E. Wentink, E. Marani, Enschede, The Netherlands
1.229
166
167
BOTULINUM TOXIN TREATMENT IN PATIENTS WITH ESSENTIAL TREMOR
S. Vohanka, B. Micankova, S. Skutilova, Brno, Czech Republic
1.230
168
TREMOR AND HIV INFECTION
P. Quilez-Ferrer, M. Aguilar, N. Calzado, X. Martinez-Lacasa, Terrassa, Spain
1.232
169
ЕXTRAPYRAMIDAL DISORDERS IN PATIENTS WITH SYMPTOMATIC
EPILEPSY
N. Myasnikova, E.V. Vostrikova, P.I. Pilipenko, Novosibirsk, Russia
1.233
170
INTRAOPERATIVE SMILE IN A MULTIPLE SCLEROSIS PATIENT WITH
MEDICATION-REFRACTORY TREMOR
A. Thompson, Z. Peng, M. Pastrana, I. Haq, M. Okun, K. Foote,
Gainesville, FL, USA
1.234
171
MOLECULAR GENETICS OF HERITABLE ESSENTIAL
TREMOR-IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS (ETINPH)
J. Zhang, A. Badr, El Paso, TX, USA
1.235
172
THE SPECTRUM OF MYOCLONUS IN BLACK AFRICAN PATIENTS - A
RETROSPECTIVE ANALYSIS
L.M. Wynand, D.S. Magazi, Pretoria, South Africa
1.236
173
CONVULSIVE SYNDROME IN CHILDREN WITH THE HEMORRHAGIC
STROKE
R. Issayeva1, K. Pushkarev2, 1Astana, 2Almaty, Kazakhstan
1.237
174
RESTLESS LEGS SYNDROME IN PATIENTS WITH ARTERIAL
HYPERTENSION
S. Khachatryan, Yerevan, Armenia
1.238
175
OPSOCLONUS-MYOCLONUS SYNDROME ASSOCIATED WITH
IRRITABILITY AND EXAGGERATED STARTLE RESPONSE IN AN ADULT
A. Dulamea1, S. Dulamea2, A. Campeanu1, A. Popp1, 1Bucharest, 2Targoviste,
Romania
1.239
GENERALIZED CHOREA WITH ABNORMAL FDG-PET FINDINGS IN A
PATIENT WITH HYPERTHYROIDISM
E.J. Chung, S.-J. Kim, Busan, Republic of Korea
1.240
176
58
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
177
THE SITUATION OF NEUROACANTHOCYTOSIS SYNDROMES IN CHINA
J. Liu, B. Bader, A. Danek, Munich, Germany
1.241
178
NEUROMUSCULAR FINDINGS IN CHOREA-ACANTHOCYTOSIS
J. Liu1, T. Arzberger1, A. Radunovic2, U. Pohl3, S. Mohiddin2, Y. Kageyama4,
R. Kiehl5, T. Lang5, B. Schoser1, H.A. Kretzschmar1, A. Danek1, B. Bader1,
1
Munich, Germany, 2London, 3Romford, UK, 4Amagasaki, Japan, 5Toronto, ON,
Canada
1.242
179
CASE SERIES: ANTI-NMDAR ENCEPHALITIS - A SYNAPTIC AUTOIMMUNE
DISORDER
C.H. Chai, B.H. Ong, S.D. Puvanarajah, N.R. Mohd Zain, M. Arip, M.H. Rafia,
Kuala Lumpur, Malaysia
1.243
180
CHOREOATHETOSIS CAUSED BY NUCLEUS CAUDATE ISCHEMIA
M.G. Şenol, E. Cengiz, F. Özdağ, M. Saraçoğlu, Istanbul, Turkey
181
HEMICHOREA- HEMIBALLISM: NON KETOTIC HYPERGLYCEMIA SYMPTOM
C. Hernando, Chorea, Vigo, Spain
1.245
182
PROFUSE SIALORRHEA AND HEMIBALLISM IN A CASE OF ANTI NMETHYL-D-ASPARTATE RECEPTOR (NMDAR) ENCEPHALITIS
R. Salazar Montero, E. James, M. Elsayed, P. Varelas, J. Bartscher, J. Corry,
T. Abdelhak, Detroit, MI, USA
1.246
HEMICHOREA IN NON-KETOTIC HYPERGLYCEMIA WITH BILATERAL
HYPERINTENSITY IN BASAL GANGLIA ON T1-WEIGHTED BRAIN MRI
C.K. Ha, H.-K. Park, Incheon, Republic of Korea
1.247
A CASE OF HEMICHOREA AS A RARE MANIFESTATION OF
POLYCYTHEMIA VERA
H.I. Ma, Y.J. Jang, Y.K. Jang, S.Y. Kang, Y.J. Kim, Anyang, Republic of Korea
1.248
HEMICHOREA AFTER STROKE: CLINICO-RADIOLOGIC CORRELATION
WITH MAGNETIC RESONANCE IMAGE
S. Al Faqih, Swiada, Syria
1.249
DECREASED METABOLISM OF THE CORTEX PREDICTS THE RATE OF
PROGRESSION IN EARLY-STAGE HUNTINGTON'S DISEASE
H.E. Shin, M.H. Kim, K.H. Lee, W.Y. Lee, J.Y. Yoon, J.S. Kim, J.W. Cho,
Seoul, Republic of Korea
1.250
187
COMPARING THE DYNAMIC RELATIONSHIP OF VOLUNTARY AND
INVOLUNTARY MOVEMENTS BETWEEN DYSKINETIC PARKINSON´S
PATIENTS AND CHOREIC HUNTINGTON´S PATIENTS
C. Duval1, R. Mann2, J. Zhou2, R. Edwards2, M.S. Jog3, 1Montréal, QC,
2
Victoria, BC, 3London, ON, Canada
1.251
188
AMÉRICO NEGRETTE AND HUNTINGTON'S DISEASE
H.A.G. Teive1, R.P. Munhoz1, M. Moscovich1, N. Becker1, E.R. Barbosa2,
A.J. Espay3, R. Weiser4, 1Curitiba, 2São Paulo, Brazil, 3Cincinnati, OH, USA,
4
Caracas, Venezuela
1.252
183
184
185
186
59
1.244
08:00-18:00
Poster Area
Poster Session
Board No
189
Abstract No
HYPERHOMOCYSTEINEMIA AS A POSSIBLE CAUSE OF HEMICHOREAHEMIBALLISMUS-SYNDROME
M.A. Santos, J. Pagonabarraga, J. Kulisevsky, Barcelona, Spain
1.253
190
ASYMMETRIC CHOREA AS PRESENTING SYMPTOM IN GRAVES´ DISEASE
H.-W. Lee, S.-P. Park, Daegu, Republic of Korea
1.254
191
LONG-TERM EXPOSURE TO TETRABENAZINE (TBZ) HAS NO ADVERSE OR
FAVORABLE IMPACT ON CHOREA AFTER IT IS WITHDRAWN
F.J. Marshall1, S. Eberly1, P. Auinger1, I. Shoulson2, S. Frank3, K. Biglan1,
K. Clarence-Smith2, E.R. Dorsey4, 1Rochester, NY, 2Washington, DC, 3Boston,
MA, 4Baltimore, MD, USA
1.255
192
SUSPECTED SEIZURES IN A CASE OF HEMIBALLISMUS RESPONSIVE TO
TETRABENAZINE THERAPY
C. Waked, Z. Huang, Jacksonville, FL, USA
1.256
193
A CROSSOVER STUDY OF A TRADITIONAL ASIAN HERBAL MEDICINE FOR
K. Iwasaki1, A. Kikuchi1, A. Takeda1, T. Satoh1, J.-I. Sawada2, H. Konno1,
T. Takahashi1, S. Takayama1, M. Tobita3, N. Yaegashi1, 1Sendai, 2Osaka,
3
Yonezawa, Japan
1.257
194
EFFECT OF CAFFEIC ACID, ROFECOXIB AND THEIR COMBINATION
AGAINST INTRASTRIATAL QUINOLINIC ACID INDUCED OXIDATIVE,
MITOCHONDRIAL AND HISTOLOGICAL ALTERATIONS
J. Mishra, H. Kalonia, A. Kumar, Chandigarh, India
1.258
195
RISPERIDONE VERSUS BEHAVIOUR THERAPY IN THE TREATMENT OF TIC
DISORDERS - A RANDOMIZED SINGLE-BLINDED TRIAL
S. de Bruijn1, C. Verdellen2, D. Cath3, M. Verbraak2, A. Wertenbroek1,
J. van de Griendt2, J. Rath1, T. van Woerkom1, Dutch Tourette Study Group,
1
The Hague, 2Arnhem, 3Utrecht, The Netherlands
1.259
196
PROTECTIVE EFFECT OF ROFECOXIB AND NIMESULIDE AGAINST INTRASTRIATAL QUINOLINIC ACID INDUCED BEHAVIORAL, OXIDATIVE STRESS
AND MITOCHONDRIAL DYSFUNCTIONS IN RATS
H. Kalonia, A. Kumar, Chandigarh, India
1.260
197
THAP1/DYT6 SEQUENCE VARIANTS IN NON-DYT1 EARLY ONSET
PRIMARY DYSTONIA IN CHINA AND THEIR EFFECTS ON RNA
EXPRESSION
F.B. Cheng1,2, L.J. Ozelius3, X.H. Wan1, J.C. Feng2, L.Y. Ma1, L. Wang1,
Y.M. Yang1, 1Beijing, 2Changchun, China, 3New York, NY, USA
1.261
CASE PRESENTATION: THE COEXISTENCE OF PSYCHOLOGICAL AND
SOMATIC FACTORS IN A PATIENT WITH PAROXYSMAL DYSKINESIA
V. Sajin, I. Moldovanu, C. Guranda, G. Pavlic, Chisinau, Moldova
1.262
198
60
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
199
FUNCTIONAL OUTCOME OF DEFEROXAMINE PRIMED HUMAN ADIPOSE
DERIVED MESENCHYMAL STEM CELL TRANSPLANTS IN A RAT MODEL
OF HUNTINGTON'S DISEASE
M.A. Edalatmanesh1, A.R. Bahrami2, H. Naderi2, E. Abbasi2, Z. Alizadeh2,
H. Nikfarjam2, 1Fars, 2Mashhad, Iran
1.263
200
DOPA-RESPONSIVE DYSTONIA PRESENTING AS WRITER'S CRAMP
C. Luca, H. Moore, C. Singer, Miami, FL, USA
1.264
201
THE CLINICAL FEATURES OF DOPA-RESPONSIVE DYSTONIA(DRD) AND
THE GCH-ⅠGENE MUTATION IN A CHINESE FAMILY
X. Chen, Y. Xue, Hefei, China
1.265
202
WHOLE-EXOME CAPTURE AND NEXT-GEN SEQUENCING IN FAMILIAL
ADULT-ONSET PRIMARY CERVICAL DYSTONIA
J. Xiao1, R.J. Uitti2, Y. Zhao1, S.R. Vemula1, J.S. Perlmutter3, Z. Wszolek2,
D.M. Maraganore4, M.S. LeDoux1, 1Memphis, TN, 2Jacksonville, FL, 3St. Louis,
MO, 4Evanston, IL, USA
1.266
203
THE GENOTYPIC-PHENOTYPIC SPECTRUM OF THAP1 DYSTONIA:
SYSTEMATIC REVIEW AND DESCRIPTION OF NEW CASES
M.S. LeDoux1, J. Xiao1, S.R. Vemula1, Y. Zhao1, M. Rudzińska2, R.W. Bastian3,
Z.W. Wszolek4, J.A. Van Gerpen4, A. Puschmann5, D. Momčilović6, 1Memphis,
TN, USA, 2Krakow, Poland, 3Downers Grove, IL, 4Jacksonville, FL, USA, 5Lund,
Sweden, 6Belgrade, Serbia
1.267
204
SUSTAINED DYSTONIA AND CHOREA IN PATIENTS WITH PRIMARY
PROGRESSIVE MULTIPLE SCLEROSIS: A CASE REPORT AND
LITERATURE REVIEW
J.G. Duan, Z.P. An, Y. Cai, J. Lei, M. Liu, Tianjin, China
1.268
205
IS PERSISTENT TARDIVE DYSTONIA A WORTH PRICE TO PAY FOR?
G. Pavlic, I. Moldovanu, S. Odobescu, L. Rotaru, G. Corcea, Chisinau, Moldova 1.269
206
A UNIQUE REDOX-SENSING SENSOR-II MOTIF IN TORSINA PLAYS A
CRITICAL ROLE IN NUCLEOTIDE AND PARTNER BINDING
L. Zhu1, L. Millen2, J.L. Mendoza2, P.J. Thomas2, 1Beijing, China, 2Dallas, TX,
USA
1.270
207
MUTATION SPECTRUM OF GENE ENCODING EPSILON-SARCOGLYCAN IN
MYOCLONUS-DYSTONIA SYNDROME
M. Rudzinska1, M. Szubiga1, M. Bik-Multanowski1, P. Janik2,
A. Potulska-Chromik2, B. Brodacki2, D. Koziorowski2, A. Szczudlik1, 1Krakow,
2
Warszawa, Poland
1.271
208
TRIGEMINAL SOMATOSENSORY EVOKED POTENTIALS RESEARCH IN
PATIENTS WITH MEIGE SYNDROME
W. Kaiyue, L. Zhanhua, S. Chunli, Dalian, China
1.272
STUDY OF IMPROVED SOMATOSENSORY EVOKED POTENTIALS IN
PATIENTS WITH MEIGE SYNDROME AND CERVICAL DYSTONIA
L. Zhou, Da Lian, China
1.273
209
61
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
CASE REPORT: NEUROFERRITINOPATHY WITH EARLY BULBAR
INVOLVEMENT
S. Petchrutchatachart, N. Limotai, P. Jagota, S. Singmaneesakulchai,
1.274
211
EXTRA-OCULAR MOVEMENT ABNORMALITIES IN WILSON'S DISEASE
M. Bagchi, N. Paul, S.K. Das, Kolkata, India
1.275
212
PROSODIC DEFICITS IN MIXED DYSARTHRIA (WILSON'S DISEASE)
R. Kaipa1, R.M. Thomas2, 1Christchurch, New Zealand, 2Mangalore, India
1.276
213
WILSON´S DISEASE IN THE SOUTH OF BRAZIL: A 40 YEARS FOLLOW-UP
STUDY
H.A.G. Teive1, R.S. De Bem1, D. Muzillo1, M.M. Deguti2, R.P. Munhoz1,
E.R. Barbosa2, 1Curitiba, 2São Paulo, Brazil
1.277
214
WILSON'S DISEASE: UPDATE ON INTEGRATED TRADITIONAL CHINESE
MEDICINAL HERBS AND WESTERN MEDICINE IN CHINA
X.-P. Wang, W. Li, Shanghai, China
1.278
MICROELECTRODE RECORDINGS IN THE BASAL GANGLIA AND
THALAMUS IN PATIENTS WITH DYSTONIA
P. Zhuang1, M. Hallett2, Y. Zhang1, J. Li1, Y. Li1, 1Beijing, China,
2
Bethesda, MD, USA
1.279
216
VARIOUS TARGETS FOR DEEP BRAIN STIMULATION FOR VARIOUS
TYPES OF DYSTONIA
T. Mandat, H. Koziara, T. Tykocki, B. Krolicki, B. Brodacki, T. Kmiec,
D. Koziorowski, P. Nauman, R. Rola, W. Bonicki, Warszawa, Poland
1.280
217
REVERSIBLE PISA SYNDROME IN A PATIENT WITH PARKINSON'S
DISEASE ON PRAMIPEXOLE
E. De Pablo-Fernandez1, Á. Sánchez-Ferro2, 1London, UK, 2Madrid, Spain
1.281
218
EFFECTIVENESS OF BOTULINUM TOXIN TYPE A IN TREATMENT OF
“PISA SYNDROM”: CASE REPORT
D. Sichinava, D. Sichinava, L. Astakhova, A. Ambartsumyan, Krasnodar, Russia 1.282
219
GPI AND STN DBS FOR GENERAL DYSTONIA
T. Mandat, B. Brodacki, H. Koziara, W. Bonicki, T. Kmiec, D. Koziorowski,
P. Nauman, Warszawa, Poland
220
THE CURATIVE EFFECT EVALUATIONS FOR BOTULINUM TOXIN-A
TREATMENT OF SPASMODIC TORTICOLLIS WITH THE GUIDANCE OF EMG
S.S. Chen, Z.H. Liang, C.L. Song, Dalian, China
1.284
221
AUDIT OF THE ACTUAL PERFORMANCE OF RECHARGEABLE MEDTRONIC
IMPLANTABLE PULSE GENERATOR (ACTIVA-RC) FOR DEEP BRAIN
STIMULATION (DBS) THERAPY IN DYSTONIA
M.J. Naushahi, N. Pavese, S. O’Riordan, P.G. Bain, C.T. Hopkins, D. Nandi,
London, UK
1.285
210
215
62
1.283
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
LONG TERM EFFICACY OF PALLIDAL DEEP BRAIN STIMULATION IN
PATIENT WITH DYT 6 DYSTONIA FROM INDIA
C. Savant Sankhla1, M. Sankhe1, J. Ray2, 1Mumbai, 2Kolkata, India
1.286
SYNERGETIC EFFECT OF INTRATHECAL BACLOFEN AND DEEP BRAIN
STIMULATION IN TREATING DYSTONIA
Y. Awaad, T. Rizk, Riyadh, Saudi Arabia
1.287
SUBTHALAMIC DEEP BRAIN STIMULATION FOR PKAN- RELATED
DYSTONIA
T. Mandat1, H. Koziara1, T. Tykocki1, B. Krolicki1, S. Barszcz1, M. Tutaj2,
R. Rola1, W. Bonicki1, P. Nauman1, T. Kmiec1, 1Warszawa, 2Krakow, Poland
1.288
225
OUTCOME OF TREATMENT WITH NEURONOX IN HEMIFACIAL SPASM
PATIENTS
S. Tiamkao, S. Tuntapakul, K. Sawanyawisuth, S. Jitpimolmard, Khon Kaen,
Thailand
1.289
226
LONG-TERM NEUROPSYCHOLOGICAL OUTCOMES OF SUBTHALAMIC
NUCLEUS (STN) DEEP BRAIN STIMULATION (DBS) IN PRIMARY CRANIAL
CERVICAL DYSTONIA (CCD)
C.A. Racine, C. Kilbane, L. Markun, M.M. Volz, P.A. Starr, J.L. Ostrem,
San Francisco, CA, USA
1.290
222
223
224
227
LOW FREQUENCY RTMS OVER THE PREMOTOR CORTEX SUPPRESS
DYSTONIA AND ABNORMAL CORTICAL EXCITABILITY: A CASE REPORT
Y.-H. Kim, W.H. Chang, J.-G. Do, O.Y. Bang, S.H. Lee, Seoul, Republic of Korea
228
BTA TREATMENT OF DIFFERENT TYPES OF OROMANDIBULAR DYSTONIA
T. Charnukha, S. Likhachev, Y. Rushkevich, S. Navosha, Minsk, Belarus
1.292
229
REPORT OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF WRITER’S
CRAMP UNDER EMG GUIDANCE
C. Song, Z. Liang, H. Ge, R. Fu, Dalian, China
1.293
230
THE CURATIVE EFFECT EVALUATIONS FOR BOTULINUM TOXIN-A
TREATMENT OF SPASMODIC TORTICOLLIS WITH THE GUIDANCE OF
'SENSORY TRICK' COMBINEWITH EMG
H.-M. Ge, Dalian, China
1.294
231
SUCCESSFUL TREATMENT OF REFRACTORY ANTEROCOLLIS WITH
BOTULINUM TOXIN TYPE A INTO BILATERAL LOWER PORTION OF
STERNOCLEIDOMASTOID MUSCLES
Z. Peng, R. Rodriguez, A. Thompson, Gainesville, FL, USA
1.296
232
SPASTIC DYSTONIA OF HIP ADDUCTOR IN PRIMARY PROGRESSIVE
MULTIPLE SCLEROSIS TREATED WITH BOTULINUM TOXIN TYPE A
S.G. Ochudło, Katowice, Poland
1.297
1.291
63
08:00-18:00
Poster Area
Poster Session
Board No
233
Abstract No
CHANGES IN SENSORIMOTOR NETWORK ACTIVATIONS AFTER
BOTULINUM TOXIN TYPE A INJECTIONS IN PATIENTS WITH CERVICAL
DYSTONIA. A FUNCTIONAL MRI STUDY
M. Nevrly, P. Hlustik, P. Otruba, R. Opavsky, P. Hok, P. Kanovsky, Olomouc,
Czech Republic
1.298
234
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
COMPARING THE EFFICACY, SAFETY AND TOLERABILITY OF LEVODOPACARBIDOPA IN PATIENTS WITH X-LINKED DYSTONIA-PARKINSONISM
(XDP)
R.D.G. Jamora1,2, P.M.D. Pasco1,2, R.A. Teleg2, R.F. Villareal-Jordan3,
R. Borres3, M.J. Monding2, C. Tolentino3, S. Sarcia2, L.V. Lee2, 1Manila,
2
Quezon City, 3Roxas City, Philippines
1.299
235
PSYCHOGENIC MOVEMENT DISORDER DURING THE FIRST GREAT WAR
C. Geny1, M. Wyart2, 1Montpellier, 2Nimes, France
236
HIGHER LEVEL GAIT DISORDERS IN THE ELDERLY SUBJECT: POSTURAL
INSTABILITY, CORTICAL AND SUBCORTICAL ABNORMALITIES
A. Demain1, M. Westby1, F. Bonneville2, M.C. Do3, S. Tézenas du Montcel1,
D. Dormont1, Y. Agid1, S. Fernandez-Vidal1, N. Chastan4, M.-L. Welter1,
1
Paris, 2Toulouse, 3Orsay, 4Rouen, France
1.301
237
NOVEL OF GAIT ANALYSIS IN EARLY PARKINSON'S DISEASE
A. Suputtitada, S. Saguanrungsirikul, Bangkok, Thailand
238
MEASURING ARM SWING DURING GAIT IN PATIENTS WITH PARKINSON´S
DISEASE USING WEARABLE SENSORS- A FEASIBILITY STUDY
A. Mirelman1,2, A. Peruzzi3, E. Gazit1, N. Giladi1, J.M. Hausdorff1,4, M. Plotnik1,
1
Tel Aviv, 2Beer Sheba, Israel, 3Sassari, Italy, 4Boston, MA, USA
1.303
239
THE ANATOMICAL CORRELATES OF FREEZING OF GAIT IN PARKINSON´S
DISEASE
M. Pilleri, R. Biundo, L. Bernardi, A. Antonini, Venice-Lido, Italy
1.304
240
KINEMATIC AND ELECTROMYOGRAPHIC CHARICTERISTICS OF
OBSTACLE GAIT IN PARKINSON PATIENTS
C.H. Kim1, M.-Y. Kim2, B.-O. Lim2, K.-S. Kim1, 1Inchon, 2Seoul, Republic of Korea 1.305
241
GAIT ANALYSIS IN PARKINSON'S DISEASE PATIENTS WITH MOTOR
FLUCTUATIONS IN DIFFERENT WALKWAYS: GAITRITE SYSTEM
R. Bhidayasiri, W. Buated, Bangkok, Thailand
1.300
1.302
1.306
242
STATIC AND TASK-ORIENTED BALANCE TESTS IN EARLY STAGES OF
P. Valkovic, G. Stefanikova, Z. Kovacikova, J. Lipkova, F. Schmidt, F. Hlavacka,
E. Zemkova, Bratislava, Slovak Republic
1.307
243
INVESTIGATION OF THE NEUROFUNCTIONAL SUBSTRATES BEHIND
PRESERVED BICYCLING ABILITIES IN PARKINSON'S DISEASE PATIENTS
WITH SEVERE GAIT DISTURBANCES
M. Maliia1, M. Rabenstein2, 1Bucharest, Romania, 2Marburg, Germany
1.308
64
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
244
DUAL TASK WALKING EFFECT ON GAIT CHARACTERISTICS IN
PROGRESSIVE SUPRANUCLEAR PALSY PATIENTS
S. Radovanovic, M. Jecmenica Lukic, N. Kresojevic, V. Markovic, N. Dragašević,
V.S. Kostic, Belgrade, Serbia
1.309
245
ATHEROSCLEROSIS IN PATIENTS WITH IDIOPATHIC RESTLESS LEGS
SYNDROME
J.S. Baik, M.S. Lee, Seoul, Republic of Korea
1.310
A NOVEL CASE OF RESTLESS LEG SYNDROME (RLS) DUE TO
INTRACEREBRAL HAEMORRHAGE
B. Chandra, L. Yeo Leong Litt, Singapore, Singapore
1.311
246
247
ENDURANCE PERFORMANCE IN ELDERLY WITH DIFFERENT DEGREES OF
KYPHOSIS AS DETERMINED BY THE OCCIPUT-WALL DISTANCE (OWD)
S. Wongsa, S. Amatachaya, J. Saengsuwan, P. Amatachaya,
T. Thaweewannakij, Khonkaen, Thailand
1.312
248
STIFF PERSON SYNDROME ASSOCIATED WITH AUTOIMMUNE
THYROIDITIS AND SARCOIDOSIS OF INTRATHORACIC LYMPH NODES:
CASE REPORT
Z.A. Zalyalova, D.M. Khasanova, Kazan, Russia
1.313
249
NEUROLOGICAL SYNDROMES ASSOCIATED WITH GLUTAMIC ACID
DECARBOXYLASE ANTIBODIES: A BRAZILIAN SERIES
H.A.G. Teive1, M. Fernandes1, A.M. Ferreira1, W.O. Arruda1, P. Lorenzoni1,
R.P. Munhoz1, P. Carrilho2, 1Curitiba, 2Cascavel, Brazil
1.314
250
4 CASES REPORT OF CEREBELLAR ATAXIA-ACANTHOCYTOSIS
Y. Jiang1, Y. Wang2, H. Zhang1, 1Shanghai, 2Wenzhou, China
1.315
251
ACUTE CEREBELLAR ATAXIA DURING STROKE LIKE EPISODE IN CNS
GNATHOSTOMIASIS
S. Singmaneesakulchai, Bangkok, Thailand
1.316
252
CEREBELLAR ATAXIA DUE TO AUTOIMMUNE DISEASE
M. Mercan, V. Doğa, A.B. Tokçaer, Ankara, Turkey
1.317
253
OTONEUROLOGICAL FINDINGS IN SPINOCEREBELLAR ATAXIA
B.S. Zeigeilboim, R.S. Santos, H. Mengelberg, A.L. Jurkiewicz,
E.M. Abdulmasshi, H. Teive, Curitiba, Brazil
1.318
254
ELECTRONYSTAGMOGRAPHY FINDINGS IN SPINOCEREBELLAR ATAXIA
TYPE 3 AND 2
R.S. Santos, B.S. Zeigelboim, A.L. Jurkiewicz, E.M. Abdulmasshi, W.O. Arruda,
H. Teive, Curitiba, Brazil
1.319
255
SPINOCEREBELLAR ATAXIA TYPE 10: DISPROPORTIONATE
CEREBELLAR SYMPTOMS AMONG AT-RISK SUBJECTS INDUCED BY
SMALL AMOUNTS OF ALCOHOL
H.A.G. Teive1, R.P. Munhoz1, T. Ashizawa2, 1Curitiba, Brazil, 2Gainesville, FL,
USA
65
1.320
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
256
IMBALANCE ASSESSMENT IN PREMANIFEST AND SYMPTOMATIC
SPINOCEREBELLAR ATAXIA PATIENTS - THE USEFULNESS OF STATIC
POSTUROGRAPHY
M. Rakowicz, L. Czerwosz, A. Sułek, R. Rola, I. Stępniak, E. Zdzienicka,
T. Jakubczyk, Warsaw, Poland
257
A CASE STUDY FOR DIFFERENTIAL ANALYSIS ON MULTIPLE SCLEROSIS
IN HUMAN LOCOMOTION
H. Yu, T. Sarkodie-Gyan, El Paso, TX, USA
1.322
258
LEVETIRACETAM AMELIORATES CHOREOATHETOSIS IN CHILDREN WITH
DYSKINETIC CEREBRAL PALSY
F. Jia, C. Niu, H. Jiang, H. Li, Changchun, China
1.323
259
LEVETIRACETAM PREVENT LEVODOPA-INDUCED DYSKINESIA IN
HEMIPARKINSONIAN MICE
H. Du, X. Cao, Wuhan, China
260
EFFECT OF LEVETIRACETAM MONOTHERAPY ON EPILEPTIC TODDLERS
WITH CEREBRAL PALSY: A OPEN, PROSPECTIVE, SHORT-TERM AND
CONTROLLED CLINICAL TRIAL
F. Jia, C. Niu, H. Jiang, L. Du, Changchun, China
1.325
261
CORRELATION OF THE 10-METER WALK TEST (10MWT) AND 6-MINUTE
WALK TEST (6MINWT) IN PATIENTS WITH SPINAL CORD INJURY (SCI)
S. Neawla, S. Amatachaya, P. Arrayawichanon, Khon Kaen, Thailand
1.326
262
SIT-TO-STAND PERFORMANCE IN INDEPENDENT AMBULATORY
PATIENTS WITH SPINAL CORD INJURY (SCI)
P. Poncumhak, S. Amatachaya, P. Wattanapun, Khon Kaen, Thailand
1.327
263
CORRELATION BETWEEN THE TIMED UP AND GO TEST AND SIT-TOSTAND TEST IN PATIENTS WITH SPINAL CORD INJURY (SCI)
K. Srisim, S. Amatachaya, J. Saengsuwan, Khon Kaen, Thailand
1.328
264
FALLS AND BALANCE ABILITY OF INDEPENDENT AMBULATORY
PATIENTS WITH SPINAL CORD INJURY (SCI)
S. Phonthee, S. Amatachay, J. Saengsuwan, W. Siritaratiwat, J. Saengsuwan,
Khon Kaen, Thailand
1.329
66
1.321
1.324
08:00-18:00
Poster Area
Poster Session
Imaging
Board No
Abstract No
1
MEDICAL IMAGING DIAGNOSIS OF PARKINSON SYNDROME
P. Zhang, Tianjin, China
2
PRECLINICAL TO CLINICAL NEURAL CHANGES IN PARKINSON´S DISEASE
T. Wu, C. Wang, P. Chan, Beijing, China
2.002
3
SUSCEPTIBILITY-WEIGHTED IMAGING IN PARKINSONIAN SYNDROMES: A
VOXEL-BASED ANALYSIS AND CORRELATIONS WITH CLINICAL SCORES
S. Cabello, C. Geny, F. Maury, S. Cassafieres, E. Le Bars,
N. Menjot de Champfleur, F. Molino, A. Bonafé, Montpellier, France
2.003
4
CLINICAL OUTCOME OF DRUG-INDUCED PARKINSONISM CAN BE
PREDICTED WITH TRANSCRANIAL MIDBRAIN SONOGRAPHY
D.-Y. Kwon, M.H. Park, J.-M. Jung, S.-B. Koh, K.W. Park, Ansan,
Republic of Korea
2.001
2.004
5
DIFFERENT SIGNALS OF MAGNETIC RESONANCE IMAGING AND
ULTRASOUND FROM PARKINSONIAN SUBSTANTIA NIGRA AND CONTROL
- IS IRON THE CAUSE?
J. Galazka-Friedman, K. Szlachta, K. Sadowski, R. Kulinski, A. Friedman,
Warszawa, Poland
2.005
6
COMPARASION STUDY OF VOLUME OF OLFACTORY BULB BY MRI
BETWEEN PARKINSON´S DISEASE AND THE NORMAL PERSON
M. Shao, S. Chen, Guangzhou, China
7
MR VOLUMETRIC ANALYSIS OF THE CORPUS CALLUM IN PATIENTS WITH
PARKINSONISM
L.-L. Chan, K.M. Ng, H. Rumpel, E.-K. Tan, Singapore, Singapore
2.007
8
CASE CONTROL DIFFUSION TENSOR IMAGING TRACTOGRAPHY STUDIES
IN POSTURAL INSTABILITY GAIT DISORDER PARKINSONISM
L.-L. Chan, K.-M. Ng, H. Rumpel, E.-K. Tan, Singapore, Singapore
2.010
9
DIFFUSION TENSOR IMAGING STUDY IN PARKINSON'S DISEASE WITH
IMPULSE CONTROL DISORDERS
G. Meco, M. Valente, R. Scatozza, A. Rubino, N. Caravona, Roma, Italy
2.011
10
ARE FP-CIT ABNORMALITIES IN PARKINSON´S DISEASE AND
PARKINSON´S DISEASE DEMENTIA CONSISTENT WITH THE BRAAK
HYPOTHESIS?
J. Birchall1, I. Jones1, N. Bajaj2, 1Derby, 2Nottingham, UK
2.012
11
IMPACT OF DATSCANTM ON CLINICAL MANAGEMENT, DIAGNOSIS, AND
DIAGNOSTIC CONFIDENCE IN PATIENTS WITH CLINICALLY UNCERTAIN
PARKINSONIAN SYNDROMES: A 1-YEAR FOLLOW-UP
N. Bajaj1, A. Kupsch2, F. Weiland3, A. Tartaglione4, S. Klutmann5, M. Buitendyk6,
P. Sherwin7, A. Tate7, I.D. Grachev7, 1Derby, UK, 2Berlin, Germany, 3Roseville,
CA, USA, 4La Spezia, Italy, 5Hamburg, Germany, 6Burlington, ON, Canada,
7
Princeton, NJ, USA
2.013
67
2.006
08:00-18:00
Poster Area
Poster Session
Imaging (Contd.)
Board No
Abstract No
12
FP-CIT DATSCAN DID NOT USEFUL IN DIFFERENTIAL DIAGNOSES OF
PARKINSON'S DISEASE SUBGROUPS
R. Ribacoba, J. Vega-Villar, G. Mauri-Capdevila, N. Zeidán-Ramón,
E. Suarez-San Martín, Oviedo, Spain
2.014
13
TRANSCRANIAL SONOGRAPHY AND 123I FP-CIT SPECT IN MOVEMENT
DISORDERS
P. Bartova1, D. Skoloudik1, O. Kraft1, J. Bernatek2, M. Havel1, P. Ressner3,
M. Nevrlý3, 1Ostrava-Poruba, 2Zlín, 3Ostrava, Czech Republic
2.015
14
[18F] FP-CIT PET ANALYSIS IN PATIENTS WITH COMBINED POSTURAL AND
REST TREMORS: CLINICAL CORRELATION STUDY
S. You, M.-J. Kim, S.R. Kim, M.J. Kim, M. Oh, J.S. Kim, S.J. Chung, Seoul,
Republic of Korea
2.016
15
RELATIONSHIP BETWEEN VISUAL HALLUCINATIONS AND CEREBRAL
BLOOD FLOW ABNORMALITY IN PARKINSON'S DISEASE
K. Okada1, H. Takayoshi1, R. Mizuhara1, Y. Iwata1, S. Yamaguchi2, 1Oda,
2
Izumo, Japan
2.017
16
BRAIN GLUCOSE METABOLISM OF VISUAL PATHWAYS IN PARKINSON'S
DISEASE WITH HALLUCINATION
H.K. Park1, J.S. Kim2, K.C. Im2, M.J. Kim2, J.-H. Lee2, M.C. Lee2, J. Kim2,
S.J. Chung2, 1Goyang, 2Seoul, Republic of Korea
2.018
17
ROLE OF 18-FDG PET SCAN IN DIFERENTIAL DIAGNOSIS OF
PARKINSONIAN SYNDROMS
C. Borrue-Fernandez, San Sebastian de los Reyes, Spain
2.019
18
SEMI-AUTOMATED SYNTHESIS, BIODISTRIBUTION AND MICROPET
IMAGING OF 18F-FP-DTBZ AS A VESICULAR MONOAMINE TRANSPORTER
LIGAND
Z. Chen, C. Liu, X. Li, J. Tang, C. Tan, H. Yu, H. Huang, Wuxi, China
2.020
19
DEMENTIA WITH LEWY BODIES CAN BE WELL-DIFFERENTIATED FROM
ALZHEIMER'S DISEASE BY MEASUREMENT OF BRAIN ACETYLCHOLIN
ESTERASE ACTIVITY BY PET
H. Shimada1,2, S. Hirano1, H. Shinotoh1,3, A. Aotsuka1, K. Sato1, N. Tanaka1,
T. Ota4, M. Asahina1, K. Fukushi1, S. Kuwabara1, T. Irie1, H. Ito1, T. Suhara1,
1
Chiba, 2Cihba, 3Matsudo, 4Bunkyo, Japan
2.021
20
EFFECT OF PRAMIPEXOLE ON REGIONAL CEREBRAL BLOOD FLOW IN
S. Hirano1, H. Shinotoh1, H. Shimada1, M. Asahina1, S. Kuwabara1, D. Eidelberg2,
T. Suhara1, 1Chiba-shi, Japan, 2Manhasset, NY, USA
2.022
21
QUANTITATIVE MAPPING OF RCBF IN THE PATIENTS WITH PARKINSON
DISEASE: OBJECTIVE EVALUATION USING STEREOTACTIC EXTRACTION
ESTIMATION ANALYSIS IN 123I-IMP SPECT
Y. Kajita1, D. Nakatsubo2, T. Nagai1, K. Yoshida1, S. Maesawa1,
T. Wakabayashi1, 1Nagoya, 2Obu, Japan
2.023
68
08:00-18:00
Poster Area
Poster Session
Imaging (Contd.)
Board No
Abstract No
22
ACCELERATED INTRANEURONAL CATECHOLAMINE LOSS RELATED TO
DECREASED VESICULAR UPTAKE IN PATIENTS WITH LEWY BODY
DISEASES
D.S. Goldstein, C. Holmes, Y. Sharabi, I.J. Kopin, Bethesda, MD, USA
23
A CASE OF ATYPICAL STIFF PERSON SYNDROME INVESTIGATED WITH
[18F]-FLUMAZENIL PET
J.-M. Kim, E.S. Oh, K.S. Park, Y.K. Kim, S.E. Kim, Seongnam, Republic of Korea
2.024
2.025
24
INCREASED MICROGLIAL ACTIVATION AND AMYLOID DEPOSITION IN
PARKINSON´S DISEASE SUBJECTS AT HIGH RISK OF DEMENTIA: A PET
STUDY
B.S. Simpson1, A.F. Ramlackhansingh1, N. Pavese1, R.A. Barker2, D.P. Breen2,
D.J. Brooks1, 1London, 2Cambridge, UK
2.026
25
CLINICAL RESEARCH OF [11C]CFT DOPAMINE TRANSPORTER PET
IMAGING IN PARKINSON'S DISEASE
W. Xian, X. Shi, X. Fu, Y. Liu, J. Chen, Y. Zheng, H. Zhou, Y. He, J. Li, Z. Liu,
Z. Pei, L. Chen, Guang Zhou, China
26
COMPARISON OF PIB(-) LEWY BODY DEMENTIA, PIB(+) LEWY BODY
DEMENTIA AND ALZHEIMER DISEASE: NEUROPSYCHIATRIC, [11C]PIB
AND [18F]FDG PET FINDINGS
C.S. Lee, J. Kim, S.J. Oh, S.J. Kim, J.H. Lee, J.S. Kim, Seoul, Republic of Korea 2.029
27
PATTERNS OF CORTICAL AND SUB-CORTICAL THINNING IN
R. Biundo1, M. Calabrese2, G. Ricchieri2, S. Facchini1, M. Pilleri1, P. Gallo2,
A. Antonini1, 1Venice-Lido, 2Padua, Italy
2.030
28
NEUROPHYSIOLOGICAL CORRELATES OF COGNITIVE DECLINE IN
PARKINSON'S DISEASE: A LONGITUDINAL
MAGNETOENCEPHALOGRAPHIC STUDY
K.T.E. Olde Dubbelink, J.W.R. Twisk, C.J. Stam, H.W. Berendse, Amsterdam,
The Netherlands
2.031
29
PROGESSION OF RECOGNITION MEMORY CEREBRAL NETWORK
DYSFUNCTION IN EARLY PARKINSON'S DISEASE
B. Segura1, N. Ibarretxe-Bilbao1,2, R. Sala-Llonch1, M.J. Martí1, F. Valldeoriola1,
P. Vendrell1, E. Tolosa1, C. Junqué1, 1Barcelona, 2Bilbao, Spain
2.032
30
DEFAULT MODE NETWORK AND EXTRASTRIATE VISUAL RESTING STATE
NETWORK IN PATIENTS WITH PARKINSON'S DISEASE DEMENTIA
I. Rektorova, L. Krajcovicova, R. Marecek, M. Mikl, Brno, Czech Republic
2.033
69
2.028
08:00-18:00
Poster Area
Poster Session
Imaging (Contd.)
Board No
Abstract No
31
CHARACTERIZATION OF PUTAMINAL ABNORMALITIES IN THE
PARKINSON VARIANT OF MSA BY SUSCEPTIBILITY-WEIGHTED IMAGING
J.-H. Lee1, J.-H. Bae2, S.-Y. Kim1, 1Yangsan-si, 2Busan, Republic of Korea
2.034
32
FEATURES OF MRI IN DIAGNOSING MULTIPLE SYSTEM ATROPHY
Y. Piao, Beijing, China
2.035
33
CEREBRAL GLUCOSE METABOLISM IN PROGRESSIVE SUPRANUCLEAR
PALSY
A. Ma, Qingdao, China
2.036
34
RESTLESS LEGS SYNDROME AS A MANIFESTATION OF ACUTE PONTINE
INFARCTION
H.-W. Shin, S.-H. Han, Seoul, Republic of Korea
2.038
35
LONGITUDINAL PET STUDIES OF MICROGLIAL ACTIVATION IN
Y.F. Tai, N. Pavese, S.J. Tabrizi, R.A. Barker, D.J. Brooks, P. Piccini, London, UK
36
PALLIDO-RETICULAR NECROSIS AND POST-ANOXIC
LEUKOENCEPHALOPATHY: PERSPECTIVES FROM CLINIC AND PATHOLOGIC
MOVEMENT DISORDERS DIAGNOSTICS
S.G. Echebarria Mendieta, Las Arenas - Getxo, Spain
2.040
2.039
Poster Session
Diagnostic Procedures
NEUROCAM - AUTOMATED ASSISTANCE TO NEUROLOGICAL
PRACTICIONERS
B. Kostek1, A. Czyzewski2, K. Kaszuba2, J. Slawek1, 1Gdansk, 2Gdynia, Poland
2.101
AUTOMATIC ASSESSMENT OF THE MOTOR STATE OF PARKINSON'S
DISEASE PATIENTS
A. Czyzewski, B. Kostek, J. Slawek, K. Kaszuba, Gdansk, Poland
2.102
TECHNOLOGY AND PARKINSON'S DISEASE: STATE-OF-THE-ART AND
TRENDS IN REMOTE MONITORING AND REHABILITATION
J. Cancela González, M. Pastorino, L. Pastor-Sanz, A.P. Gonzalez Marcos,
M.T. Arredondo Waldmeyer, Madrid, Spain
2.103
40
AUTOMATIC ASSESSMENT OF BRADYKINESIA IN PD PATIENTS
M. Pastorino1, J. Cancela Gonzalez1, L. Pastor-Sanz1, M.T. Arredondo
Waldmeyer1, J.A. Martín Pereda1, F. Villagra2, M.A. Pastor2, 1Madrid,
2
Pamplona, Spain
2.104
41
DIAGNOSIS AND MONITORING OF PARKINSON'S DISEASE PATIENTS
BASED ON MOTOR SIGNALS
L. Pastor-Sanz, M.T. Arredondo Waldmeyer, J. Cancela González,
M. Pastorino, F. del Pozo, Madrid, Spain
2.105
37
38
39
70
08:00-18:00
Poster Area
Poster Session
Diagnostic Procedures
Board No
42
43
Abstract No
IS MDS-UPDRS USEFUL IN ELDERLY PATIENTS?
C. Geny, F. Maury, A. Gabelle, N. Menjot de Champfleur, S. Cassafieres,
J. Touchon, Montpellier, France
2.106
INSTRUMENTED TIMED-UP AND GO TEST WITH A 3D CAMERA FOR
MOBILITY DETECTION
X. Yao, B. Jansen, R. Deklerck, J. Cornelis, Brussels, Belgium
2.107
44
IDENTIFICATION AND CHARACTERIZATION OF PARKINSON'S DISEASE IN
ASYMPTOMATIC PATIENTS
G.M. Pasinetti, New York, NY, USA
2.108
45
ASSESSMENT OF FINE MOTOR CONTROL IN PARKINSON´S DISEASE
WITH THE NEUROSKILLTM ANALYSIS OF HANDWRITING DYNAMICS
R. Shrairman1, C.F. O'Brien2, A. Landau1, 1Boulder, CO, 2San Diego, CA, USA
46
APPLICATION OF “SNIFFIN' STICKS” ODOR IDENTIFICATION TEST IN
CHINESE PATIENTS WITH PARKINSON'S DISEASE: A MATCHED CASECONTROL STUDY
W. Chen, S. Chen, B. Li, Z.-M. Xu, Q. Xiao, J. Liu, Y. Wang, G. Wang,
S.-D. Chen, Shanghai, China
2.110
DIFFERENCES IN OLFACTORY FUNCTION BETWEEN PARKINSON'S
DISEASE AND VASCULAR PARKINSONISM
M. Iijima, M. Osawa, S. Uchiyama, Tokyo, Japan
2.111
48
THE ODOR STICK IDENTIFICATION TEST FOR JAPANESE
DIFFERENTIATES PARKINSON'S DISEASE FROM MULTIPLE SYSTEM
ATROPHY AND PROGRESSIVE SUPRA NUCLEAR PALSY
M. Suzuki, M. Yoshioka, M. Hashimoto, M. Murakami, M. Noya, M. Urashima,
Tokyo, Japan
2.112
49
CONTRAST SENSITIVITY VISUAL ACUITY IS DEFICIENT IN PARKINSON´S
DISEASE AND DEGRADES MOTOR PERFORMANCE
C. Swigler, A. Martin, F. Milice, M. Walley, L. LaPointe, G. Maitland,
C. Saunders, Tallahassee, FL, USA
2.113
50
PERIPAPILLARY RETINAL NERVE FIBER LAYER THICKNESS IN PATIENTS
WITH PARKINSON'S DISEASE, PATIENTS WITH DIFFERENT GENETICS
STATUS
T. Gurevich, H. Shabtai, E. Naftaliev, M. Neudorfer, Y. Balash, E. Rosenberg,
A. Mirelman, J. Knaani, A. Bar Shira, Z. Gan Or, A. Orr-Urtreger, A. Kesler,
N. Giladi, Tel Aviv, Israel
2.114
51
PERIPAPILLARY RETINAL NERVE FIBER LAYER THICKNESS IN PATIENTS
WITH PARKINSON'S DISEASE AND MULTIPLE SYSTEM ATROPHY
Y. Balash, T. Gurevich, M. Neudorfer, E. Naftaliev, H. Shabtai, A. Rosenberg,
A. Ezra, A.D. Korczyn, N. Giladi, A. Kesler, Tel Aviv, Israel
2.115
2.109
47
71
08:00-18:00
Poster Area
Poster Session
Diagnostic Procedures (Contd.)
Board No
Abstract No
52
VESTIBULOMETRIC FUNCTION TESTS IN PATIENTS WITH VEGETATIVE
DYSFUNCTION
I.P. Maryenko, S. Likhachev, Minsk, Belarus
53
POSTUROGRAPHIC EVALUATION OF DIZZINESS COMPLAINING PATIENTS
UNDER SUSPICION TO DEVELOP PARKINSON´S DISEASE
H. Cho, Daejeon, Republic of Korea
2.117
54
AN ALGORITHM FOR THE DIAGNOSIS IN PATIENTS PRESENTING
PARKINSONISM AND COGNITIVE DEFICITS IN NEUROLOGICAL AND
GERIATRIC PRACTICES
C. Latxague, F. Perez, F. Tison, ARPADEM Study Group*, Pessac, France
2.116
2.119
55
EEG AND TRANSCRANIAL DOPPLEROGRAFY OF MIDDLE CEREBRAL
ARTERY IN ASSESSMENT OF PATHOGENESIS OF PARKINSON'S DISEASE
U. Askhonov, G.H. Askhanov, Namangan, Uzbekistan
2.120
56
BROAD-BAND DIRECTIONAL EEG CONNECTIVITY CHANGES DURING
MOTOR PREPARATION PREDICTS PARKINSON'S DISEASE SEVERITY
J. Chiang1, G. Tropini1,2, Z.J. Wang1, M.J. McKeown1, 1Vancouver, BC,
2
Toronto, ON, Canada
2.121
EQUALLY SEVERE ABNORMALITIES IN ANAL SPHINCTER EMG IN
PATIENTS WITH PARKINSON'S DISEASE AND MULTIPLE SYSTEM
ATROPHY IN EARLY STAGE
J. Linder, R. Libelius, E. Nordh, L. Forsgren, Umeå, Sweden
2.122
THE SPECIFICITY OF POWER-LAW EXPONENT TO EVALUATE THE
SEVERITY OF MOVEMENT DISORDERS FOR PARKINSON´S DISEASE
C. Wu, W. Pan, Y. Liu, Y. Sun, H. Zhi, D. Cai, Shanghai, China
2.123
57
58
123
59
CARDIAC I-METAIODOBENZYLGUANIDINE SCINTIGRAPHY IN
PARKINSON'S DISEASE (PD) PATIENTS WITH SCANS WITHOUT EVIDENCE
OF DOPAMINERGIC DEFICIT (SWEDDS)
W. Jang, J.Y. Ahn, H.-T. Kim, Seoul, Republic of Korea
2.125
60
CEREBRAL PATHOLOGIES STUDY BY MEANS OF MAGNETIC
ENCEPHALOGRAPHY DATA
S.A. Makhortykh, Pushshino, Russia
2.126
61
A RESEACH OF BLOOD PLASMA α-SYNUCLEIN PROTEIN
CONCENTRATION IN PATIENT WITH PARKINSON DISEASE
L. Jiao, M. Chen, Guiyang, China
2.127
62
APPLICATION OF H-MRS IN PARKINSON´S DISEASE AND
SPINOCEREBELLAR ATAXIA
Y. Chen, Tianjin, China
2.128
63
VERIFICATION OF EXPRESSIONS OF KIR2 AS POTENTIAL PERIPHERAL
BIOMARKERS IN LYMPHOCYTES FROM PATIENTS WITH PARKINSON´S
DISEASE
S. Chen, G. Yaxing, W. Gang, Shanghai, China
2.129
72
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
CHANGE IN GLUTATHIONE-S-TRANSFERASE-PI EXPRESSION IN BLOOD
OF PARKINSON'S DISEASE PATIENTS FOLLOWING EXPOSURE TO
OXIDATIVE STRESS: POTENTIAL USE AS A BIOMARKER
A. Korff, B. Pfeiffer, M. Smeyne, M. Kocak, R. Pfeiffer, R. Smeyne, Memphis,
TN, USA
2.130
65
CSF CLUSTERIN IS ASSOCIATED WITH COGNITIVE IMPAIRMENT AND
ALZHEIMER'S DISEASE BIOMARKERS IN PARKINSON'S DISEASE
PATIENTS
K.D. van Dijk, W. Jongbloed, C.E. Teunissen, T. Koene, H.J. Groenewegen,
H.W. Berendse, W.D. van de Berg, R. Veerhuis, Amsterdam, The Netherlands
2.131
66
DECREASED NURR1 AND PITX3 GENE EXPRESSION IN CHINESE
H.-M. Liu, Q.-Q. Tao, W. Le, Shanghai, China
2.132
67
NEURON-SPECIFIC PROTEIN ENOLASE AS DIAGNOSTIC MARKER OF
PARKINSON DISEASE
D. Usmanova, Tashkent, Uzbekistan
2.133
68
AN OLD LEGEND TOWER OF HANOI AS A TOOL OF THE
NEUROPSYCHOLOGICAL ASSESSMENT IN PATIENTS WITH PARKINSON´S
DISEASE
R. Obereigneru, K. Obereigneru, K. Farnikova, M. Dolejs, L. Vanacova,
P. Kanovsky, Olomouc, Czech Republic
2.134
69
CHARACTERISING NON MOTOR PATTERNS OF EARLY MORNING OFF
PERIODS IN PARKINSON´S DISEASE: AN INTERNATIONAL STUDY
A. Rizos1, T. Klemencic Kozul1, A. Martin1, I. Koch1, S. Tluk1, B. Kessel2,
P. Martinez-Martin3, P. Odin4, A. Antonini5, C. Falup-Pecurariu6, A. Dos Santos7,
K. Ray Chaudhuri1, 1London, 2Orpington, UK, 3Madrid, Spain, 4Lund, Sweden,
5
Venice, Italy, 6Brasov, Romania, 7Slough, UK
2.135
70
PARKINSON DISEASE OR ESSENTIAL TREMOR
K. Fedorova, P. Pilipenko, E. Vostricova, L. Shepankevich, N. Myasnikova,
L. Ahundova, E. Kononova, Novosibirsk, Russia
71
DETERMINANTS OF CORTICAL EXCITABILITY CHANGES IN PARKINSON'S
DISEASE
J. Antczak, M. Rakowicz, M. Derejko, M. Banach, E. Inglot, J. Sienkiewicz,
Warszawa, Poland
2.137
72
A COMPARATIVE FOLLOW-UP FMRI STUDY FOR A SIMPLE MOTOR TASK
IN PD AND MSA
M. Saxena, S.S. Kumaran, V. Goyal, M. Behari, New Delhi, India
2.138
73
CLINICAL AND MRI, 18F-FDG PET DIAGNOSTIC CHARACTERISTICS OF 23
PROGRESSIVE SUPRANUCLEAR PALSY
F.X. Wang, C. Sun, B.-S. Zhang, Weihai, China
64
73
2.136
2.139
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
74
ABERRANT DIFFUSION TENSOR MRI CHANGES IN SENSORIMOTOR AREA
OF DYT6 PRIMARY DYSTONIA
F.B. Cheng1,2, X.H. Wan1, F. Feng1, B. Hou1, 1Beijing, 2Changchun, China
2.140
75
THE 18[F] -FDG PET STUDY ON THE IDIOPATHIC PARKINSON'S DISEASE
AND SEVERAL PARKINSONIAN-PLUS SYNDROME
P. Zhao, B. Zhang, S. Gao, Tianjin, China
76
TO DISCUSS THE MRI DIFFERENCE OF HEREDITARY SPINOCEREBELLAR
ATAXIA AND PARKINSON PLUS SYNDROM PATIENTS
P. Zhang, Tianjin, China
2.142
77
THE MESENCEPHALIC AREA MEASURED BY BRAIN SONOGRAPHY IN THE
DIFFERENTIAL DIAGNOSIS OF PARKINSONISMS
J.F. Vazquez, I. Sastre, J.I. Tembl, I. Martinez, P. Sahuquillo, V. Parkhutik,
A. Lago, J.A. Burguera, Valencia, Spain
2.143
78
CSF BIOMARKERS OF CENTRAL CATECHOLAMINE DEFICIENCY IN THE
DIAGNOSIS OF PARKINSON DISEASE AND OTHER SYNUCLEINOPATHIES
D.S. Goldstein, C. Holmes, Y. Sharabi, Bethesda, MD, USA
2.144
79
IDENTIFICATION OF PLASMA GLYCOPROTEINS AS BIOMARKERS OF
C. Pan, S. Lu, M. Shi, J. Zhang, Seattle, WA, USA
80
ACTIGRAPHIC ASSESSMENT OF PERIODIC LEG MOVEMENTS IN
PATIENTS WITH RESTLESS LEGS SYNDROMEV
M.A. Poncini, M. Siccoli, E. Werth, C.L. Bassetti, R. Poryazova, C.R. Baumann,
Zurich, Switzerland
2.146
81
THE STUDY OF ANORECTAL MANOMETRY FOR MULTIPLE SYSTEM
ATROPHY AND PARKINSON DISEASE
X. Liu, D. Fan, Beijing, China
2.147
COGNITIVE-MOTIVATIONAL DEFICITS IN ADHD: DEVELOPMENT OF A
CLASSIFICATION SYSTEM
R. Gupta, Allahabad, India
2.148
82
2.141
2.145
83
THE AVAILABILITY OF FDG PET CT AND ROTATORY CHAIR TEST IN
CEREBELLAR TYPE OF MULTIPLE SYSTEMIC ATROPHY: A CASE REPORT
J.H. Shin, H.J. Cho, H.K. Song, Seoul, Republic of Korea
2.149
84
A POSSIBLE NEW BIOMARKER FOR PARKINSON'S DISEASE:
PHARMACOLOGICAL MRI (PHMRI) TO DISCRIMINATE ANIMALS WITH
MPTP-VERSUS AGE-RELATED PARKINSONISM IN RHESUS MONKEYS
Z. Zhang, A. Andersen, P. Hardy, Y. Ai, R. Grondin, D.M. Gash, G.A. Gerhardt,
Lexington, KY, USA
2.150
RELIABILITY AND VALIDITY OF A PATTERN IDENTIFICATION
QUESTIONNAIRE FOR KOREAN STROKE PATIENTS
B. Kang, T. Moon, T. Park, J. Lee, M. Ko, M. Lee, Daejeon, Republic of Korea
2.151
85
74
08:00-18:00
Poster Area
Poster Session
Therapeutical Interventions
Board No
Abstract No
86
INTEROBSERVER RELIABILITY OF PULSE DIAGNOSIS USING
TRADITIONAL KOREAN MEDICINE FOR STROKE PATIENTS
M. Ko, T. Park, J. Lee, B. Kang, T. Moon, J. Choi, T. Choi, M. Lee, Daejeon,
Republic of Korea
2.152
87
RECENT PHARMACOTHERAPY FOR PARKINSON'S DISEASE, A REVIEW
J. Wang, Y.M. Zhao, C.Y. Guo, D.-S. Zhang, Zhangjiakou, China
2.201
88
PRECLINICAL EVALUATION OF KOM-1962, A POTENT SELECTIVE
INHIBITOR OF CATECHOL-O-METHYLTRANSFERASE, AS A NOVEL DRUG
CANDIDATE FOR PARKINSON´S DISEASE
I. Wanajo, S. Tazawa, S. Tanaka, A. Yamamoto, T. Ishikawa, N. Tanaka,
S. Kikuchi, Y. Takehana, N. Shibata, Azumino-City, Japan
2.203
89
THE DYNAMIC STAT EFFECT OF COMPOUND REHMANNIA PRESCRIPTION
ON TH AND GENE EXPRESSION OF LD RATS WITH PARKINSON'S
DISEASE
J.C. He, Shanghai, China
2.204
90
SELENITE BENEFITS EMBRYONIC STEM CELLS THERAPY IN
PARKINSON'S DISEASE THROUGH INHIBITING INFLAMMATION
L.-P. Tian, S. Zhang, L. Xu, Y. Wang, W. Li, W. Chen, J.-Q. Ding, S.-D. Chen,
Shanghai, China
2.205
91
EPIGALLOCAETECHIN GALLATE (EGCG) INHIBITS a-SYNUCLEIN
AGGREGATION: A POTENTIAL AGENT FOR PARKINSON DISEASE
Y. Zhang1, Y. Xu1, Y. Deng1, W. Wong2, P.L. McGeer2, H. Qing1, 1Beijing, China,
2
Vancouver, BC, Canada
2.206
92
THE BENEFICIAL EFFECT OF INTRASTRIATAL BOTULINUM NEUROTOXIN
IN RATS WITH HEMIPARKINSONISM DEPENDS ON THE DEPLETION OF
ACETYLCHOLINE
A. Wree, E. Mix, R. Benecke, A. Hawlitschka, Rostock, Germany
2.207
93
EFFECT OF CD4 AND CD8 ON MPTP INDUCED PAKINSON DISEASE IN
C57BL/6 MICE
Y. Zhang, Chongqing, China
2.209
94
CHEMICALLY MODIFIED PEPTIDES FOR INHIBITING α-SYNUCLEIN
AGGREGATION
F.M. Zhou, L. Zhang, Y. Peng, Y.-N. Liu, Changsha, China
2.210
95
LEVO-CARNITORS AS EMERGING NEUROPROTECTIVE EPIGENETIC
MOLECULAR MEDICINES
P. Kumar1,2,3, R.N. Jegathambigai3, 1Kuala Lumpur, Malaysia, 2Grand Cayman,
Cayman Islands, 3Sungai Petani, Malaysia
2.211
96
®
AFFITOPE BASED VACCINES: A NOVEL AND SAFE
IMMUNOTHERAPEUTIC STRATEGY FOR PARKINSON'S DISEASE
H. Weninger1, E. Masliah2, E. Rockenstein2, R. Santic1, A. Schneeberger1,
F. Mattner1, W. Schmidt1, M. Mandler1, 1Vienna, Austria, 2San Diego, CA, USA
75
2.212
08:00-18:00
Poster Area
Poster Session
Therapeutical Interventions (Contd.)
Board No
97
Abstract No
CHRONIC L-DOPA TREATMENT IMPAIRS MOTOR LEARNING IN A
UNILATERAL 6-HYDROXY-DOPAMINE RAT MODEL OF PARKINSON´S
DISEASE
E.M. Murphy, Cardiff, UK
2.213
98
IMPAIRED CONSOLIDATION OF MOTOR LEARNING IN PARKINSON'S
DISEASE
L.-A. Leow1,2, A.M. Loftus1,2, G. Hammond1, 1Crawley, 2Joondalup, WA, Australia
99
THE ROLE OF THE CENTRAL CHOLINERGIC NEUROTRANSMITTER
SYSTEM IN SLEEP DISORDERS IN PATIENTS WITH PARKINSON´S
DISEASE
I.V. Krasakov, I.V. Litvinenko, O.V. Tichomirova, Saint-Petersburg, Russia
2.215
THE NEW NEUROPROTECTIVE AGENT HEMANTANE REDUCES L-DOPAINDUCED DYSKINESIA IN HEMIPARKINSONIAN RATS
I. Kapitsa, E. Ivanova, A. Nepoklonov, I. Kokshenev, E. Valdman, T. Voronina,
Moscow, Russia
2.216
2.214
100
101
PHARMACOKINETIC PROFILE OF THE SELECTIVE DOPAMINE D4
RECEPTOR ANTAGONIST L-745,870 IN THE MPTP-LESIONED NON-HUMAN
PRIMATE MODEL OF PARKINSON'S DISEASE
P. Huot, J.B. Koprich, T.H. Johnston, S.H. Fox, J.M. Brotchie, Toronto, ON,
Canada
2.217
102
BERBERINE ATTENUATES CALYCULIN A-INDUCED CYTOTOXICITY AND
TAU HYPERPHOSPHORYLATION IN HEK293 CELLS
G. Yu, Wuhan, China
2.218
103
KETOGENIC DIET: A POSSIBLE THERAPEUTIC TARGET FOR PARKINSON'S
DISEASE?
V.K. Sharma, Shimla, India
2.219
104
EFFECTS OF ENGRAFTED HAIR FOLLICLE STEM CELLS IN ALZHEIMER'S
DISEASE RATS
M. Nobakht1, B. Esmaeilzadeh1, S.M. Hoseini2, 1Tehran, 2Babol, Iran
2.220
105
ANTIOXIDANT EFFECT OF RASAGILINE IS NOT DEPENDENT ON
INHIBITION OF DOPAMINE OXIDATIVE METABOLISM BY MAO IN RAT
STRIATUM IN VIVO
Y. Aluf1,2, S. Khatib2, J. Vaya2, J.P.M. Finberg1, 1Haifa, 2Kiryat Shmona, Israel
2.221
106
MODIFICATION OF DOPAMINE OXIDATIVE METABOLISM BY MAO
SUBTYPES A AND B FOLLOWING DOPAMINERGIC AND SEROTONERGIC
STRIATAL DENERVATION
O. Sader-Mazbar, J.P.M. Finberg, Haifa, Israel
2.222
76
08:00-18:00
Poster Area
Poster Session
Board No
107
Abstract No
NICOTINE AMELIORATES BEHAVIORAL DEFICITS AND OXIDATIVE
STRESS IN A 6-HYDROXYDOPAMINE RAT MODEL OF PARKINSON'S
DISEASE
A. Ciobica, L. Hritcu, M. Padurariu, V. Bild, Iasi, Romania
2.223
108
FACTORS DETERMINING THE MAGNITUDE OF LEVODOPA RESPONSE IN
S. You, S.R. Kim, I.H. Kwon, S.J. Kim, S.J. Chung, J.S. Kim, C.S. Lee, Seoul,
Republic of Korea
2.224
109
PARKINSON'S UK PATIENT SURVEY AND MEDICINES' MANAGEMENT
AUDIT IN THE ROYAL DEVON AND EXETER HOSPITAL, UK, 2011
A. Goff, S. Jackson, Exeter, UK
2.225
110
ONE OUT OF TEN PATIENTS DISCONTINUE ANTI-PARKINSON TREATMENT
DUE TO NOCEBO ADVERSE EVENTS: A META-ANALYSIS OF 47
RANDOMIZED TRIALS
P. Stathis, M. Smpiliris, D.D. Mitsikostas, Athens, Greece
2.226
111
THE CORRELATION ANALYSIS OF INDIVIDUALIZED TREATMENT AND
DISEASE PROGRESSION OF PARKINSON DISEASE
H. Zhao1, H.Z. Liang2, C.H. Zhu2, 1Daliao, 2Dalian, China
2.227
112
PATHOPHYSIOLOGY OF MOTOR COMPLICATIONS IN PARKINSON´S
DISEASE
Y.M. Li1, Y. Geng2, L. Meng1, X.Z. Kong1, M.W. Wang1, 1Shijiazhuang,
2
Shjiazhuang, China
2.228
113
DYSKINESIA IN PARKINSON'S DISEASE - IMPAIRMENTS OF INHIBITION
DURING VOLUNTARY CONTRACTION. A TRANSCRANIAL MAGNETIC
STIMULATION (TMS) STUDY
S.R. Filipović, A. Kačar, N. Kresojević, M. Jelić, S. Milanović, N. Dragašević,
M. Ljubisavljević, V.S. Kostić, Beograd, Serbia
2.229
114
PYM50028, AN ORALLY ACTIVE NEUROTROPHIC FACTOR MODULATOR,
ENHANCES THE EFFECT OF L-DOPA AND REDUCES L-DOPA-INDUCED
DYSKINESIA IN MPTP-LESIONED MACAQUES
T.H. Johnston1, J.B. Koprich1, S.H. Fox1, N.L. Meyers2, C.L. Ward2,
R.I. Hickling2, P.A. Howson2, J.M. Brotchie1, 1Toronto, ON, Canada,
2
Huntingdon, UK
2.230
115
ADX48621, A MGLUR5 NEGATIVE ALLOSTERIC MODULATOR ALLEVIATES
L-DOPA-INDUCED CHOREA AND DYSTONIA IN THE MPTP MACAQUE
MODEL OF PARKINSON´S DISEASE
C. Keywood1, E. Bezard2, M. Hill2, Q. Li2, F. Girard1, S. Poli1, V. Mutel1,
1
Plan les Ouates, Switzerland, 2Manchester, UK
2.231
116
TEST-RETEST RELIABILITY OF THE PURDUE PEGBOARD IN DRUG ON
AND OFF-PHASE FOR PERSONS WITH PARKINSON´S DISEASE
H. Mehdizadeh, G. Taghizadeh, H. Ashayeri, Tehran, Iran
77
2.232
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
INTERPRETATION OF RESPONSE CATEGORIES IN PATIENT-REPORTED
RATING SCALES: A TEST-RETEST STUDY AMONG PEOPLE WITH
PARKINSON'S DISEASE AND OTHER NEUROLOGICAL DISORDERS
I. Knutsson1, K. Samuelson1, P. Hagell1,2, 1Lund, 2Kristianstad, Sweden
2.233
RISK FACTORS FOR LEVODOPA-RELATED DYSKINESIAS IN
PARKINSON'S DISEASE
H. Zhang, S. Chen, N. Ren, Y. Liu, Jinan, China
2.234
"LEVODOPA PHOBIA" CAUSING FLEXED POSTURE IN PARKINSON'S
DISEASE
H. Takahasahi, A. Mizuma, Y. Gotoh, H. Chiba, S. Takagi, Isehara, Japan
2.235
120
NEW TREATMENT FOR CLINICAL STABILIZATION IN PARKINSON´S
DISEASE
E. de Font-Réaulx, Mexico, Mexico
2.236
121
EFFECT OF TETRAHYDROBIOPTERIN AND PHARMACOLOGICAL
CHAPERONES ON TYROSINE HYDROXYLASE; CORRECTION OF
NEUROTRANSMITTER DEFICIENCIES
M. Ying1, C.N. Sarkissian2, T. Scherer3, B. Thöny3, A. Martinez1, 1Bergen,
Norway, 2Montreal, QC, Canada, 3Zürich, Switzerland
2.237
117
118
119
122
COFFEE OR CHOCOLATE, WHAT DO YOU LIKE TO DRINK WITH
YOUR L-DOPA?
L.C. Jimenez-Botello1,2, M.A. Soriano-Ursua1, M.R. Avila-Costa2,
O. Picazo-Picazo1, J. Correa-Basurto1, 1Ciudad de Mexico, 2Tlalnepantla, Mexico
123
SUSTAINED-RELEASE FORMULATION OF LEVODOPA METHYL ESTER
/BENSERAZIDE REDUCE LEVODOPA-INDUCED DYSKINESIA IN
6-OHDA-LEISONED RATS
X. Yang, T. Ren, W. Yuan, Z. Liu, Shanghai, China
2.239
124
RASAGILINE IMPROVES THE QUALITY OF SLEEP IN PATIENTS WITH
PARKINSON'S DISEASE: RESULTS OF THE RASAGILINE EFFECT ON
SLEEP TRIAL (REST)
M. Panisset, S. Chouinard, REST Study Investigators, Montreal, QC, Canada
2.240
125
COMPUTATION OF BINDING AFFINITY OF CATECHOL-OMETHYLTRANSFERASE-OPICAPONE COMPLEXES
N. Palma1, M.J. Bonifacio1, A.I. Loureiro1, P. Soares-da-Silva1,2, 1S. Mamede do
Coronado, 2Porto, Portugal
2.241
126
BRAIN AND PERIPHERAL LEVODOPA PHARMACOKINETICS IN THE
CYNOMOLGUS MONKEY FOLLOWING ADMINISTRATION OF OPICAPONE,
A NOVEL CATECHOL-O-METHYLTRANSFERASE INHIBITOR
M.J. Bonifacio1, J.S. Sutcliffe2, L. Torrão1, L. Wright1, P. Soares-da-Silva1,3,
1
S. Mamede do Coronado, Portugal, 2Singapore, Singapore, 3Porto, Portugal
2.242
2.238
78
08:00-18:00
Poster Area
Poster Session
Board No
127
Abstract No
OPICAPONE: CHARACTERIZATION OF A NOVEL PERIPHERAL LONGACTING CATECHOL-O-METHYLTRANSFERASE INHIBITOR
M.J. Bonifacio1, L. Torrão1, A.I. Loureiro1, L.C. Wright1, P. Soares-da-Silva1,2,
1
S. Mamede do Coronado, 2Porto, Portugal
2.243
128
PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF
OPICAPONE, A NOVEL COMT INHIBITOR, DURING FIRST ADMINISTRATION
TO HEALTHY MALE SUBJECTS
T. Nunes1, J.F. Rocha1, R. Pinto1, R. Machado1, L.C. Wright1, A. Falcao2,
L. Almeida3, P. Soares-da-Silva1,4, 1S. Mamede do Coronado, 2Coimbra,
3
Aveiro, 4Porto, Portugal
2.244
129
PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF
OPICAPONE, A NOVEL COMT INHIBITOR, DURING MULTIPLE RISING DOSE
REGIMENS IN HEALTHY MALE SUBJECTS
J.F. Rocha1, T. Nunes1, M. Vaz-da-Silva1,2, R. Machado1, L.C. Wright1,
A. Falcao3, L. Almeida4, P. Soares-da-Silva1,2, 1S. Mamede do Coronado, 2Porto,
3
Coimbra, 4Aveiro, Portugal
2.245
130
THE EFFICACY AND SAFETY OF TOLCAPONE IN PATIENTS WITH
PARKINSON'S DISEASE
C. Zhang, Tianjin, China
2.246
131
INCREASED DOPAMINE OUTPUT AND ALTERED METABOLIC PROFILE OF
DOPAMINE FOLLOWING DEUTERIUM SUBSTITUTIONS IN THE L-DOPA
MOLECULE
T. Malmlöf, K. Feltmann, T.H. Svensson, B. Schilström, Stockholm, Sweden
2.247
132
GASTRORETENTIVE EXTENDED-RELEASE FORMULATIONS IMPROVE THE
PHARMACOKINETICS AND PHARMACODYNAMICS OF LEVODOPA IN
C. Chen, V.E. Cowles, M. Sweeney, Menlo Park, CA, USA
2.248
133
EFFICACY OF RASAGILINE IN COMBINATION WITH DOPAMINE AGONIST
THERAPY: RESULTS FROM A POST-MARKETING OBSERVATIONAL STUDY
IN PATIENTS WITH PARKINSON'S DISEASE
H. Reichmann1, W.H. Jost2, 1Dresden, 2Wiesbaden, Germany
2.249
134
TOLCAPONE FOR THE TREATMENT OF PARKINSON'S DISEASE WITH
MOTOR FLUCTUATIONS
Y. Wang, Tianjin, China
2.250
135
IMPACT OF LEVODOPA ON IMPROVING LIMB SYMMETRY DURING
WALKING IN PARKINSON DISEASE
M.S. Jog1, F. Rahimi1, A. South1, L. Zhu1, C. Bee1, C. Duval2, 1London, ON,
2
Montreal, QC, Canada
2.251
136
LEVODOPA MEDICATION IMPROVES IMPLICIT SEQUENCE LEARNING ON
THE SERIAL REACTION TIME TASK IN PARKINSON'S DISEASE
M. Beigi1, L. Wilkinson1,2, A. Parton1, M. Jahanshahi1, 1London, UK, 2Bethesda,
MD, USA
2.252
79
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
137
INTRAJEJUNAL LEVODOPA INFUSION IN THE UK: COMPARATIVE REVIEW
OF MOTOR AND NON-MOTOR EFFECTS IN TREATED VERSUS
UNTREATED ADVANCED PARKINSON'S PATIENTS
P. Reddy1, P. Martinez-Martin2, A. Rizos1, A. Martin1, G.C. Faye1, I. Forgacs1,
K. Ray Chaudhuri1, 1London, UK, 2Madrid, Spain
2.253
138
INTERIM RESULTS FROM ONGOING, LONG-TERM, OPEN-LABEL STUDY
OF LEVODOPA/CARBIDOPA INTESTINAL GEL IN PATIENTS WITH
PARKINSON'S DISEASE AND SEVERE MOTOR FLUCTUATIONS
P. Odin1, K. Chatamra2, A.J. Espay3, D.G. Standaert4, H.H. Fernandez5,
J. Benesh6, W. Robieson6, S.L. Hass6, R.A. Lenz6, 1Lund, Sweden, 2Weesp, The
Netherlands, 3Cincinnati, OH, 4Birmingham, AL, 5Cleveland, OH,
6
Abbott Park, IL, USA
2.254
139
IMPROVEMENT OF IMPULSIVE CONTROL DISORDERS IN PARKINSON´S
DISEASE WITH JEJUNAL LEVODOPA INFUSION
E. Lopez-Valdes, M.J. Catalan, C. Villanueva, R. Garcia-Ramos, E. De Pablo,
Madrid, Spain
2.255
SYMPTOMATIC NEUROPATHY IN PARKINSON´S DISEASE PATIENTS
DURING DUODENAL LEVODOPA INFUSION TREATMENT
F. Mancini1, D. Calandrella1, M. Del Fante1, G. Riboldazzi2, R. Zangaglia3,
C. Pacchetti3, L. Manfredi1, A. Antonini4, 1Milano, 2Varese, 3Pavia, 4Venice, Italy
2.256
141
SUICIDE IN PD PATIENT TREATED WITH DUODOPA - SECOND CASE
D. Flisar, A. Avberšek, Maribor, Slovenia
2.257
142
LONG ACTING DOPAMINE AGONISTS IN CLINICAL PRACTICE: A
COMPARATIVE MULTICENTRE EUROPEAN SURVEY IN YOUNG AND OLD
PD
A. Rizos1, I. Koch1, G. Durner1, A. Martin1, S. Tluk1, T. Henriksen2, B. Kessel3,
A. Antonini4, P. Odin5,6, C. Falup-Pecurariu7, P. Martinez-Martin8, P. Reddy1
K. Ray Chaudhuri1, EUROPAR, 1London, UK, 2Copenhagen, Denmark,
3
Orpington, UK, 4Venice, Italy, 5Lund, Sweden, 6Bremerhaven, Germany,
7
Brasov, Romania, 8Madrid, Spain
2.258
143
IMPROVEMENT OF ICDS AND SLEEP DISORDERS IN PD PATIENTS
TREATED WITH ROTIGOTINE PATCH SWITCHING FROM OTHER
DOPAMINE-AGONISTS
G. Riboldazzi1,2, M. Perini3, R. Maestri4, G. Frazzitta5, 1Cunardo, 2Varese,
3
Gallarate, 4Montescano (PV), 5Montescano, Italy
2.259
THE EFFICACY AND SAFETY OF 24 HOUR ROTIGOTINE TRANSDERMAL
PATCH IN THE TREATMENT OF EARLY PARKINSON'S DISEASE:
A META-ANALYSIS
G.M. Ramiro, N. Fabiana, R.D. Jamora, Manila, Philippines
2.260
140
144
145
ROTIGOTINE DO NOT AFFECT COGNITIVE FUNCTIONS IN EARLY-MILD DE
NOVO PARKINSON'S DISEASE PATIENTS
L. Brusa, C. Massimetti, V. Pavino, R. Bove, C. Iani, G. Koch, P. Stanzione,
Rome, Italy
2.261
80
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
146
THE EFFICACY AND SAFETY OF PRAMIPEXOLE IN CLINICAL RESEARCH
C. Li, Tianjin, China
147
PATIENT-REPORTED CONVENIENCE OF ONCE-DAILY VS TID DOSING
DURING LONG-TERM STUDIES OF PRAMIPEXOLE IN EARLY AND
ADVANCED PARKINSON'S DISEASE
A. Schapira1, P. Barone2, R. Hauser3, Y. Mizuno4, O. Rascol5, M. Busse6,
C. Debieuvre7, M. Fraessdorf6, W. Poewe8, for the Pramipexole ER Studies
Group, 1Queen Square, UK, 2Napoli, Italy, 3Tampa, FL, USA, 4Tokyo, Japan,
5
Toulouse, France, 6Ingelheim am Rhein, Germany, 7Reims, France, 8Innsbruck,
Austria
2.263
148
NEUROPSYCHIATRIC PROFILE OF PATIENTS ON TREATMENT WITH
PRAMIPEXOLE, ROPINIROLE OR LEVODOPA IN MONOTHERAPY: HEADTO-HEAD COMPARISON
J.P. Perez1, J. Pagonabarraga1, S. Sierra2, B. Pascual-Sedano1, A. Gironell1,
J. Kulisevsky1, Trapezio Study Group, 1Barcelona, 2Pamplona, Spain
2.262
2.264
149
LONG-TERM SAFETY AND SUSTAINED EFFICACY OF EXTENDEDRELEASE PRAMIPEXOLE IN EARLY AND ADVANCED PARKINSON'S
DISEASE
W. Poewe1, P. Barone2, R. Hauser3, Y. Mizuno4, O. Rascol5, M. Busse6, C.
Debieuvre7, M. Fraessdorf6, A. Schapira8, for the Pramipexole ER Studies Group,
1
Innsbruck, Austria, 2Napoli, Italy, 3Tampa, FL, USA, 4Tokyo, Japan, 5Toulouse,
France, 6Ingelheim am Rhein, Germany, 7Reims, France, 8London, UK
2.265
150
TWO-YEAR, PLACEBO-CONTROLLED SAFETY AND TOLERABILITY DATA
FOR SAFINAMIDE AS ADD-ON TO LEVODOPA IN PATIENTS WITH
PARKINSON'S DISEASE (PD)
R. Borgohain1, J. Szasz2, P. Stanzione3, R. Guiliani4, V. Lucini4, R. Anand5, for
the Study 018 Investigators, 1Hyderabad, India, 2Targu Mures, Romania, 3Rome,
4
Bresso, Italy, 5St Moritz, Switzerland
2.266
151
LONG-TERM EFFICACY OF SAFINAMIDE AS ADD-ON TO LEVODOPA IN
PARKINSON'S DISEASE (PD) USING AN 'ON' AND 'ON-OFF' TREATMENT
ANALYSIS
R. Anand1, R. Borgohain2, M. Bhatt3, F. Stocchi4, D. Chirileanu5, V. Lucini6, For
the Study 018 Investigators, 1St Moritz, Switzerland, 2Hyderabad, 3Mumbai, India,
4
Rome, Italy, 5Timisoara, Romania, 6Bresso, Italy
2.267
152
FIRST 2-YEAR, PLACEBO-CONTROLLED STUDY IN PARKINSON'S
DISEASE PATIENTS WITH MOTOR FLUCTUATIONS INDICATES
SAFINAMIDE MAY BENEFIT PATIENTS WITH MORE SEVERE DYSKINESIA
R. Anand1, R. Borgohain2, F. Stocchi3, R. Guiliani4, P. Rice5, E. Forrest4, V.
Lucini4, The Study 016/018 Investigators, 1St Moritz, Switzerland, 2Hyderabad,
India, 3Rome, 4Bresso, Italy, 5Chicago, IL, USA
2.268
81
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
153
SAFINAMIDE AS ADD-ON TO LEVODOPA IN PARKINSON'S DISEASE WITH
MOTOR FLUCTUATIONS MAY IMPROVE RESPONDER RATES VERSUS
PLACEBO DURING LONG-TERM TREATMENT
R. Anand1, C. Meshram2, J. Szasz3, M. Bhatt4, R. Guiliani5, E. Forrest5, V. Lucini5,
for the Study 018 Investigators, 1St Moritz, Switzerland, 2Nagpur, India, 3Targu
Mures, Romania, 4Mumbai, India, 5Bresso, Italy
2.269
154
BUPROPION ON FREEZING OF GAIT IN PARKINSON´S DISEASE
Y.S. Park, W.C. Kim, Seongnam-si, Republic of Korea
2.270
155
DEVELOPMENT OF INHALED APOMORPHINE FOR PATIENTS WITH
FLUCTUATING PARKINSON'S DISEASE: DOSE-FINDING RESULTS
D. Grosset1, K. Grosset1, F. Morgan2, Inhaled Apomorphine Study Group,
1
Glasgow, 2Chippenham, UK
2.271
156
THE TREATMENT OF PAINFUL DIAPHRAGMATIC DYSTONIA IN IDIOPATHIC
PARKINSON´S DISEASE WITH APOMORPHINE
C.E. Pollock, A. Ross Russell, M. Silva, Gloucester, UK
2.272
157
THE EFFECTIVE TREATMENT OF PAINFUL DYSTONIC FEET IN
PARKINSON´S DISEASE WITH APOMORPHINE
A.L. Ross Russell, C.E. Pollock, M. Silva, Gloucester, UK
158
DOPAMINE DYSREGULATION SYNDROME WITH SEROTONIN SYNDROME
IN PARKINSON´S DISEASE: CASE REPORT
D.D. Ren1, W. Luo1, B. Wang1, Y.Y. Fan1, X.H. Gui2, B.R. Zhang1, 1Hangzhou,
2
Shaoxing, China
2.274
159
QUETIAPINE USE FOR PSYCHOSIS IN PARKINSON'S DISEASE: A
RETROSPECTIVE STUDY IN A TERTIARY MOVEMENT DISORDER CENTRE,
SINGAPORE
W. Li, L. Tan, P.N. Lau, W.L. Au, K.Y. Tay, Singapore, Singapore
2.276
160
OPTIMIZATION OF PHASE III STUDY DESIGN FOR PIMAVANSERIN IN THE
TREATMENT OF PARKINSON´S DISEASE PSYCHOSIS (PDP)
R. Mills, D. Bahr, H. Williams, San Diego, CA, USA
2.277
161
USE OF BOTULIUM TOXIN TYPE A IN A MOVEMENT DISORDERS CLINIC:
EXPANDING THE USES. A 24 MONTH FOLLOW-UP
C. Borrue-Fernandez, R. Lobato, C. Barbosa-Lopez, San Sebastian de los
Reyes, Spain
2.278
162
ADVERSE EVENTS TO ANTIPARKINSONIAN MEDICATIONS IN
PARKINSONIAN AND NON-PARKINSONIAN PATIENTS
S. Perez-Lloret1, M.V. Rey1, N. Fabre1, F. Ory1, U. Spampinato2, O. Rascol1,
J.-L. Montastruc1, 1Toulouse, 2Bordeaux, France
2.279
163
RELATIONSHIP BETWEEN POLYPHARMACY AND FREQUENCY OF
ADVERSE EVENTS TO ANTIPARKINSONIAN DRUGS: A PRELIMINARY
STUDY
M.V. Rey1, S. Perez-Lloret1, U. Spampinato2, J.-L. Montastruc1, O. Rascol1,
1
Toulouse, 2Bordeaux, France
2.280
82
2.273
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
DARKENING OF WHITE HAIR IN PARKINSON`S DISEASE INDUCED BY
LEVODOPA RICH MUCUNA PRURIENS (VELVET BEANS) EXTRACT
POWDER
R.P. Munhoz, P. Dare, H. Teive, Curitiba, Brazil
2.281
165
FACTORS RELATED TO ORTHOSTATIC HYPOTENSION IN PARKINSON'S
DISEASE
S. Perez-Lloret1, M.V. Rey1, N. Fabre1, F. Ory1, U. Spampinato2,
J.-L. Montastruc1, O. Rascol1, 1Toulouse, 2Bordeaux, France
2.282
166
REVERSIBLE ANTECOLLIS ASSOCIATED WITH DOPAMINE AGONIST IN A
PATIENT WITH PARKINSON'S DISEASE
H.J. Kim, B.S. Jeon, H.J. Kang, J.-Y. Kim, S.H. Kim, S.-H. Han, Seoul,
Republic of Korea
2.283
167
IMPULSE-CONTROL DISORDERS IN PARKINSON'S DISEASE PATIENTS
S. Perez-Lloret1, M.V. Rey1, N. Fabre1, F. Ory1, U. Spampinato2,
J.-L. Montastruc1, O. Rascol1, 1Toulouse, 2Bordeaux, France
168
TRANSDERMAL ROTIGOTINE CAUSES IMPULSE CONTROL DISORDERS IN
PATIENTS WITH RESTLESS LEGS SYNDROME
S.R. Schreglmann, A.R. Gantenbein, C.R. Baumann, Zurich, Switzerland
2.285
169
MIGRATORY EDEMA REALATED TO RASAGILINE TREATMENT
M.J. Catalan, E. Lopez-Valdes, C. Villanueva, R. Garcia-Ramos, Madrid, Spain
2.286
170
ROTIGOTINE-INDUCED NAIL DYSCHROMIA IN A PATIENT WITH
PARKINSONS DISEASE
R.P. Munhoz, H. Teive, Curitiba, Brazil
2.287
171
COMBINED ZOLPIDEM AND CARBIDOPA/LEVODOPA TREATMENT OF
PROGRESSIVE SUPRANUCLEAR PALSY (PSP): A CASE REPORT WITH
VIDEO DOCUMENTATION
S. Chen, S. Juneja, S.L. Jaffe, Shreveport, LA, USA
2.288
172
A NEW TREATMENT ALGORITHM FOR TARDIVE DYSKINESIA OR
DYSTONIA
P.N. van Harten1,2, D.E. Tenback1,3, 1Amersfoort, 2Maastricht, 3Utrecht,
The Netherlands
2.289
ONCE YEARLY ZOLEDRONIC ACID IN OSTEOPOROTIC PD PATIENTS
COMPARED TO OSTEOPOROTIC POSTMENOPAUSAL WOMEN
M. Invernizzi1, S. Carda2, A. Baricich1, C. Cisari1, 1Novara, Italy, 2Lousanne,
Switzerland
2.290
EFFECTS OF INITIAL POLYTHERAPY ON SPASMS AND EEG IN NEWLY
DIAGNOSED WEST SYNDROME
2.291
164
173
174
83
2.284
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
175
THE ACUTE EFFECTS OF NON-INVASIVE TRANSCRANIAL PULSED
CURRENT STIMULATION (TPCS) ON GAIT AND BALANCE VARIABLES OF
G. Alon, M.W. Rogers, L.M. Shulman, Baltimore, MD, USA
2.292
176
EFFECTS OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION ON
PARKINSONISM OF MULTIPLE SYSTEM ATROPHY: CLINICAL,
ELECTROPHYSIOLOGICAL AND FUNCTIONAL MRI STUDY
H. Wang1, L.L. Li2, B. Hou1, S. Wu1, F. Feng1, Y.H. Qiu2, L.Y. Cui1, 1Beijing,
2
Shenzhen, China
2.293
177
LOW FREQUENCY REPETITIVE DEEP TRANSCRANIAL MAGNETIC
STIMULATION IMPROVES MOTOR PERFORMANCE IN PATIENTS WITH
O.S. Cohen1, A. Zangen2, R. Amiaz3, G. Yahalom1, Z. Nitsan1, L. Ephraty1,
Y. Orlev1, E. Kozlova1, H. Strauss1, S. Hassin-Baer1, 1Ramat-Gan, 2Rehovot,
3
Ramat-GAn, Israel
2.294
178
PSYCHOGENIC MOVEMENT DISORDERS AND RECOVERY AFTER MOTOR
CORTEX TRANSCRANIAL MAGNETIC STIMULATION
N. Chastan, D. Maltête, S. Derrey, O. Guillin, R. Lefaucheur, A. Lebas,
G. Gourcerol, D. Hannequin, J. Weber, D. Parain, Rouen, France
2.295
179
WHAT IS PREFERRING HIGH OR LOW FREQUENCY RTMS STIMULATION IN
PARKINSON'S DISEASE?
J. Málly, Sopron, Hungary
2.296
180
PLASTICITY INDUCTION BY PAIRING SUBTHALAMIC NUCLEUS DEEP
BRAIN STIMULATION AND MOTOR CORTICAL TRANSCRANIAL MAGNETIC
K. Udupa, N. Bahl, C. Gunraj, F. Mazzella, E. Moro, M. Hodaie, A. Lozano,
A. Lang, R. Chen, Toronto, ON, Canada
2.297
181
THE USEFULLNESS OF INTRAOPERATIVE COMPUTED TOMOGRAPHY
FOR DEEP BRAIN STIMULATION
Y.S. Park, W.C. Kim, H.S. Kim, S.S. Chung, Seongnam, Republic of Korea
2.299
182
SAFETY DATA IN A RANDOMIZED CONTROLLED TRIAL OF CONSTANT
CURRENT DBS VERSUS LEAD PLACEMENT ALONE FOR PARKINSON'S
DISEASE MOTOR FLUCTUATIONS
M. Tagliati1, B.V. Gallo2, G.T. Mandybur3, J.E. Arle4, W.J. Elias5, B. Ford6,
S.S. Horn7, S.W. Hung8, J. Jankovic9, F.S. Junn10, F.J. Marshall11, R.M. Stewart12,
D.M. Swope13, L. Verhagen14, M.S. Okun15, 1Los Angeles, CA, 2Miami, FL,
3
Cincinnati, OH, 4Burlington, MA, 5Charlottesville, VA, 6New York, NY,
7
Philadelphia, PA, 8Milwaukee, WI, 9Houston, TX, 10Dearborn, MI, 11Rochester,
NY, 12Dallas, TX, 13Loma Linda, CA, 14Chicago, IL, 15Gainesville, FL, USA
2.300
183
DIRECT TARGETING THE SUBTHALAMIC NUCLEUS WITH 3.0T MR
IMAGING FOR DEEP BRAIN STIMULATION
Y.-C. Shi, Y.-M. Wang, Wulumuqi City, China
84
2.301
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
184
MICRORECORDING OPTIMIZES FINAL ELECTRODE PLACEMENT FOR
SUBTHALAMIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE
T. Mandat1, M. Tutaj2, H. Koziara1, P. Nauman1, W. Bonicki1, R. Rola1,
1
Warszawa, 2Krakow, Poland
2.302
185
SUBTHALAMIC NEURON ACTIVITY IN PATIENTS WITH PARKINSON
DISEASE: NEUROPHYSIOLOGICAL CRITERIA FOR DBS ELECTRODE
IMPLANTATION
Y. Kajita1, Y. Kaneoke2, T. Nagai1, K. Yoshida1, D. Nakatsubo3, S. Maesawa4,
T. Wakabayashi4, 1Nagoya, 2Wakayama, 3Obu, 4Aichi, Japan
2.303
186
THE DYNAMIC OF SUBTHALAMIC LOW FREQUENCY OSCILLATIONS
AFTER LEVODOPA INTAKE AND DURING ONGOING DEEP BRAIN
M. Rosa1, G. Giannicola1, S. Marceglia1, E. Scelzo1, L. Rossi1, D. Servello1,
C. Menghetti1, C. Pachetti2, M. Locatelli1, E. Caputo3, F. Cogiamanian1,
G. Ardolino1, S. Barbieri1, A. Priori1, 1Milan, 2Pavia, 3Bari, Italy
2.304
187
LONG-TERM RECORDINGS OF LOCAL FIELD POTENTIALS FROM DEEP
BRAIN STIMULATING ELECTRODES IMPLANTED IN THE SUBTHALAMIC
NUCLEUS
A. Abosch1, N.F. Ince1, J. Wu2, 1Minneapolis, 2Fridley, MN, USA
2.305
188
WHAT THE SUBTHALAMIC LOCAL FIELD POTENTIALS SAY AFTER YEARS
OF CHRONIC STIMULATION IN PARKINSON'S DISEASE?
G. Giannicola1, M. Rosa1, D. Servello1, C. Menghetti1, S. Marceglia1, L. Rossi1,
C. Pacchetti2, M. Porta1, E. Scelzo1, S. Barbieri1, A. Priori1, 1Milan, 2Pavia, Italy
2.306
189
THE MOTOR CONTROL NETWORKS ACTIVATED BY EFFECTIVE DEEP
BRAIN STIMULATION OF SUBTHALAMIC NUCLEUS IN MPTP MONKEYS, A
H215O-PET STUDY
T. Asakawa1, K. Sugiyama1, T. Yamashita1, T. Nozaki1, Y. Magata1, H. Tsukada1,
H. Onoe2, H. Namba1, 1Hamamatsu, 2Kobe, Japan
2.307
190
THE ROLE OF THE SUBTHALAMIC NUCLEUS IN COGNITIVE FUNCTIONS.
A VIEWPOINT BASED ON DEPTH RECORDINGS
I. Rektor, M. Baláž, M. Bočková, I. Rektorová, Brno, Czech Republic
2.308
191
BILATERAL SUBTHALAMIC NUCLEUS STIMULATION VERSUS
PREOPERATIVE MEDICAL THERAPY IN PARKINSON'S DISEASE: A
SYSTEMATIC REVIEW OF STUDIES WITH ONE YEAR FOLLOW-UP
W. Xian, X. Fu, J. Chen, Y. Liu, Y. Zheng, J. Liu, X. Zhou, J. Li, Z. Liu, Z. Pei,
L. Chen, Guang Zhou, China
2.309
192
NEUROPSYCHOLOGICAL FINDINGS IN PATIENTS WITH PARKINSON'S
DISEASE SUBMITTED TO UNILATERAL ABLATIVE PROCEDURES
A. Heluani, F. Porto, J. Oliveira Jr, A. Campos, L. Mendes, S. Listik, A. Cukiert,
Sao Paulo, Brazil
2.310
85
08:00-18:00
Poster Area
Poster Session
Board No
193
Abstract No
NEUROPSYCHOLOGICAL FINDINGS IN PATIENTS WITH PARKINSON'S
DISEASE SUBMITTED TO BILATERAL SUBTHALAMIC NUCLEUS DEEP
BRAIN STIMULATION
A. Heluani, L. Mendes, J. Oliveira Jr, A. Campos, F. Porto, S. Listik, A. Cukiert,
Sao Paulo, Brazil
2.311
194
RELATIONSHIP BETWEEN QUALITY OF LIFE, PHYSICAL ACTIVITY AND
LIFE-SPACE IN ADVANCED PARKINSON´S DISEASE BEFORE AND AFTER
STN DBS
J.-F. Daneault1, B. Carignan2, S. Barbat-Artigas2, S. Plouffe2, P. Villeneuve2,
M. Aubertin-Leheudre2, C. Duval2, A.F. Sadikot1, 1Montreal, 2Montréal, QC,
Canada
2.312
195
DEEP BRAIN STIMULATION OF THE SUBTHALAMIC NUCLEUS IMPROVES
SENSE OF WELL-BEING IN PARKINSON'S DISEASE
L.M. McDonald1, D. Page1,2, L. Wilkinson1,3, M. Jahanshahi1, 1London, UK,
2
Ballito, South Africa, 3Bethesda, MD, USA
2.313
196
QUALITY OF LIFE IN PATIENTS WITH MEDICALLY REFRACTORY
PARKINSON'S DISEASE WHO WERE CANDIDATES FOR SURGERY
A. Heluani, L. Mendes, F. Porto, J. Oliveira Jr, A. Campos, S. Listik, A. Cukiert,
Sao Paulo, Brazil
2.314
HOW DOES STN-DBS AFFECT MOOD STATUS IN PD PATIENTS? AN
UPDATE OF THE LITERATURE
A. Papanastasiou, Z. Kefalopoulou, C. Constantoyannis, K. Assimakopoulos,
Patras, Greece
2.315
197
198
CORRELATION OF RCBF AND SURGICAL OUTCOME IN PARKINSON
DISEASE: OBJECTIVE EVALUATION USING STEREOTACTIC EXTRACTION
ESTIMATION ANALYSIS IN 123I-IMP SPECT
Y. Kajita1, Y. Kaneoke2, T. Nagai1, K. Yoshida1, D. Nakatsubo3, S. Maesawa1,
T. Wakabayashi1, 1Nagoya, 2Wakayama, 3Obu, Japan
2.316
199
APPLICATION OF NEURO-NAVIGATION SYSTEM IN TARGET COORDINATE CALCULATION FOR SUBTHALAMIC DEEP BRAIN STIMULATION
L. Qiao, Y. Zhang, J. Li, P. Zhuang, D. Xiao, Y. Li, Beijing, China
2.317
200
QUALITY OF LIFE IN PATIENTS SUBMITTED TO ABLATIVE AND
NEUROMODULATORY SURGERY FOR PARKINSON'S DISEASE
A. Heluani, L. Mendes, F. Porto, J. Oliveira Jr, A. Campos, S. Listik, A. Cukiert,
Sao Paulo, Brazil
2.318
IMPACT OF DEEP BRAIN STIMULATION ON QUALITY OF LIFE IN
PARKINSON'S DISEASE: LONG-TERM FOLLOW-UP
D. Morand1, B. Pereira1, J.-J. Lemaire1, P.-P. Derost1, M. Ulla1, F. Durif1,
J.-P. Azulay2, 1Clermont-Ferrand, 2Marseille, France
2.319
201
202
DEEP BRAIN STIMULATION - OUR EXPERIENCE FROM KELANTAN,
NORTH EASTERN STATE OF MALAYSIA
S. Bhaskar, J. Tharakan, J.M. Abdullah, A.R. Ghani, Z. Idris, M.S. Pieter,
Kota Bharu, Malaysia
86
2.320
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
203
DEEP BRAIN STIMULATION FOR MOVEMENT DISORDERS IN A SERIES OF
276 PATIENTS
Z. Yuqing, Beijing, China
2.321
204
DEEP BRAIN STIMULATION IN CHINA: PRESENT AND FUTURE
W.-H. Hu, K. Zhang, F.-G. Meng, Y. Ma, J.-G. Zhang, Beijing, China
2.322
205
DEEP BRAIN STIMULATION OF THE DORSAL STRIATUM FOR TINNITUS
S.W. Cheung, P.S. Larson, San Francisco, CA, USA
2.323
206
THE BILATERAL STN-DBS CAN IMPROVE MOTOR AND NON-MOTOR
SYMPTOMS IN MODERATE AND ADVANCED PD PATIENTS: A TWO-YEAR
FOLLOW-UP STUDY
X. Fu, J. Liu, Y. Liu, W. Xian, J. Chen, Y. Zheng, H. Zhou, Y. He, J. Li, Z. Liu,
Z. Pei, L. Chen, Guangzhou, China
2.324
207
THE BILATERAL STN-DBS CAN IMPROVE MOTOR AND NONMOTOR
SYMPTOMS IN PATIENTS OF PARKINSON'S DISEASE: A ONE-YEAR
FOLLOW-UP STUDY
Y. Liu, X. Fu, W. Xian, Y. Zheng, J. Chen, H. Zhou, Z. Pei, L. Chen, Guangzhou,
China
2.325
208
EFFECTS OF BILATERAL SUBTHALAMIC NUCLEUS DEEP BRAIN
STIMULATION ON IMPULSE CONTROL AND REPETITIVE BEHAVIOR
DISORDERS IN PARKINSON`S DISEASE
B.S. Jeon, H.-J. Kim, Seoul, Republic of Korea
2.326
209
EFFICACY OF CHRONIC BILATERAL STN-DBS ON ALTERED EYE-TO-FOOT
CO-ORDINATION IN STANDING ADVANCED PARKINSONIAN PATIENTS
DURING LARGE GAZE AND WHOLE-BODY REORIENTATIONS
M.J. Naushahi, L.A. Ah-Kye, P.-Y. Lee, D. Anastasopoulos, N. Pavese,
P.G. Bain, A.M. Bronstein, D. Nandi, London, UK
2.327
210
PRE-POST GAIT KINEMATIC AND STATIC BALANCE ANALYSIS FOR
PARKINSON DISEASE PATIENTS UNDERWENT DBS-STN OPERATION
P. Stathis, E. Boviatsis, M. Smpiliris, N. Darras, M. Themistocleous,
D. Magafosis, M. Tziomaki, I. Panourias, D. Sakas, Athens, Greece
2.328
GAIT ASYMMETRY ASSESSMENT IN PARKINSON DISEASE PATIENTS
BEFORE AND AFTER DBS-STN
P. Stathis, E. Boviatsis, M. Smpiliris, N. Darras, M. Themistocleous,
D. Magafosis, M. Tziomaki, I. Panourias, D. Sakas, Athens, Greece
2.329
BODY WEIGHT GAIN AND METABOLIC CHANGES AFTER DEEP BRAIN
STIMULATION IN PATIENTS WITH PARKINSON'S DISEASE
I. Rieu, P. Derost, M. Ulla, A. Marques, B. Debilly, Y. Boirie, F. Durif,
Clermont-Ferrand, France
2.330
CLINICAL IMPACT OF THALAMOTOMY AND DEEP BRAIN THALAMIC
STIMULATOR IN MOVEMENT DISORDERS NOT RESPONDING TO
MEDICATION
C. Maurice, Montreal, QC, Canada
2.331
211
212
213
87
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
214
NON-MOTOR EFFECTS OF SUBTHALAMIC NUCLES DEEP BRAIN STIMULATION
FOR ADVANCED PARKINSON´S DISEASE PATIENTS
H. Toda, M. Watanabe, H. Saiki, C. Yoshioka, S. Fujimoto, Osaka, Japan
2.332
215
REMISSION OF L-DOPA RESPONSIVE PAIN IN PARKINSON'S DISEASE AFTER
SUBTHALAMIC DEEP BRAIN STIMULATION
O. Sueruecue, H. Vogel, M. Uhl, C. Baumann, Zurich, Switzerland
2.333
216
EFFICACY OF SUBTHALAMIC NUCLEUS DEEP BRAIN STIMULATION FOR LEG
TREMOR CONTROL IN PARKINSON'S DISEASE
P. Hedera, F.T. Phibbs, D.P. Charles, P.E. Konrad, J. Neimat, T.L. Davis, Nashville,
TN, USA
2.334
217
LONG TERM EFFECT OF SUBTHALAMIC NUCLEUS STIMULATION(STN) IN
K.J. Lee, Seoul, Republic of Korea
2.335
218
PSYCHOGENIC LEVODOPA-INDUCED DYSKINESIA EMERGING AFTER
SUCCESSFUL SUBTHALAMIC NUCLEUS DEEP BRAIN STIMULATION (STN-DBS):
CASE REPORT AND VIDEO
W. Hu, B. Klassen, M. Stead, Rochester, MN, USA
2.336
219
TREATMENT OF STATUS DYSTONICUS WITH PALLIDAL DEEP BRAIN
STIMULATION - CASE REPORT
T. Mandat, H. Koziara, R. Rola, T. Tykocki, W. Bonicki, P. Nauman, Warszawa, Poland
2.337
220
DEEP BRAIN STIMULATION IN 10 PATIENTS WITH SEVERE GILLES DE LA
TOURETTE SYNDROME
J. Li, Beijing, China
2.338
221
TERMINOLATERAL NEURORRAPHY IN NERVE INJURIES
C.E. Cavalcanti, A.C. Ribeiro, São Luis, Brazil
222
FACTORS PREDICTING OF THE EFFICACY OF STN-DBS FOR ELDERLY
PARKINSON'S DISEASE
Y. Suzuki, K. Ogawa, H. Shiota, S. Kamei, H. Oshima, C. Fukaya, T. Yamamoto,
Y. Katayama, Tokyo, Japan
2.340
223
EARLY, POSTOPERATIVE MICROLESION EFFECT AS A PREDICTOR OF
SUBTHALAMIC DEEP BRAIN STIMULATION EFFECTIVENESS FOR
PARKINSON'S DISEASE
T. Tykocki, T. Mandat, P. Nauman, Warsaw, Poland
224
MAJOR CAUSES OF POOR SELECTION IN RETROSPECT IN SUBTHALAMIC
DEEP BRAIN STIMULATION FOR PARKINSON'S DISEASE
B.S. Jeon, H.-J. Kim, Seoul, Republic of Korea
2.342
225
CAN A PATIENT WITH COMPLEX MIXED DEMENTIA BE APPROPRIATELY
APPROVED FOR DBS?
L. Jaffe, San Diego, CA, USA
88
2.339
2.341
2.343
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
226
PROTEOMIC ANALYSIS OF VARIATION IN THE CEREBROSPINAL FLUID OF
PARKINSON'S DISEASE PATIENTS PRE- AND POST-DBS
E.-S. Wang, J. Hu, L. Lu, J.-G. Guo, J.-W. Hu, C.-C. Jiang, Shanghai, China
2.344
227
WALKING AND LOW INTENSITY STRENGTHENING PROGRAM FACILITATE
AMBULATORY, MOTOR AND QUALITY OF LIFE IMPROVEMENT IN PEOPLE
WITH PARKINSON'S DISEASE
C.M. Kwok, K.F. Hui, P.W. Ng, H.T. Lui, C.Y. Yick, K.Y. Wong, T.K. Au,
Hong Kong, China
2.345
228
THE EFFECTS OF HOME EXERCISE PROGRAM ON BALANCE AND
ACTIVITY' OF DAILY LIVING IN PARKINSONIAN PATIENTS
A. Koc, Yozgat, Turkey
2.347
229
POPULATION-BASED STUDY ON RISK OF PARKINSON'S DISEASE
ASSOCIATED WITH DEMENTIA AND DEPRESSION
C.-C. Liao1, Y.-W. Yang1, F.-C. Sung2, 1Taipei, 2Taichung, Taiwan
2.348
230
CLINICAL STUDY ON INSOMNIA EVALUATION OF RELATIVE FACTORS
AND REHABILITATION INTERVENTION IN PATIENTS WITH PARKINSON'S
DISEASE
X. Zhang, Q. Guan, Jiaxing, China
2.350
231
IMPROVING FUNCTIONAL OUTCOMES WITH MULTIDISCIPLINARY TEAM
ASSESSMENT AND INTERVENTION IN PARKINSON`S DISEASE
C.P. Padmakumar, M. Rees, T. Lewis, S. Holzhauser, A. Johnson, K. Bullen,
Newcastle, NSW, Australia
2.351
232
TREATMENT OF ARTICULATORY DYSFUNCTION IN PARKISON´S DISEASE
USING REPETATIVE TRANSCRANIAL MAGNETIC STIMULATION
B. Murdoch, Brisbane, QLD, Australia
2.353
233
EFFECTS OF DIFFERENT EXERCISES IN THE PATIENTS WITH
PARKINSON'S DISEASE
S.-M. Cheon, H.-R. Sung, B.-K. Chae, S.-H. Kim, J.W. Kim, Busan,
Republic of Korea
2.354
234
RATIONALE AND DESIGN OF SPIRITT: A RANDOMISED CONTROLLED
TRIAL OF A DOMICILIARY-BASED SPECIALIST PARKINSON´S
INTEGRATED REHABILITATION TEAM
H. Gage1, K. Bryan1, S. Ting1, P. Williams1, J. Kaye1, B. Castleton2, P. Trend1,
D. Wade3, 1Guildford, 2Woking, 3Oxford, UK
2.355
235
POSSIBILITIES AND LIMITS OF REHABILITATION PROGRAM IN
PARKINSON´S DISEASE AND PARKINSONIAN SYNDROMES
A.S. Nica, G. Mologhianu, A. Murgu, C. Brailescu, L. Miron, B. Mitoiu, M. Ivascu,
T. Papacocea, Bucharest, Romania
2.356
236
USING ECOLOGICAL EVENT-BASED ACOUSTIC GUIDES TO CUE GAIT IN
W. Young, M. Rodger, C. Craig, Belfast, Ireland
89
2.357
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
POSTURAL STABILITY IN PARKINSON'S DISEASE PATIENTS AFTER TAI
CHI TRAINING: A RANDOMIZED CONTROLLED TRIAL
F. Li, K. Fitzgerald, Eugene, OR, USA
2.358
QUALITY OF LIFE SCALE IN PARKINSON'S DISEASE IN RELATION TO
AMBULATORY INDEPENDENCY
C.M. Kwok, C.Y. Yick, Hong Kong, Hong Kong S.A.R.
2.359
239
STUDY OF PLANTAR PRESSURE IN PARKINSON SISEASE PATIENTS
X. Chen, L. Chen, J. Li, D. Huang, Guangzhou, China
2.360
240
PHYSICAL THERAPY IMPROVES SYMPTOMS IN CERVICAL DYSTONIA
PATIENTS WITH INCOMPLETE RESPONSE TO ONOBOTULINUM INJECTION
A. Griffith, A. Zylstra, P. Agarwal, Kirkland, WA, USA
2.361
241
NEUROMUSCULAR TAPING FOR THE TREATMENT OF DROP HEAD
SYNDROME IN MULTISYSTEM ATROPHY
M. Pilleri, C. Berlingieri, A. Turolla, S. Rossi, M. Agostini, A. Lacatena,
2.362
QI DANCE IN PATIENT WITH PARKINSON'S DISEASE
H.J. Lee, S.-Y. Kim, Y. Chae, M.-Y. Kim, C. Yin, W.-S. Jung, K.H. Cho,
S.-N. Kim, H.-J. Park, H. Lee, Seoul, Republic of Korea
2.363
ANTI-SPASTIC EFFECTS OF THE DIRECT APPLICATION OF VIBRATORY
STIMULI IN POST-STROKE PATIENTS: A RANDOMIZED CONTROLLED
STUDY
S. Matsumoto1, T. Noma1, S. Etoh2, M. Shimodozono1, K. Kawahira1,
1
Kirishima City, 2Kishima City, Japan
2.364
FUNCTIONAL AND CLINICAL MEASURES CORRELATING WITH DRIVING
ABILITY IN INDIVIDUALS WITH PARKINSON'S DISEASE
M. Masterson, A. Thompson, L. Elmer, Toledo, OH, USA
2.365
237
238
242
243
244
245
ABNORMAL HAND MOVEMENT OF ALIEN HAND SYNDROME IS RELATED
TO DISINHIBITION OF CORTICAL MOTOR CIRCUIT
H.-Y. Jung, Y.-W. Park, D.-H. Jeong, Incheon, Republic of Korea
2.366
246
AUGMENTING THE CARTESIAN MEDICAL DISCOURSE WITH AN
UNDERSTANDING OF THE PERSON´S LIFE WORLD, LIVED BODY, LIFE
STORY AND SOCIAL IDENTITY
H. Sunvisson1, B. Habermann2, S. Weiss3, P. Benner4, 1Örebro, Sweden,
2
Indianapolis, IN, 3Greenbrae, 4San Francisco, CA, USA
247
“EDUTOUR” AND “E-TOUR” A NEW PSYCO-EDUCATIONAL PROGRAMME
FOR TOURETTE'S SYNDROME AND THEIR FAMILIES
A. Bayes, A. Prats, M.D.l.C. Crespo, C. Lopez, R. de la Rosa Garcia, A. Luna,
Barcelona, Spain
2.368
90
2.367
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
248
INFLUENCE OF DEVELOPMENTAL QUOTIENT AND AGE OF INITIAL
REHABILITATION ON MOTOR ABILITY IMPROVEMENT IN CHILDREN WITH
CEREBRAL PALSY
2.369
249
ANALYSIS OF SURGICAL INTRATHECAL [I.T.] BACLOFEN [ITB] IMPLANT
RESULTS EMPHASIZING REVISION SURGERY IN A MIXED
PEDIATRIC/ADULT POPULATION
Y. Awaad1, T. Rizk1, N. Roosen2, 1Riyadh, Saudi Arabia, 2Detroit, MI, USA
2.370
250
MULTIORGAN FAILURE WITH RENAL INFARCTION AFTER TREATMENT OF
CEREBRAL INFARCTION
M.-C. Joo, Iksan, Republic of Korea
2.371
251
DEEP BRAIN STIMULATION IN TOURETTE'S SYNDROME: A DESCRIPTION
OF 3 PATIENTS WITH EXCELLENT OUTCOME
R. Savica, M. Stead, K. Mack, K. Lee, K. Bryan, Rochester, MN, USA
2.372
Poster Session
Other
252
PARKINSON'S DISEASE-INDUCED HEART ATROPHY AND VAGAL
WITHDRAWAL IN TRANSGENIC MICE: A SHORT COMMUNICATION
F.V.L. Ladd, A.A.B.L. Ladd, A.J. Moreto, A.L. Moreira, A.A.P. Silva, P.C. Brum,
K. Coelho, M.L.Z. Dagli, F. Costa-Pinto, M.L. Andersen, D. Casarini, D. Arita,
A.A. Coppi, São Paulo, Brazil
3.125
253
HUMAN α-SYNUCLEIN FIBRILS INDUCE α-SYNUCLEIN AGGREGATION IN
VITRO AND BEHAVIORAL ALTERATIONS IN VIVO UPON INOCULATION IN
WILDTYPE MICE
A.H.N. Tran1, N.T.T. Le1, F. Moda2, Z. Paolo1, F. Tagliavini2, S. Gustincich1,
G. Legname1, 1Trieste, 2Milan, Italy
3.361
254
M1 MACHRS IN BASAL GANGLIA AND IMPLICATIONS FOR TREATMENT
Z. Xiang, A.D. Thompson, C.K. Jones, C.W. Lindsley, P.J. Conn, Nashville, TN,
USA
3.362
255
GENETIC VARIATION OF BDNF IN PARKINSON'S DISEASE
K.M. Prakash, Y. Zhao, E.K. Tan, Singapore, Singapore
91
3.011
08:00-18:00
Poster Area
Poster Session
Genetics
Board No
Abstract No
1
EDUCATION COURSE: GENETICS OF PARKINSON´S DISEASE
3.001
2
PARKINSON´S DISEASE AND GENETICS
S. Shaafi, M. Nikanfar, Tabriz, Iran
3.002
3
ROLE OF ESTROGEN RECEPTORS IN THE NIGROSTRIATAL DOPAMINE
SYSTEM
D. Haixia, W. Qiang, Y. Wang, H. Dong, Nanjing, China
3.004
4
ASSOCIATION BETWEEN ESTROGEN RECEPTOR GENE POLYMORPHISMS
AND PARKINSON´S DISEASE IN HAN CHINESE POPULATION
R. Chen, B. Zhang, S. Wang, Tianjin, China
3.005
5
CHARACTERIZATION OF A LIBRARY OF CLONES ISOLATED FROM A
HUMAN VENTRAL MESENCEPHALIC NEURAL STEM CELL LINE
GENERATING DOPAMINERGIC NEURONS
T. Ramos-Moreno, J.G. Lendinez, A. del Arco, M.J. del Pino, E. Gonzalez-Seiz,
A. Martinez-Serrano, Madrid, Spain
3.006
6
ANALYSIS OF GENE EXPRESSION IN PERIPHERAL BLOOD IN PATIENTS
WITH PARKINSON´S DISEASE
E. Filatova, M. Shadrina, A. Karabanov, P. Slominsky, S. Illarioshkin,
S. Limborska, Moscow, Russia
3.007
7
SOME GENETIC ASPECTS OF PARKINSON´S DISEASE IDENTIFIED IN THE
ARAL SEA REGION, THE REPUBLIC OF UZBEKISTAN
D. Izyumov1,2, G. Izyumova2, 1Tashkent, 2Urgench, Uzbekistan
3.009
8
GENE EXPRESSION PROFILING OF PERIPHERAL BLOOD FOR DETECTION
M.K. Karlsson1,2, H.-M. Andersen1, S. Sæbø2, A. Lönneborg1, 1Oslo, 2Ås, Norway
3.010
9
GENETIC VARIATION OF BDNF IN PARKINSON'S DISEASE
K.M. Prakash, Y. Zhao, E.K. Tan, Singapore, Singapore
3.011
10
POLYGENIC DETERMINANTS OF PARKINSON'S DISEASE
J. Guo, L. Wang, X. Yan, B. Tang, Changsha, China
3.012
11
POPULATION STUDY OF (CAG/CAA)N ALLELE VARIATION IN THE TATA
BOX-BINDING PROTEIN AND ATXN2-TBP MUTATIONS IN A FAMILIY WITH
TYPICAL PARKINSON
J. Laffita, L. Laguna Salvia, Y. Vázquez Mojena, M. Verdecia Ramírez,
L.C. Velázquez Pérez, J.A. Valdevila Figueira, N. Canales Ochoa,
T. Cruz Mariño, Holguin, Cuba
3.013
12
INTEGRATION OF CLINICAL AND MICROARRAY DATA WITH CANONICAL
PARTIAL LEAST SQUARES FOR PREDICTION OF PARKINSON´S DISEASE
M.K. Karlsson1,2, H.-M. Andersen1, A. Lönneborg1, S. Sæbø2, 1Oslo, 2Ås, Norway
3.014
93
08:00-18:00
Poster Area
Poster Session
Genetics (Contd.)
Board No
13
14
Abstract No
PLA2G6 POLYMORPHISMS AND HAPLOTYPES IN PREDICTING
PARKINSON´S DISEASE RISK IN CHINESE POPULATION
L. Zhanyun, G. Jifeng, T. Beisha, Changsha, China
3.015
ASSOCIATION OF GWAS SINGLE-NUCLEOTIDE POLYMORPHISMS WITH
PD IN CHINESE PATIENTS
P.Y. Chen, F.H. Shang, W. Song, K. Chen, L.P. Pan, R. Huang, P.J. Li,
Z.Z. Zheng, Chengdu Sichuan, China
3.016
15
ASSOCIATION OF MUTATIONS IN THE GLUCOCEREBROSIDASE GENE
WITH PARKINSON DISEASE IN A KOREAN POPULATION
Y.J. Kim1,2, J.M. Choi1, W.C. Kim3, C.H. Lyoo4, S.Y. Kang2, P.H. Lee4, J.S. Baik4,
S.B. Koh4, H.-I. Ma2, Y.H. Sohn4, M.S. Lee4, 1Anyang-si, 2Chooncheon,
3
Seongnam-si, 4Seoul, Republic of Korea
3.017
16
PREVALENCE OF PARKIN (PARK2) MUTATIONS AND DELETIONS IN
PARKINSON'S DISEASE PATIENTS FROM EXTREMADURE (SOUTHERN
SPAIN)
R. Ronco-Barrantes1, I. Casado-Naranjo1, F. Castellanos2, C. Duran3,
R. Gonzalez-Polo1, M. Niso-Santano1, R. Gómez-Sanchez1,
J.M. Bravo-San Pedro1, E. Pizarro-Estrella1, M. Gómez-Gutiérrez1,
G. Gámez-Leyva1, J. Martin-Zurdo2, R. Rodriguez-López1, J.M. Fuentes1,
1
Caceres, 2Plasencia, 3Badajoz, Spain
3.018
17
ASSOCIATION OF PARKINSON'S DISEASE WITH SIX SNPS LOCATED ON
FOUR PARKS GENES IN NORTHERN HAN CHINESE POPULATION
Y. Zhou1, F. Li1, X. Tian1, L. Zhu1, Y. Yang2, X. Luo1, Y. Ren1, H. Pang1,
1
Shenyang, 2Dalian, China
3.019
18
DJ-1 BASED PEPTIDE AS A NOVEL NEUROPROTECTIVE STRATEGY IN
N. Lev, Y. Barhum, T. Ben-Zur, E. Melamed, D. Offen, Tel Aviv, Israel
3.020
19
PROTEOMIC ANALYSIS OF DJ-1 INTERACTING PROTEINS IN
PARKINSON´S
Y. Zhang, L. Wu, Z.Q. Wang, S. Zhang, Y.X. Gui, Y.S. Cheng, L. Cao,
J.Q. Ding, S.D. Chen, Shanghai, China
3.021
THE ANTI-OXIDANT MECHANISM OF DJ-1 IN THE PATHOGENESIS OF
PARKINSON'S DISEASE
Z. Wang, J. Ding, S. Chen, Shanghai, China
3.022
20
21
FREQUENCY OF THE MUTATIONS IN THE PARK2, PINK1 AND DJ-1 GENES
IN POLISH PATIENTS WITH THE EARLY-ONSET PARKINSON DISEASE
D. Koziorowski1, D. Hoffman-Zacharska1, J. Sławek2, P. Górka1, J. Bal1, A.
Roszmann2, A. Friedman1, 1Warsaw, 2Gdansk, Poland
3.023
94
08:00-18:00
Poster Area
Poster Session
Genetics (Contd.)
Board No
Abstract No
A NOVEL SUBSTRATE OF PINK1 IMPLICATED IN THE AUTOPHAGY AND
APOPTOSIS PATHWAYS
G. Arena, V. Gelmetti, L. Torosantucci, D. Vignone, E.M. Valente, Rome, Italy
3.024
ANALYSIS OF EXON REARRANGEMENTS IN PARK2, SNCA AND PINK1
GENES IN PATIENTS WITH PARKINSON'S DISEASE FROM RUSSIA
E. Semenova, M. Shadrina, P. Slominsky, E. Fedotova, G. Bagyeva,
S. Illarioshkin, Moscow, Russia
3.025
24
MUTATIONAL ANALYSIS OF PARK2, SNCA AND LRRK2 IN PARKINSON'S
DISEASE PATIENTS OF SOUTH INDIA
P. Vishwanathan1, A.V. Srinivasan1, M. Jayaraman1, C.R.S. Srisailapathy1,
A. Ramesh1,2, 1Chennai, 2Kasargod, India
3.026
25
LRRK2 DIRECTLY PHOSPHORYLATES AKT1 AS A POSSIBLE
PHYSIOLOGICAL SUBSTRATE: IMPAIRMENT OF THE KINASE ACTIVITY BY
PARKINSON'S DISEASE-ASSOCIATED MUTATIONS
E. Ohta, F. Kawakami, M. Kubo, F. Obata, Sagamihara, Japan
3.027
26
LRRK2 MODULATES NOTCH SIGNALING THROUGH ENDOSOMAL
PATHWAY
Y. Kobayashi1, K. Uemura1, T. Kanao2, R. Takahashi1, Y. Imai2, 1Kyoto, 2Tokyo,
Japan
3.028
27
SUBTLE DIFFERENCES IN COGNITIVE FUNCTION OF HEALTHY G2019S
LRRK2 MUTATION CARRIERS
A. Thaler1, A. Mirelman1,2, E. Simon3,4, A. Orr-Urtreger1, T. Gurevich1, N. Giladi1,
1
Tel Aviv, 2Beer Sheba, Israel, 3Bellaire, TX, 4New-York, NY, USA
3.029
28
LACK OF ASSOCIATION BETWEEN THREE SNPS ON PARK9, PARK15 AND
BST1 GENES AND PARKINSON´S DISEASE IN NORTHERN HAN CHINESE
POPULATION
L. Zhu1, Y. Zhou1, F. Li1,2, Y. Yang3, X. Luo1, Y. Ren1, H. Pang1, 1Shenyang,
2
Baotou, 3Dalian, China
3.030
29
LOSS OF PINK1 FUNCTION PROMOTES AUTOPHAGY VIA PP2A
DOWNREGULATION IN DOPAMINERGIC CELLS AND A MURINE MODEL
W. Yang, Z. Qi, Y. Fu, P. Gong, Y. Zhuang, H. Jia, H. Yang, Beijing, China
3.031
DIFFERENTIAL REGULATION OF NMDA RECEPTOR FUNCTION BY DJ-1
AND PINK1
Q. Wan, N. Chang, Reno, NV, USA
3.032
22
23
30
31
THE AGGREGATED WT-α-SYNUCLEIN AND A53T PROMOTE
INFLAMMATION THROUGH ACTIVATION OF NADPH OXIDASE COMPLEX IN
BV-2 AND PRIMARY MICROGLIA
W. Kang, J. Liu, S. Chen, Shanghai, China
3.033
95
08:00-18:00
Poster Area
Poster Session
Genetics (Contd.)
Board No
32
Abstract No
INTRACELLULAR TRAFFICKING OF A53T MUTANT a-SYNUCLEIN
INVOLVED IN MICROGLIAL PERSISTENT ACTIVATION
Y.-W. Wu, Q. Yang, J.-Q. Ding, J. Liu, Shanghai, China
3.034
33
TGF-Β1 POLYMORPHISMS AND RISK OF PARKINSON'S DISEASE IN A HAN
CHINESE POPULATION
R. Li, Qingdao, China
3.035
34
THE ASSOCIATION BETWEEN PROMOTER POLYMORPHISM OF THE
INTERLEUKIN-10 (IL-10) GENE AND PARKINSON'S DISEASE IN CHINESE
HAN POPULATION
Q.D. Li, qingdao, China
3.036
35
LACK OF ASSOCIATION BETWEEN POLYMORPHISMS IN USP24 AND
USP40 GENES AND PARKINSON'S DISEASE IN CHINESE SUBJECTS
R. Huang, F.H. Shang, W. Song, P.Y. Chen, K. Chen, P.J. Li, L.P. Pan,
Z.Z. Zheng, Chengdu Sichuan, China
3.037
36
SNP RS2046571 OF THE HAS2 GENE WITH PARKINSON'S DISEASE IN
THE CHINESE POPULATION
Y. Rili, G. Jifeng, T. Beisha, Changsha, China
3.038
37
ASSOCIATION OF 5-59A/G POLYMORPHISM IN INTRON REGION OF
HTRA2 GENE WITH PARKINSON´S DISEASE
X.Y. Zhao1, Y.S. Chen2, 1Jiande, 2Zhanjiang, China
3.039
38
ASSOCIATION OF INTRON RS12138592 A/G POLYMORPHISM OF
UBIQUITIN SPECIFIC PROTEASES (USP24) GENE WITH PARKINSON
DISEASE
Z. Lin, Zhanjiang, China
3.040
FIBROBLAST GROWTH FACTOR 20 (FGF20) POLYMORPHISM IS A RISK
FACTOR FOR PARKINSON´S DISEASE IN CHINESE POPULATION
H. Li, J. Pan, Q. Xiao, S. Chen, Shanghai, China
3.041
CAFFEINE-MEDIATED RISK OF PARKINSON´S DISEASE IS GREATER IN
SLOW NAT2 GENOTYPE CARRIERS: CLINICAL, GENETIC AND
MOLECULAR STUDY
J.-W. Lim, P. Kumar, Y. Zhao, J.C. Allen, S. Shenolikar, E.-K. Tan, Singapore,
Singapore
3.042
41
HER2 POLYMORPHIC ASSOCIATION WITH PARKINSON'S DISEASE AT
CODONS 655 AND 1170
V. Wang1, T.-C. Chuang1, B.-W. Soong2, D.-I. Shan2, M.-C. Kao3, 1New Taipei
City, 2Taipei, 3Taichung, Taiwan
3.043
42
VARIANT IN THE 3' REGION OF SNCA ASSOCIATED WITH PARKINSON'S
DISEASE AND SERUM α-SYNUCLEIN LEVELS
Y. Hu, B. Tang, J. Guo, X. Wu, Q. Sun, L. Shen, X. Yan, C. Wang, L. Tan,
H. Zhang, Changsha, China
3.044
39
40
96
08:00-18:00
Poster Area
Poster Session
Genetics (Contd.)
Board No
43
44
45
Abstract No
CANNABINOID CB2 RECEPTOR GENE EXPRESSION DIFFERENCES IN
PARKINSON'S DISEASE POST-MORTEM BRAIN SAMPLES AND
LYMPHOCYTES FROM RECENTLY DIAGNOSED AND NON-TREATED
PATIENTS
F. Navarrete1, J.A. Molina2, C. Leiva3, J. Manzanares1, 1San Juan de Alicante,
2
Madrid, 3Alicante, Spain
3.045
SEARCHING FOR MODIFIER GENES IN A GENOME-WIDE ASSOCIATION
STUDY OF LRRK2 G2019S CARRIERS
K. Nicodemus, Oxford, UK
3.046
UNDERSTANDING MOLECULAR MECHANISMS UNDERLYING LEUCINERICH REPEAT KINASE 2 (LRRK2)-RELATED PARKINSON'S DISEASE (PD)
H. Liu1, P.W. Ho1, J.W. Ho1, D.B. Ramsden2, Z. Zhou1, S. Ho1, 1Hong Kong,
Hong Kong S.A.R., 2Birmingham, UK
3.048
46
LEVODOPA-INDUCED DYSKINESIA IN PARKINSON´S DISEASE PATIENTS
CARRYING THE LEUCINE-RICH REPEAT KINASE 2 (LRRK2) G2019S
MUTATION
G. Yahalom1, N. Kaplan1, A. Vituri2, O.S. Cohen1,2, R. Inzelberg1,2, H. Strauss1,
E. Kozlova1, Y. Orlev1, A.D. Korczyn2, S. Rosset2, S. Hassin-Baer1,2, 1TelHashomer, 2Tel-Aviv, Israel
3.049
47
THE ASSOCIATION BETWEEN LRRK2 S1647T POLYMORPHISM AND
COGNITIVE FUNCTION IN PARKINSON´S DISEASE
Y. Zheng, Q. Wu, Y. Fang, Y. He, H. Zhou, Y. Liu, J. Chen, W. Xian, X. Fu,
C. Shen, C. Guo, L. Chen, Z. Pei, Guangzhou, China
3.050
48
POLYMORPHISMS IN THE SLC6A3 GENE ENCODING FOR THE DOPAMINE
TRANSPORTER ARE ASSOCIATED WITH LEVODOPA-INDUCED
DYSKINESIA IN PARKINSON'S DISEASE
S. Hassin1, N. Kaplan1, O.S. Cohen1, A. Vituri2, R. Inzelberg1, G. Yahalom1,
Z. Nitzan1, L. Efraty1, O. Tunkel1, E. Friedman3, S. Rosset2, A.D. Korczyn2,
1
Ramat-Gan, 2Tel Aviv, 3Ramat Gan, Israel
3.051
49
META ANALYSIS BETWEEN VAL166MET LOCUS POLYMORPHISM IN BDNF
GENE AND DEMENTIA WITH LEWY BODIES
H. Le, N. Yuping, L. Xinni, Z. Xiaomei, S. Haishan, Guangzhou, China
3.052
50
ASSOCIATION OF CATECHOL-O-METHYLTRANSFERASE
POLYMORPHISMS WITH PARKINSON'S DISEASE AND MOTOR
COMPLICATIONS
B. Yin, L. Zhang, W. Sun, W. Wang, Harbin, China
51
THE PREVALENCE OF CANCER IN PATIENTS WITH PARKINSON´S
DISEASE WHO ARE CARRIERS OF THE G2019S MUTATION IN THE LRRK2
GENE
A. Mirelman1,2, A. Thaler1, T. Gurevich1, A. Shkedy1, A. Bar Shira1,
A. Orr-Urtreger1, N. Giladi1, 1Tel Aviv, 2Beer Sheba, Israel
3.054
97
3.053
08:00-18:00
Poster Area
Poster Session
Genetics (Contd.)
Board No
Abstract No
52
GENETIC ANALYSIS OF THE LINGO4 GENE IN PATIENTS WITH ESSENTIAL
TREMOR
H. Liang, W. Zheng, H. Xu, J. Lei, Z. Song, X. Jiang, Z. Zeng, H. Deng,
Changsha, China
3.055
53
ASSOCIATIONS BETWEEN GCH1 POLYMORPHISMS AND PRIMARY
DYSTONIA AND PARKINSON'S DISEASE IN AN AUSTRALIAN CASECONTROL SERIES
J.R.B. Newman1, G.T. Sutherland1, R. Boyle2, N. Limberg2, S. Blum2,
J. O'Sullivan2, P. Silburn2, G.D. Mellick1,2, 1Nathan, 2Brisbane, QLD, Australia
3.056
54
MOVEMENT DISORDERS ARE PREVALENT IN PATIENTS WITH FAMILIAL
CREUTZFELDT-JAKOB DISEASE (F-CJD) CARRYING THE E200K
MUTATION
O. Cohen1, I. Prohovnik2, A.D. Korczyn3, R. Inzelberg1, Z. Nitsan1, S. Appel1,
E. Kahana4, H. Rosenmann5, J. Chapman1, 1Ramat-Gan, Israel, 2New York, NY,
USA, 3Tel-Aviv, 4Ashkelon, 5Jerusalem, Israel
3.057
55
ANALYSIS OF LRRK2 VARIANT IN ESSENTIAL TREMOR
E.-K. Tan, K. Prakash, W. Au, L.-C. Tan, Singapore, Singapore
56
DE NOVO MUTATED ATAXIN-2 INTERMEDIATE-LENGTH POLYGLUTAMINE
ASSOCIATED WITH FAMILIAR ALS AND PARKINSONISM/ESSENTIAL
TREMOR
J. Laffita1, J.M. Rodríguez Pupo1, R. Moreno Sera1, V. Kourí2,
P.A. Martínez Rodríguez2, L.C. Velázquez Pérez1, Y. Vázquez Mojena1,
L.E. Almaguer Mederos1, 1Holguin, 2Havana, Cuba
3.059
57
NOVEL VARIANTS IN HTRA2 GENE ASSOCIATED WITH PARKINSON'S
DISEASE AND MITOCHONDRIAL DYSFUNCTION
M.-L. Chen1, C.-H. Lin1, G.S. Chen2, C.-H. Tai1, R.-M. Wu1, 1Taipei, 2Shalu,
Taiwan
3.060
58
ANALYSIS OF SERUM MICRORNAS IN SCA3/MJD PATIENTS
Y.T. Shi, B. Tang, H. Jiang, ChangSha, China
3.061
59
ATAXIN-2 INTERMEDIATE POLYGLUTAMINE EXPANSIONS CONTRIBUTE
TO RISK OF ALS AND OF EARLY ONSET HEREDITARY PD
S. Gispert1, A. Kurz1, S. Waibel2, P. Bauer3, I. Liepelt3, C. Geisen1, A.D. Gitler4,
T. Becker5, M. Weber6, D. Berg3, P.M. Andersen7, O. Riess3, A.C. Ludolph2,
G. Auburger1, 1Frankfurt/Main, 2Ulm, 3Tübingen, Germany, 4Philadelphia, PA,
USA, 5Bonn, Germany, 6St. Gallen, Switzerland, 7Umeå, Sweden
3.062
60
PRENATAL DIAGNOSIS FOR TWO PATIENTS AND ONE PRESYMPTOMATIC
PATIENT WITH SCA3/MJD
Y.T. Shi, B.S. Tang, H. Jiang, Changsha, China
3.063
61
SPINOCEREBELLAR ATAXIAS - GENOTYPE-PHENOTYPE CORRELATION
IN 104 BRAZILIAN FAMILIES
R.P. Munhoz, H. Teive, W.O. Arruda, Curitiba, Brazil
98
3.058
3.064
08:00-18:00
Poster Area
Poster Session
Genetics (Contd.)
Board No
Abstract No
62
A NOVEL MISSENSE MUTATION IN THAP1 IN TWO AUSTRALIAN PATIENTS
WITH PRIMARY DYSTONIA
J.R.B. Newman1, R.S. Boyle2, A.C. Lehn2, G.D. Mellick1,2, 1Nathan, 2Brisbane,
QLD, Australia
3.065
63
WILSON´S DISEASE IN SOUTHERN BRAZIL: MUTATIONAL ANALYSIS,
GENOTYPE-PHENOTYPE CORRELATION AND DESCRIPTION OF TWO
NOVEL MUTATIONS IN THE ATP7B GENE
H.A.G. Teive1, R.S. De Bem1, R.P. Munhoz1, S. Raskin1, D. Muzillo1,
M.M. Deguti2, E.L.R. Cançado2, T.F. Araújo2, M.C. Nakhle2, E.R. Barbosa2,
1
Curitiba, 2São Paulo, Brazil
3.066
COMPOUD HETEROZYGOUS ATP7B MUTATIONS LEADING TO
HYPOCERULOPLASMINEMIA BUT NOT CLINICAL WILSON´S DISEASE IN
AN ADULT PATIENT
H.A.G. Teive, W.O. Arruda, R.P. Munhoz, R.S. De Bem, S. Raskin, Curitiba,
Brazil
3.067
64
65
EXOME SEQUENCING IDENTIFIES NOVEL SACSIN GENE MUTATIONS IN A
CHINESE FAMILY
L. Shen, Z. Zhan, X. Liao, Z. Hu, J. Wang, J. Du, B. Tang, Changsha, China
3.069
66
AUTOSOMAL DOMINANT CORTICAL MYOCLONUS AND EPILEPSY
(ADCME) - NEW MUTATION IN POLISH FAMILY?
S. Budrewicz1, M. Koszewicz1, E. Koziorowska-Gawron1, K. Slotwinski1,
R. Podemski1, P. Striano2, 1Wroclaw, Poland, 2Genoa, Italy
67
ATYPICAL HEREDITARY HYPEREKPLEXIA CAUSED BY HETEROZYGOUS
DELETION MUTATION IN THE GLRA1 EXON-1
W.T. Yoon, W.Y. Lee, C.-S. Ki, J.W. Cho, Seoul, Republic of Korea
3.071
68
AUTISM SPECTRUM DISORDER ASSOCIATED WITH LOW BRAIN
SEROTONIN AND MUTATIONS IN THE SEROTONIN TRANSPORTER
SLC29A4 AND IN SEROTONIN RELATED GENES
D. Adamsen1, V. Ramaekers2, R. Bruggmann1, H. Ho3, J. Wang3, B. Thony1,
1
Zurich, Switzerland, 2Liège, Belgium, 3Seattle, WA, USA
3.072
EPIGENETIC DNA-METHYLATION IN THE CORE ATAXIN-2 GENE
PROMOTER: NOVEL PHYSIOLOGICAL AND PATHOLOGICAL
IMPLICATIONS
J. Laffita1, P.O. Bauer2, V. Kourí3, L. Peña Serrano1, J. Roskams4, D. Almaguer
Gotay1, J. Aguiar Santiago1, Y. González-Zaldívar1, L.E. Almaguer Mederos1,
D.A. Cuello-Almarales1, J.C. Montes Brown1, 1Holguin, Cuba, 2Saitama, Japan,
3
Havana, Cuba, 4Vancouver, BC, Canada
3.073
69
99
3.070
08:00-18:00
Poster Area
Poster Session
Genetics (Contd.)
Board No
Abstract No
70
TRANSCRIPTOME PROFILING OF BLOOD MONONUCLEAR CELLS FROM
SCA2 PATIENTS ACCORDING TO CEREBELLAR OR PARKINSONIAN
PHENOTYPES
C. Simonin1, E. Mutez1, B. Sablonnière1, A. Duflot1, M. Figeac1, F. Lepretre1,
L. Defebvre1, A. Kreisler1, C. Vanbesien1,2, D. Devos1, B. Frigard3, A. Destée1,
M.-C. Chartier-Harlin1, 1Lille, 2Villeneuve d'Ascq, 3Wasquehal, France
3.074
71
UNEXPANDED AND INTERMEDIATE POLYMORPHISMS AT SCA2 LOCUS
(ATXN2) IN THE CUBAN POPULATION: EVIDENCES ABOUT THE ORIGIN OF
EXPANDED ALLELES
J. Laffita, L.C. Velázquez-Pérez, N. Santos Falcón, T. Cruz-Mariño, Y. González
Zaldívar, Y. Vázquez Mojena, D. Almaguer-Gotay, L.E. Almaguer Mederos,
R. Rodríguez Labrada, Holguin, Cuba
3.075
72
AN EARLY ONSET SOUTH INDIAN PARKINSON'S DISEASE PATIENT WITH
NOVEL C.798_799INSA MUTATION - A CASE VIGNETTE
P. Vishwanathan1, A.V. Srinivasan1, M. Jayaraman1, C.R.S. Srisailapathy1,
A. Ramesh1,2, 1Chennai, 2Kasargod, India
3.076
73
NOVEL PLA2G6 GENE MUTATION IS ASSOCIATED WITH AUTOSOMAL
RECESSIVE EARLY-ONSET PARKINSONISM
X. Yan, J. Guo, C. Shi, B. Tang, Changsha, China
74
THE NOVEL THAP1 GENE MUTATION, CHARACTERIZED BY
PHENOTYPICAL HETEROGENEITY
D. Koziorowski, M. Jurek, D. Hoffman-Zacharska, J. Bal, A. Friedman, Warsaw,
Poland
3.078
75
ISAACS SYNDROME: REPORT OF TWO CASES
C.E. Cavalcanti, A.C. Ribeiro, Sao Luis, Brazil
76
MITOCHONDRIAL D-LOOP HOMOPLASMIC T16519C POINT MUTATION AND
IDENTIFICATION OF NOVEL MARKERS ASSOCIATED WITH FRDA
PATIENTS IN INDIAN POPULATION
I.S. Mudila, M. Faruq, A.K. Srivastava, M. Mukerji, New Delhi, India
3.080
77
THE ASSOCIATION OF DIARHEA & TEETHING IN INFANTS IS
ASSOSSIATED MORE IRRITABLE BOWEL SYNDROM AND NEUROGENIC
PROBLEM
H. Ghaffari, R. Ghaffari, M. Makani, M. Ebrahimzadeh, M. Falaki, M. Jariani,
R. Falaki, Demeshg, Sierra Leone
78
3.077
3.079
3.081
ENHANCED SPONTANEOUS APOPTOSIS OF PERIPHERAL BLOOD
LYMPHOCYTES IN PATIENTS WITH PARKINSON´S DISEASE ASSOCIATED
WITH MUTATIONS IN THE GLUCOCEREBROSIDASE GENE
T.S. Usenko1, A.K. Emelyanov1, T.M. Boukina2, A.F. Yakimovskii1,
A.S. Drosdova1, S.N. Pchelina1, 1Saint Petersburg, 2Moscow, Russia
3.082
100
08:00-18:00
Poster Area
Poster Session
Animal Models
Board No
Abstract No
PRENATAL SENSITIZATION AND POSTNATAL PRECIPITATION IN A
MODEL OF PARKINSONISM
C.G. Charlton, G.V. Muthian, Nashville, TN, USA
3.101
PREDICTION AND CHARACTERIZATION OF ARABIDOPSIS THALIANA
HOMOLOGS OF PARKINSON DISEASE-ASSOCIATED GENES BASED ON
SEQUENCE SIMILARITIES AND MOLECULAR MODELING
K. Kwon1, K. Baek2, C. Park1, 1Daejeon, 2Yongin, Republic of Korea
3.103
CELL-DEATH PATHWAYS DOWNSTREAM OF MITOCHONDRIA IN HUMAN
DOPAMINERGIC NEURON DEGENERATION
D. Pöltl, S. Schildknecht, M. Leist, Konstanz, Germany
3.104
GLYPHOSATE INDUCED CELL DEATH THROUGH APOPTOTIC AND
AUTOPHAGIC MECHANISMS
G. Wang, Y.-X. Gui, X.-N. Fan, H.-M. Wang, S.-D. Chen, Shanghai, China
3.105
83
PARAQUAT NEUROTOXICITY IS MEDIATED BY THE DOPAMINE
TRANSPORTER AND ORGANIC CATION TRANSPORTER-3
P. Rappold1, M. Cui1, A. Chesser1, J. Tibbett1, J. Grima1, L. Duan2, J. Javitch2,
K. Tieu1, 1Rochester, 2New York, NY, USA
3.106
84
PARAQUAT ACTIVATES THE IRE1/ASK1/JNK CASCADE ASSOCIATED
WITH APOPTOSIS IN SH-SY5Y CELLS
I. Son1, W. Yang1, E. Tiffany-Castiglioni2, Y. Kim3, M. Lee1, 1Gunpo,
Republic of Korea, 2College Station, TX, USA, 3Seoul, Republic of Korea
3.107
85
ELECTROPHYSIOLOGY OF NEOSTRIATAL NEURONS IN A RAT MODEL
OF PARKINSON´S DISEASE INDUCED BY PARAQUAT AND MANEB
D. He, H. Xu, R. Chen, X. Cai, N. Chen, A. Zhu, Shanghai, China
3.108
86
EFFECT OF CHRONIC ADMINISTRATION OF SODIUM SALICYLATE ON
THE MOTOR FUNCTIONS IN THE ROTENONE INDUCED PD MODEL
B. Nehru, Chandigarh, India
3.109
87
ROTENONE INDUCED NIGROSTRIATAL DEGENERATION IN RODENTS
AS A MODEL FOR NEUROPROTECTIVE STRATEGIES FOR PARKINSON'S
DISEASE
A. Norazit1,2, M.N. Nguyen2,3, C. Dickson2, B.L. Cavanagh2, A. Mackay-Sim2,
A.C.B. Meedeniya2,3, 1Kuala Lumpur, Malaysia, 2Brisbane, 3Gold Coast, QLD,
Australia
3.110
PARKINSON DISEASE DERIVED hONS CELLS ARE MORE SENSITIVE TO
ROTENONE TOXICITY THAN CONTROL CELLS
J. Shan, M. Todorovic, S.A. Wood, G.D. Mellick, Brisbane, QLD, Australia
3.111
TRANSCRIPTOME PROFILING OF BLOOD MONONUCLEAR CELLS FROM
RATS EXPOSED TO CUMULATIVE LOW DOSES OF THE PARKINSON´S
DISEASE-LINKED PESTICIDE ROTENONE
C. Vanbesien-Mailliot1,2, E. Mutez1, A. Kreisler1, C. Simonin1, A. Duflot1,
P. Semaille1, S. Peckeu1, A. Destée1, M.-C. Chartier-Harlin1, 1Lille, 2Villeneuve
d'Ascq, France
3.112
79
80
81
82
88
89
101
08:00-18:00
Poster Area
Poster Session
Animal Models (Contd.)
Board No
Abstract No
90
EVALUATION OF ROTENONE TO PRODUCE AN EXPERIMENTAL MODEL
FOR PARKINSON´S DISEASE. A NEUROPROTECTIVE EFFECT OF
COENZYME Q-10
A.M. Shehata, Cairo, Egypt
3.113
91
COMMON DIFFERENTIALLY EXPRESSED PROTEINS IN SUBSTANTIA
NIGRA OF MOUSE MODELS WITH CHRONIC PARKINSON'S DISEASE
INDUCED BY ROTENONE AND MPTP
C. Zhou, G. Peng, X. Yang, Y. Yang, J. Wan, C. Zhao, Chongqing, China
3.114
92
ENVIRONMENTALLY-INDUCED SYNUCLEINOPATHY IN A NOVEL
PROGRESSIVE RAT MODEL OF PARKINSONISM
P. Yarowsky, K. Mc Dowell, W.-B. Shen, Baltimore, MD, USA
3.117
93
PRIMATE AND RODENT MODELS OF PARKINSON'S DISEASE BASED ON
VIRAL VECTOR MEDIATED OVEREXPRESSION OF ALPHA SYNUCLEIN
J.B. Koprich, T. Johnston, P. Huot, J.M. Brotchie, Toronto, ON, Canada
3.118
94
STRIATAL LONG-TERM DEPRESSION AND DOPAMINE SIGNALING
IMPAIRMENT IN A53T- α-SYNUCLEIN OVEREXPRESSING MICE
G. Auburger1, A. Kurz1, K.L. Double2, I. Lastres-Becker1, A. Tozzi3,4,
M. Tantucci3, V. Bockhart5, M. Bonin6, M. Garcia-Arencibia7, S. Nuber8,
F. Schlaudraff9, B. Liss9, J. Fernandez-Ruiz10, M. Gerlach11, U. Wuellner12,
H. Lueddens5, P. Calabresi3,13, S. Gispert1, 1Frankfurt/Main, Germany, 2Sydney,
NSW, Australia, 3Perugia, 4Roma, Italy, 5Mainz, 6Tübingen, Germany, 7Madrid,
Spain, 8Tuebingen, 9Ulm, 10Madrid, 11Wuerzburg, 12Bonn, Germany, 13Rome, Italy
3.119
95
α-SYNUCLEIN PROMOTES CLATHRIN-MEDIATED NMDA RECEPTOR
ENDOCYTOSIS AND ATTENUATES NMDA-INDUCED DOPAMINERGIC CELL
DEATH
S. Yu1, F. Cheng1, X. Li1, Y. Li1, G. Liu1, A. Baskys2, K. Ueda3, P. Chan1,
1
Beijing, China, 2Irvine, CA, USA, 3Tokyo, Japan
3.120
96
SPATIAL AND WORKING MEMORY IS IMPAIRED IN α-SYNUCLEIN
KNOCKOUT MICE
V.S. Kokhan1, G. Van`kin1, M. Neganova1, N. Ninkina1,2, 1Chernogolovka,
Russia, 2Cardiff, UK
3.121
97
A NOVEL SERIES OF HUMAN α-SYNUCLEIN BAC TRANSGENIC MOUSE
MODELS TO DISSECT IN VIVO PATHOGENIC MECHANISMS IN
PARKINSON'S DISEASE (PD)
T. Murphy Weitz, S.M. Fleming, S. Ren, Y. Wang, M.-F. Chesselet, X.W. Yang,
Los Angeles, CA, USA
3.122
A NOVEL BAC α-SYNUCLEIN-GFP TRANSGENIC MOUSE MODEL FOR
IMAGING OF α-SYNUCLEIN AGGREGATION
C. Hansen, T. Björklund, R. Murmu, J.-Y. Li, Lund, Sweden
3.123
98
102
08:00-18:00
Poster Area
Poster Session
Board No
99
Abstract No
TRANSGENIC ZEBRAFISH MODELS FOR THE STUDY OF DOPAMINE
NEURON DEVELOPMENT, DEGENERATION AND REGENERATION
Y. Xi, R. Godoy, S. Noble, M. Ekker, Ottawa, ON, Canada
3.124
100
EVALUATION OF DRUGS ACTING ON CB1-A2A RECEPTOR OLIGOMERS IN
RAT MODELS OF PARKINSON'S DISEASE
N. Simola1, G. Costa1, C.E. Muller2, M.T. Armentero3, R. Franco4, A. Pinna1,
1
Cagliari, Italy, 2Bonn, Germany, 3Pavia, Italy, 4Barcelona, Spain
3.126
101
EFFECT OF UNILATERAL LESION WITH THE SELECTIVE PROTEASOME
INHIBITOR LACTACYSTIN ON ROTATIONAL BEHAVIOR AND DA METABOLISM
IN RATS
J. Konieczny, T. Lenda, M. Zapała, E. Lorenc-Koci, Krakow, Poland
3.127
102
NEUROCHEMICAL RESPONSES AND DYNAMIC CHANGES OF GLIAL AND
NEURONAL CELLS IN THE SUBSTANTIA NIGRA OF A LACTACYSTIN RAT
MODEL
L.W. Chen, L. Duan, X.Y. Jiao, Y.X. Ding, L. Zhang, Xi'an, China
3.128
103
THE ROLE OF NDFIP1 IN IRON-INDUCED CELL DAMAGE IN MES23.5
DOPAMINERGIC CELLS
W. Jia, H. Xu, H. Jiang, J. Xie, Qingdao, China
3.129
104
NEUROCHEMICAL AND BEHAVIOURAL CHARACTERISATION OF SINGLE
INTRANIGRAL INJECTION OF LPS INDUCED NEUROINFLAMMATORY RAT
MODEL OF PD
N. Sharma, Chandigarh, India
3.130
105
CONTRIBUTION OF NITRERGIC TRANSMISSION TO THE MODULATION OF
L-DOPA ACTIVITY IN THE 6-OHDA MODEL OF PARKINSON'S DISEASE.
THERAPEUTIC IMPLICATIONS
A. Czarnecka, T. Lenda, J. Konieczny, H. Domin, K. Kamińska, E. Lorenc-Koci,
Krakow, Poland
3.131
106
COMPARISON OF FOUR GDNF-VARIANTS IN THE 6-OHDA RAT MODEL OF
M.H. Piltonen, M.M. Bespalov, P.T. Männistö, Helsinki, Finland
3.132
107
PERGOLIDE ATTENUATES MEMORY DEFICIENCIES AND OXIDATIVE
STRESS INDUCED BY A 6-HYDROXYDOPAMINE MODEL OF PARKINSON'S
DISEASE
M. Padurariu, L. Hritcu, A. Ciobica, A. Neagu, Iasi, Romania
3.133
103
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
108
NEUROCHEMICAL AND BEHAVIORAL CHANGES CORRESPONDING TO
THE ADVANCED PARKINSON'S DISEASE WITH COEXISTENT DEPRESSION
IN RATS TREATED UNILATERALLY WITH 6-OHDA
E. Lorenc-Koci, T. Lenda, K. Kamińska, A. Czarnecka, J. Konieczny, Krakow,
Poland
3.134
109
CHANGES OF THE PKA/PP2A/ CDK5/DARPP-32 PATHWAY IN 6-OHDALESIONED RATS FOLLOWING LONG-TERM TREATMENT WITH L-DOPA
L. Jin, Q. Guan, Q. Zhan, Shanghai, China
3.135
IN VIVO STRIATAL ACTIVITY DURING SELF ROTATION FOLLOWING
UNILATERAL DOPAMINE DEPLETION
C. Yu, H. Yin, Durham, NC, USA
3.136
OXIDATIVE STRESS, α-SYNUCLEIN, AND EPIGENETIC AFFECTS IN THE
PARKINSONIAN BRAIN
A. Siddiqui, S. Chinta, I. Hansen, A. Rane, J. Andersen, Novato, CA, USA
3.137
TOXIC EFFECTS OF OVER-LOAD COPPER CHLORIDE ON PRIMARY
CULTURED RAT ASTROCYTES
H.-L. Hu, X.-P. Wang, Y.-L. Zhao, Shanghai, China
3.138
ALTERATIONS IN MARKERS OF AGING IN SUBSTANTIA NIGRA OF MICE
LACKING GLUTATHIONE S-TRANSFERASE PI (GSTPI)
Y. Jiao, A. Pani, H. Jang, Y. Dou, J. Smith, S. Richard, Memphis, TN, USA
3.139
110
111
112
113
114
THE CONTRIBUTION OF THE MYD88 - DEPENDENT PATHWAY IN ANIMAL
MODELS OF PARKINSONISM
J. Drouin-Ouellet, M. Cote, C. Gibrat, M. Bousquet, F. Calon, J. Kriz, D. Soulet,
F. Cicchetti, Quebec, QC, Canada
3.140
115
NURR1 DETERMINES THE PREFERENTIAL DEGENERATION OF MIDBRAIN
DOPAMINERGIC NEURONS IN A PARKINSON'S DISEASE MOUSE MODEL
X. Lin1,2, L. Parisiadou2, G. Liu2, J. Yu2, H. Cai2, 1Guangzhou, China, 2Bethesda,
MD, USA
3.141
116
CAENORHABDITIS ELEGANS AS A MODEL SYSTEM OF PARKINSON
DISEASE FOR HIGH-CONTENT SCREENING
S. Lehtonen, M. Oksanen, M. Lakso, G. Wong, M. Courtney, J. Koistinaho,
Kuopio, Finland
117
HIGH FAT CONSUMPTION AGGRAVATES DOPAMINERGIC DEPLETION IN A
MOUSE MODEL OF PARKINSON'S DISEASE
M. Bousquet, M. Vandal, I. St-Amour, P. Julien, F. Cicchetti, F. Calon, Quebec,
QC, Canada
3.143
118
ENHANCEMENT OF THE SYNAPTIC DOPAMINE AVAILABILITY BY
ACUPUNCTURE TREATMENT TO IMPROVE MOTOR FUNCTION IN A
MOUSE MODEL OF PARKINSON'S DISEASE
S.-N. Kim, A.-R. Doo, J.-Y. Park, Y. Chae, I. Shim, H. Lee, W. Moon, H. Lee,
H.-J. Park, Seoul, Republic of Korea
104
3.142
3.144
08:00-18:00
Poster Area
Poster Session
Board No
119
Abstract No
COMBINED TREATMENT OF ACUPUNCTURE WITH LEVODOPA
ALLEVIATES LEVODOPA-INDUCED DYSKINESIA ON A 6-OHDA-INDUCED
PARKINSON'S DISEASE MOUSE MODEL
S.-N. Kim, A.-R. Doo, H. Bae, S.-R. Min, Y. Chae, I. Shim, H. Lee, H.-J. Park,
Seoul, Republic of Korea
3.145
120
MODULATION OF ADULT NEUROGENESIS IN THE OLFACTORY BULB IN
AN ACUTE MOUSE MODEL OF PARKINSON'S DISEASE
W.-H. Chiu, T. Carlsson, M. Arend, G. Höglinger, W.H. Oertel, V. Ries, Marburg,
Germany
3.146
121
MESENCEPHALIC CELL CULTURES FROM CYP2E1 KNOCKOUT MICE: A
MODEL FOR MPP+ METABOLIC AND TOXICITY STUDIES
G.U. Corsini, Pisa, Italy
3.147
SALSOLINOL DAMAGES INTESTINAL MYENTERIC PLEXUS NEURONS IN
RATS
M. Kurnik, K. Gil, A. Bugajski, P. Thor, Krakow, Poland
3.148
AN EXPERIMENTAL STUDY OF ESTABLISHING PD DYSKINESIA MODEL
THROUGH COMPLETE DAMAGE TO SUBSTANTIA NIGRA IN RATS
C. Chen, R. Wang, H. Tan, M. Shao, Guangzhou, China
3.149
DROSOPHILA MODEL TO DISSECT THE SIGNALING PATHWAYS
MEDIATING THE TOXICITY OF FUNGAL VOCS IN DOPAMINERGIC
NEURONS: VOCS AND PARKINSON´S DISEASE?
A.A. Inamdar, J.W. Bennett, New Brunswick, NJ, USA
3.150
EVALUATION OF TWO EXPERIMENTAL DESIGNS FOR LEVODOPAINDUCED DYSKINESIA IN A RAT MODEL OF PARKINSON'S DISEASE
E. Ivanova, I. Kapitsa, A. Nepoklonov, I. Kokshenev, Moscow, Russia
3.151
126
EFFECTS OF COMPOUND REHMANNIA FORMULA ON THE AMINO ACID
NEUROTRANSMITTER CONTENT IN THE BRAIN OF THE LEVODOPAINDUCED DYSKINESIAS RATS
C.-G. Zhang, J.-C. He, Shanghai, China
3.152
127
ROLE OF SLEEP HOMEOSTASIS ON THE DEVELOPMENT OF LEVODOPAINDUCED DYSKINESIA: A LOCAL-FIELD CORTICAL ACTIVITY STUDY IN
THE 6-OHDA RAT
S. Galati, A. Salvadè, C. Bassetti, C.J. Moeller, Lugano, Switzerland
3.153
128
FUNCTIONAL AND MORPHOLOGICAL MODIFICATIONS OF BILATERAL
INTRASTRIATAL BOTULINUM NEUROTOXIN A APPLICATION IN WISTAR
RATS
D.-L. Draeger, C. Holzmann, A. Hawlitschka, E. Mix, R. Benecke, A. Wree,
Rostock, Germany
3.154
LOW CONCENTRATIONS OF LEAD MAY AFFECT ON
PENTYLENETETRAZOLE INDUCED SEIZURE THRESHOLD IN MICE
A. Mesdaghinia1, A. Heydari1, H. Yazdanpanah2, M. Saghazadeh2, 1Kashan,
2
Shiraz, Iran
3.155
122
123
124
125
129
105
08:00-18:00
Poster Area
Poster Session
Board No
130
131
Abstract No
ETHOSUXIMIDE REDUCES ALLODYNIA AND HYPERALGESIA AND
POTENTIATE MORPHINE EFFECTS IN CHRONIC CONSTRICTION INJURY
MODEL OF NEUROPATHIC PAIN
H.R. Banafshe, G. Hamidi, Kashan, Iran
3.156
UPREGULATION OF ETK AFTER RAT TRAUMATIC BRAIN INJURY
K.-Y. Chen, C.-C. Wu, Y.-W. Yu, Y.-H. Chen, S.-W. Huang, J.-W. Lin, W.-T. Chiu,
Y.-H. Chiang, Taipei, Taiwan
3.157
Poster Session
Neuroprotection
132
SIMVASTATIN PREVENTS DOPAMINERGIC NEURODEGENERATION IN
EXPERIMENTAL PARKINSONIAN MODELS: THE ASSOCIATION WITH ANTIINFLAMMATORY RESPONSES
Q. Wang, J. Yan, Y. Xu, Guangzhou, China
3.201
133
STATINS PROTECT NEURONAL CELLS AGAINST L-DOPA NEUROTOXICITY
THROUGH THE ACTIVATION OF PI3K AND FREE RADICAL SCAVENGING
IN PC12 CELL CULTURE
S.-H. Koh1, H.-H. Park1, N.-Y. Choi1, J. Park1, H.-J. Yu2, K.-Y. Lee1, Y.J. Lee1, H.T. Kim1, 1Guri, 2Seongnam, Republic of Korea
3.202
134
ADENOVIRUS VECTOR MEDIATED 14-3-3 Γ GENE TRANSFER PROTECTS
DOPAMINERGIC NEURONS IN MODELS OF PARKINSON'S DISEASE
X. Chen, Haikou, China
135
ERYTHROPOIETIN PREVENTS L-DOPA NEUROTOXICITY THROUGH
ANTIOXIDANT EFFECT AND THE ACTIVATION OF THE PI3K PATHWAY
S.-H. Koh1, H.-J. Yu2, J. Park1, N.-Y. Choi1, H.-H. Park1, K.-Y. Lee1, Y.J. Lee1, H.T. Kim1, 1Guri, 2Seongnam, Republic of Korea
3.204
136
NECDIN PREVENTS LOSS OF DOPAMINERGIC NEURONS IN ANIMAL
MODELS OF PARKINSON'S DISEASE
T. Yasuda1,2, K. Yoshikawa1, S. Przedborski3, Y. Mizuno2, H. Mochizuki1,2, 1Suita,
2
Sagamihara, Japan, 3New York, NY, USA
3.205
137
A NOVEL NEUROPROTECTIVE THERAPY FOR PARKINSON'S DISEASE
USING A VIRAL NON-CODING RNA THAT PROTECTS MITOCHONDRIAL
COMPLEX I ACTIVITY
W.-L. Kuan, M. Fletcher, E. Poole, S. Karniely, P. Tyers, J. Sinclair, R. Barker,
Cambridge, UK
138
3.203
3.206
LYCOPENE ATTENUATES OXIDATIVE STRESS AND COGNITIVE DECLINE
IN ROTENONE-INDUCED PARKINSON´S DISEASE
R. Sandhir, S. Chauhan, H. Kaur, Chandigarh, India
3.207
106
08:00-18:00
Poster Area
Poster Session
Neuroprotection
Board No
139
Abstract No
PROPHYLACTIC NEUROMODULATORY EFFECT OF FISH OIL
SUPPLEMENTS AND SYNERGISTIC ACTION WITH QUERCETIN AGAINST
ROTENONE INDUCED OXIDAITVE IMPAIRMENTS IN RAT BRAIN
K.M. Denny Joseph, M. Muralidhara, Mysore, India
3.208
140
S-SULFHYDRATION OF Β-TUBULIN BY HYDROGEN SULFIDE INCREASES
MICROTUBULE STABILITY AND PROTECTS CELLS AGAINST ROTENONEINDUCED CELL INJURY
L. Xie, J.S. Bian, Singapore, Singapore
3.209
141
PHYTOCANNABINOIDS TETRAHYDROCANNABINOL AND CANNABIDIOL
ACT AGAINST ROTENONE INDUCED DAMAGES IN MURINE CELL
CULTURES
R. Moldzio, B. Pöhn, C. Krewenka, B. Kranner, J.C. Duvigneau, W.-D. Rausch,
Vienna, Austria
3.210
+
142
BEE VENOM ATTENUATES MPP -INDUCED NEUROTOXICITY IN HUMAN
NEUROBLASTOMA SH-SY5Y CELLS
A.-R. Doo, S.-N. Kim, S.-T. Kim, J.-Y. Park, S.-H. Chung, B.-Y. Cheo, Y. Chae,
H. Lee, C.-S. Yin, H.-J. Park, Seoul, Republic of Korea
143
NBM-T-L-BMX-OS01, A NOVEL HISTONE DEACETYLASE INHIBITOR HAS
PROTECTIVE EFFECTS ON MPTP-INDUCED PARKINSON'S DISEASE
MOUSE MODEL
Y.-C. Yang1, J.-M. Yang2, W.-J. Huang2, C.-L. Huang2, T.-Y. Kuo1, J.-S. Huang2,
A.-L. Chen2, Z.-H. Wen3, C.-N. Chen2, 1I-Lan, 2Taipei, 3Kaohsiung, Taiwan
3.211
3.212
144
NANOWIRED DELIVERY OF CEREBROLYSIN INDUCES RAPID BRAIN
PROTECTION IN A MOUSE MODEL OF PARKINSON´S DISEASE
H.S. Sharma1, R. Tian2, H. Moessler3, A. Sharma1, D.F. Muresanu4, 1Uppsala,
Sweden, 2Fayetteville, AR, USA, 3Unterach, Austria, 4Cluj-Napoca, Romania
3.213
145
STRUCTURAL SPECIFICITY OF AKT-MEDIATED NEUROPROTECTION BY
OXICAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AGAINST 1METHYL-4-PHENYL PYRIDINIUM-INDUCED CELL DEATH
Y. Tasaki, J. Yamamoto, T. Omura, T. Noda, N. Kamiyama, K. Yoshida,
M. Satomi, T. Sakaguchi, M. Asari, T. Ohkubo, K. Shimizu, K. Matsubara,
Asahikawa, Japan
3.214
146
PHOTOBIOMODULATION NEUROPROTECTS MIDBRAIN DOPAMINERGIC
CELLS IN A CHRONIC MPTP MOUSE MODEL OF PARKINSON DISEASE
C. Peoples1, S. Spana1, K. Ashkan2, A.L. Benabid3, J. Stone1, G.E. Baker2,
J. Mitrofanis1, 1Sydney, NSW, Australia, 2London, UK, 3Grenoble, France
3.215
CDNF PROTECTS THE NIGROSTRIATAL DOPAMINE SYSTEM AND
PROMOTES RECOVERY AFTER MPTP TREATMENT IN MICE
M. Airavaara1, B.K. Harvey1, M.H. Vouitilainen2, H. Shen1, J. Chou1,
P. Lindholm2, M. Lindahl2, R.K. Tuominen2, M. Saarma2, Y. Wang1, B. Hoffer1,
1
Baltimore, MD, USA, 2Helsinki, Finland
3.217
147
107
08:00-18:00
Poster Area
Poster Session
Neuroprotection (Contd.)
Board No
Abstract No
148
INVESTIGATION OF POTENTIAL NEUROPROTECTIVE EFFECTS OF
HEMANTANE ON DNA DAMAGE AND LIPID PEROXIDATION IN MICE WITH
MPTP-INDUCED PARKINSONISM
A. Nepoklonov, A. Zhanataev, E. Anisina, K. Kolyasnikova, N. Zolotov,
Moscow, Russia
3.218
149
EFFECTS OF THE NOVEL ANTIPARKINSONIAN DRUG HEMANTANE AND
AMANTADINE ON MEMORY AND LEARNING IN RATS WITH
INTRACEREBRAL POSTTRAUMATIC HAEMATOMA
S. Kotelnikova, A. Nepoklonov, V. Krayneva, E. Valdman, T. Voronina, Moscow,
Russia
3.219
150
NIGROSTRIATAL DOPAMINERGIC SYSTEM OF CONDITIONAL GDNF
KNOCK-OUT MICE DOES NOT DISPLAY INCREASED VULNERABILITY TO
AGING
J. Kopra, J.-O. Andressoo, J. Mijatovic, C. Amberg, P. Piepponen, M. Saarma,
Helsinki, Finland
3.220
151
AMANTADINE PROTECTS DOPAMINE NEURONS BY A DUAL ACTION:
REDUCING ACTIVATION OF MICROGLIA AND INDUCING EXPRESSION OF
GNDF IN ASTROGLIA
B. Ossola1, N. Schendzielorz1, S.-H. Chen2, G.S. Bird2, R.K. Tuominen1,
P.T. Männistö1, J.-S. Hong2, 1Helsinki, Finland, 2Research Triangle Park, NC,
USA
3.221
152
REGULATION OF BDNF SIGNALING CASCADES IN RAT BRAIN BY
CHRONIC UNPREDICTABLE STRESS AND ANTIDEPRESSANT TREATMENT
R. Banerjee, A.C. Mondal, Uttarpara, India
3.222
153
IMPAIRMENTS OF ERK SIGNAL TRANSDUCTION IN THE BRAIN IN A RAT
MODEL OF ANTIDEPRESSANT SENSITIVE CHRONIC DEPRESSION
A.C. Mondal1, R. Banerjee1, A.K. Ghosh2, 1Uttarpara, 2Kolkata, India
3.223
154
NEUROPROTECTION BY BDNF AGAINST GLUCOSE DEPRIVATIONINDUCED CELL DEATH IS MEDIATED BY ERK1/2 AND PI3-KINASE
PATHWAYS
N. Vakili Zahir, Z. Khaje Piri, M.H. Ghahremani, Tehran, Iran
3.225
155
NEUROPROTECTIVE EFFECT OF DIPEPTIDE ANALOGUE OF BDNF - GSB106 IN VITRO AND ITS INFLUENCE ON THE SYNTHESIS OF HEME
OXYGENASE-1
I.O. Logvinov, T.A. Antipova, A.V. Tarasiuk, T.A. Gudasheva, S.B. Seredenin,
Moscow, Russia
3.226
156
STUDY OF GLYCOSAMINOGLYCANS IN PARKINSON´S DISEASE AND
THEIR IMPLICATIONS IN GDNF INDUCED PLASTICITY IN VITRO
M.O. Ouidja1, M.B. Huynh1, S. Lehri-Boufala1, C. Morin1, G. Zhang1,2,
E.C. Hirsch3, R. Raisman-Vozari3, D. Papy-Garcia1, 1Créteil, France, 2Beijing,
China, 3Paris, France
108
3.227
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
157
BEHAVIORAL EFFECTS OF A NOVEL DIPEPTIDE MIMETIC OF THE NERVE
GROWTH FACTOR IN RODENT MODELS OF PARKINSON´S DISEASE
P. Povarnina, T. Gudasheva, S. Seredenin, Moscow, Russia
3.228
158
DECREASED LEVEL OF NURR1 IN HETEROZYGOUS YOUNG ADULT MICE
LEADS TO EXACERBATED ACUTE AND LONG-TERM TOXICITY AFTER
REPEATED METHAMPHETAMINE EXPOSURE
Y. Luo1, Y. Wang1, S.Y. Kuang1, Y.-H. Chiang2, B. Hoffer1, 1Baltimore, MD, USA,
2
Taipei, Taiwan
3.229
159
THE OBSERVATION OF SYNERGISTIC PROTECTION BY GDNF AND E2 ON
INJURED DOPAMINERGIC NEURONS VIA ELECTRON MICROSCOPY
Z. Shi, M. Wang, L. Li, H. Dong, H. Yu, D. Gao, Xuzhou, China
3.230
160
CHEMICALS POSSESSING A NEUROTROPHIN-LIKE ACTIVITY ON
DOPAMINERGIC NEURONS IN PRIMARY CULTURE
R. Raisman-Vozari1, F. Schmidt2, P. Champy2, B. Seon-Meniel2, X. Franck2,
G. Le Douaron2, B. Figadère2, 1Paris, 2Châtenay-Malabry, France
3.231
161
RESTORATION OF THE DOPAMINERGIC ACTIVITY IN THE BRAIN OF
PARKINSON'S DISEASE PATIENTS USING SV40-BASED VIRAL GENE
DELIVERY VECTORS
P. de Haan, W. de Vries, E.Ch. Wolters, Leiden, The Netherlands
3.232
162
EFFECT OF MCI-186 ON THE INTRACELLULAR CALCIUM AND MEMBRANE
FLUIDITY IN THE RATS WITH PARKINSON´S DISEASE
Y. Ming, Zhenjiang, China
3.233
163
GINSENOSIDE RD PROTECTS NEURONS AGAINST GLUTAMATE-INDUCED
EXCITOTOXICITY BY INHIBITING CA2+ INFLUX
C. Zhang, M. Shi, G. Zhao, Xi’an, China
3.234
164
ISOTHIOCYANATES PROTECT AGAINST DOPAMINERGIC CELL DEATH IN
IN VITRO AND IN VIVO MODELS OF PARKINSON'S DISEASE
F. Morroni, P. Hrelia, C. Bolondi, G. Cantelli-Forti, A. Tarozzi, Bologna, Italy
3.235
165
THE EFFECTS OF (-)-EPIGALLOCATECHIN-3-GALLATE IN PARKINSONIAN
RATS WITH PARTIAL UNILATERAL 6-HYDROXYDOPAMINE-LESION
T.M. Kääriäinen1, M. Piltonen2, M.M. Forsberg1, 1Kuopio, 2Helsinki, Finland
3.236
166
NEUROPROTECTIVE RFFECT OF L-CARNITINE AND CENTELLA ASIATICA
EXTRACT ON 6-HYDROXYDOPAMINE (6-OHDA)-INDUCED CHANGES IN
THE REPAIR-MECHANISM AND GENOTOXICITY IN AGED RATS
K. Ponnusamy1,2, J.R. Naidu1,3, 1Sungai Petani, 2Kuala Lumpur, 3Penang,
Malaysia
3.237
167
ORAL PELARGONIDIN EXERTS DOSE-DEPENDENT NEUROPROTECTION
IN 6-HYDROXYDOPAMINE RAT MODEL OF HEMI-PARKINSONISM
M. Roghani, A. Niknam, M.-R. Jalali-Nadoushan, M. Khalili, T.
Baluchnejadmojarad, Tehran, Iran
109
3.238
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
168
NEUROPROTECTIVE AND NEURORESCUE EFFECT OF NARINGIN IN
6-HYDROXYDOPAMINE-LESIONED RAT MODEL OF PARKINSON´S
DISEASE: EVIDENCE FOR INVOLVEMENT OF POSSIBLE MECHANISMS
M. Golechha1, R. Kumar2, J. Bhatia1, U. Chaudhry1, D. Saluja1, D.S. Arya1,
1
New Delhi, India, 2Chicago, IL, USA
3.239
169
DECREASED SEROTONERGIC RECEPTORS REGULATION IN 6HYDROXYDOPAMINE LESIONED RATS: NEUROPROTECTION BY COMITOGENIC SEROTONIN AND GABA IN COMBINATION WITH BONE
MARROWS CELLS
P.K. Korah, C.S. Paulose, Cochin, India
3.240
ARSENIC INDUCED DOPAMINERGIC DEFICITS AND PROTECTION BY
CURCUMIN IN RATS
R.S. Yadav, L.P. Chandravanshi, A.B. Pant, V.K. Khanna, Lucknow, India
3.241
170
171
INHIBITION OF MONOAMINE OXIDASE-B BY CURCUMIN AND
TETRAHYDROCURCUMIN IN THE MICE MODEL OF PARKINSON'S DISEASE
S. Sabesan Muthukumaran, A. Rajeswari, Annamalai Nagar, India
3.242
172
INCREASING ENDOGENOUS NEUROGENESIS USING NEUROSTEROIDS:
A NOVEL THERAPEUTIC STRATEGY TO TREAT PARKINSON´S DISEASE
S. Adeosun1, X. Hou1, Y. Jiao2, B. Zheng1, P. Kyle1, I. Paul1, J. Farley1,
C. Stockmeier1, S. Bigler1, R. Smeyne2, J. Wang1, 1Jackson, MS, 2Memphis,
TN, USA
3.243
173
LOW-DOSE RADIATION STIMULATES NEUROCHEMICAL RESPONSE AND
CELL PROLIFERATION OF BOTH NEURAL STEM CELLS AND GLIOMA
STEM CELLS IN VITRO
Y.X. Ding, L.C. Wei, M. Shi, Y.H. Liu, L.W. Chen, Xi'an, China
3.244
174
EFFECTS OF URATE OXIDASE TRANSGENE OR KNOCKOUT IN A MOUSE
MODEL OF PARKINSON'S DISEASE
X. Chen, T. Burdett, C. Desjardins, Y. Xu, M.A. Schwarzschild, Boston, MA, USA
3.245
175
BLOCKING DRP-1 FUNCTION IS NEUROPROTECTIVE IN ANIMAL MODELS
P. Rappold1, S. Lim1, M. Cui1, L. Chen2, W. Bowers1, X. Zhuang2, K. Tieu1,
1
Rochester, NY, 2Chicago, IL, USA
3.246
176
MODULATION OF CYTOKINES PRODUCTION AND MICROGLIAL PPARGAMMA LEVELS BY ROSIGLIAZONE IN PARKINSON´S DISEASE
A. Pisanu, S. Spiga, L. Frau, A.R. Carta, Cagliari, Italy
3.247
BAG5 INTERACTS WITH THE PARKINSON-ASSOCIATED PROTEIN PINK1
AND PROTECTS AGAINST OXIDATIVE MITOCHONDRIAL DAMAGE
J. Guo, X. Wang, X. Yan, B. Tang, Changsha, China
3.248
177
110
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
INVOLVEMENT OF ESTROGEN RECEPTORS AND OXIDATIVE STRESS IN
NEUROPROTECTIVE EFFECT OF SILYMARIN IN HEMI-PARKINSONIAN
RATS
T. Baluchnejadmojarad, M. Roghani, M. Mafakheri, Tehran, Iran
3.249
NEUROPROTECTIVE ROLE OF 17Β-ESTRADIOL ADMINISTRATION ON
ALTERED AGE RELATED NEURONAL PARAMETERS IN FEMALE RATS
P. Kumar, R.K. Kale, N.Z. Baquer, New Delhi, India
3.250
180
CORTICAL INHIBITION AND IMPROVEMENT OF MOTOR PERFORMANCE
BY LOW-FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC
STIMULATION OVER M1 IN PARKINSON'S DISEASE
X. Ma, Q. Ma, Y. Wang, J. Guo, P. Gu, M. Wang, Shijiazhuang, China
3.251
181
RETINAL PIGMENT EPITHELIAL (RPE) CELL TRANSPLANTATION
RESTORES MOTOR COORDINATION IN THE RAT MODEL OF
PARKINSON´S DISEASE (PD)
H.S. Gambhir, S. Vivekanandhan, V. Goyal, G. Shukla, R. Mathur, M. Behari,
New Delhi, India
3.252
178
179
182
MINOCYCLINE ATTENUATED MICROGLIAL ACTIVATION AND
DEGENERATIVE LOSS OF DOPAMINERGIC NEURONS IN THE SUBSTANTIA
NIGRA OF A LACTACYSTIN RAT MODEL
L. Duan, X.Y. Jiao, Y.X. Ding, L. Zhang, L.W. Chen, Xi'an, China
3.254
183
INCREASED HISTAMINE BY THIOPERAMIDE EXERTS ITS NEURONAL
PROTECTIVE EFFECT THROUGH POSTSYNAPTIC H1 RECEPTOR IN
NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY RAT MODEL
3.255
184
UNCOUPLING PROTEIN-4 (UCP4) INCREASES NEURONAL ATP
PRODUCTION VIA RESPIRATORY COMPLEX-II ACTIVATION - A
BIOENERGETIC STUDY
P.W.-L. Ho1, J.W.-M. Ho1, H.-M. Tse1, D.H.-F. So1, H.-F. Liu1, K.-H. Chan1,
M.H.-W. Kung1, D.B. Ramsden2, S.-L. Ho1, 1Hong Kong, Hong Kong S.A.R.,
2
Birmingham, UK
3.256
185
THE NEUROPROTECTIVE EFFECTS OF JNK3-N-TAT THROUGH INHIBITING
THE ACTIVATION OF JNK3 AND PROTECTING MITOCHODRIA
J. Pan, H. Li, S. Chen, Shanghai, China
3.257
186
RESVERATROL INCREASES THE LIFE SPAN OF MANGANESE TREATED
DROSOPHILA MELANOGASTER
E. Bonilla, R. Contreras, S. Medina-Leendertz, M. Mora, V. Villalobos, Y. Bravo,
Maracaibo, Venezuela
3.258
187
ELECTRO-ACUPUNCTURE PROTECTS DOPAMINERGIC NEURONS FROM
IRON RELATED OXIDATIVE STRESS-MEDIATED DAMAGE IN MEDIAL
FOREBRAIN BUNDLE-LESIONED RATS
Y.-P. Yu1,2, A.-M. Xie3, D.-Z. Wang1, Z.-G. Li1, 1Wendeng, 2Dalian, 3Qingdao,
China
111
3.259
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
188
D-Β-HYDROXYBUTYRATE IS NEUROPROTECTIVE IN MOUSE MODELS OF
S. Lim1, A. Chesser1, J. Grima1, P. Rappold1, D. Blum2, S. Przedborski3, K. Tieu1,
1
Rochester, NY, USA, 2Place de Verdun, France, 3New York, NY, USA
3.260
189
DEREGULATION OF GENE EXPRESSION IN PERIPHERAL BLOOD
MONONUCLEAR CELLS AT DIFFERENT STAGES OF THE PARKINSON´S
DISEASE
E. Mutez1, A. Duflot1, M. Figeac1, D. Hot1, R. Blervaque1, C. Vanbesien1,2,
P. Semaille1, C. Simonin1, A. Kreisler1, A. Destée1, M.-C. Chartier-Harlin1, 1Lille,
2
Villeneuve d'Ascq, France
3.262
190
THE ANTIDYSKINETIC EFFECT OF EXERCISE ON L-DOPA-TREATED
HEMIPARKINSONIAN MICE
A.S. Aguiar Jr, A. Hoeller, E.L. Moreira, P.A. Oliveira, F.M. Cordova, A.A. Castro,
R.B. Leal, A.S. Latini, R.D. Prediger, Florianópolis, Brazil
3.263
191
FURTHER EVIDENCES OF EXERCISE-INDUCED NEUROPROTECTION IN 6OHDA-HEMIPARKINSONIAN MICE
A.S. Aguiar Jr1,2, G. Boemer1, M. Duzzioni1, R. Raisman-Vozari2, R.D. Prediger1,
1
Florianópolis, Brazil, 2Paris, France
3.264
Poster Session
BASIC SCIENCE
192
CYTOKINES ASSOCIATED WITH PARKINSON'S DISEASE
Y. Huang, G. Halliday, Sydney, NSW, Australia
3.301
193
INHIBITORY FUNCTIONS IN PARKINSON´S DISEASE
N. Gamboz1, A. Granà2, E. Biasutti2, C. Semenza3,4, 1Naples, 2Udine, 3Padova,
4
Venice, Italy
3.302
INTRACELLULAR AND EXTRACELLULAR MECHANISM OF α-SYNUCLEIN
METABOLISM
Y. Watanabe, H. Tatebe, T. Tokuda, T. Mizuno, M. Nakagawa, M. Tanaka,
Kyoto, Japan
3.303
THE STUDY ON SAFETY AND IMMUNIZATION EFFECT AFTER
INOCULATION WITH OPTIMIZED HUMAN α-SYNUCLEIN DNA VACCINE
G. Peng, Y. Yang, Chongqing, China
3.304
α-SYNUCLEIN NEUROPATHOLOGY IS CONTROLLED BY NUCLEAR
RECEPTORS AND ENHANCED BY DOCOSAHEXANOIC ACID IN A MOUSE
MODEL FOR PARKINSON'S DISEASE
E. Yakunin, V. Loeb, H. Kisos, R. Sharon, Jerusalem, Israel
3.305
194
195
196
197
GLYCOSAMINOGLYCANS MODULATE α-SYNUCLEIN AGGREGATION AND
APOPTOSIS IN MPP+ TREATED CELLS
S. Lehri-Boufala1, M.O. Ouidja1, V. Barbier-Chassefière1, R. Raisman-Vozari2,
D. Papy-Garcia1, C. Morin1, 1Creteil, 2Paris, France
3.306
112
08:00-18:00
Poster Area
Poster Session
Basic Science
Board No
Abstract No
198
IN VITRO AMPLIFICATION OF VARIOUS α-SYNUCLEIN FIBRILS
A. Aravinthan, R. Dhamodharan, H.J. Shin, W.K. Lim, Busan, Republic of Korea 3.307
199
LINKS BETWEEN SMALL UBIQUITIN-LIKE MODIFIER, SUMO-1, HSP90 AND
THE AUTOPHAGY- LYSOSOME SYSTEM IN α-SYNUCLEINOPATHY AND
TAUOPATHY
M.B. Wong1, J. Goodwin1, A. Meedeniya1, C. Richter-Landsberg2, W.P. Gai3,
D.L. Pountney1, 1Southport, QLD, Australia, 2Oldenburg, Germany, 3Adelaide,
SA, Australia
3.308
200
THE GUANINE NUCLEOTIDE EXCHANGE FACTOR KALIRIN-7 IS A NOVEL
SYNPHILIN-1 INTERACTING PROTEIN
Y.C. Tsai, O. Riess, A.S. Soehn, H.P. Nguyen, Tuebingen, Germany
3.309
THE PUZZLE OF BOTULINUM TOXIN AND PAIN
Z. Lackovic, I. Matak, L. Bach-Rojecky, B. Filipovic, Z. Gagula, N. Durovic,
I. Stracenski, Zagreb, Croatia
3.310
201
202
PARKINSON DISEASE AND PAIN: DOPAMINERGIC MODULATION ON THE
MECHANICAL HYPERALGESIA IN HEMIPARKINSONIAN RATS
S.T. Maciel, R.A. Domenici, E.T. Fonoff, R.L. Pagano, São Paulo, Brazil
3.311
203
PAIN MEASUREMENT OF PATIENTS WITH PARKINSON'S DISEASE BY
SKIN IMPEDANCE
K. Kagechika, Uchinada, Japan
3.312
204
CHANGES IN BEHAVIORAL RESPONSE TO PAIN IN ROTENONE MODEL OF
PARKINSON´S DISEASE IN AGED RATS
M. Ljubisavljevic1,2, O. El-Agnaf1, F. Ismail1, J. Oommen1, J. Hayate1,
S. Filipovic2, 1Al Ain, United Arab Emirates, 2Belgrade, Serbia
3.313
205
CD200-CD200R DYSFUNCTION EXACERBATES MICROGLIA ACTIVATION
AND DOPAMINERGIC NEURODEGENERATION IN RAT MODEL OF
PARKINSON'S DISEASE
S. Zhang, X.-J. Wang, L.-P. Tian, J. Pan, Q.-Q. Lu, Y.-J. Zhang, J.-Q. Ding,
S.-D. Chen, Shanghai, China
3.314
206
EFFECTS OF BONE MARROW STEM CELLS
INTRACEREBROVENTRICULAR TRANSPLANTATION ON THE BEHAVIOR
AND COGNITION OF PARKINSON DISEASE RATS
P. Gu, Z.-X. Zhang, D.-S. Cui, Y.-Y. Wang, M.-W. Wang, Shijiazhuang, China
3.315
207
LMX1B CAN PROMOTE DOPAMINERGIC NEURONS DIFFERENTIATION
FROM EMBRYONIC STEM CELLS
L.-P. Tian, S. Zhang, Y.-J. Zhang, J.-Q. Ding, S.-D. Chen, Shanghai, China
3.316
208
THE SIMULATED MICROGRAVITY ENHANCES THE DIFFERENTIATION OF
MESENCHYMAL STEM CELLS INTO NEURONS
J. Chen, Xi'an, China
3.317
113
08:00-18:00
Poster Area
Poster Session
Basic Science (Contd.)
Board No
Abstract No
209
D3 DOPAMINE RECEPTOR FACILITATES INFILTRATION OF CD4+ T-CELLS
AND NEURODEGENERATION OF SUBSTANTIA NIGRA IN A MOUSE MODEL
H. Gonzalez Velozo, C. Prado Terrazas, R. Pacheco Rivera, Santiago, Chile
3.318
210
DEEP BRAIN STIMULATION AND ON-LINE EXECUTIVE CONTROL IN
PARKINSON'S DISEASE
T. Hasbroucq, F. Fluchère, F. Vidal, B. Burle, J.-P. Azulay, Marseille, France
3.319
211
INSIGHTS INTO THE MECHANISM OF PARADOXICAL KINESIA FROM
SUBTHALAMIC NUCLEUS RECORDINGS IN PARKINSON'S DISEASE
A. Anzak1,2, A. Pogosyan1,2, H. Tan1, T. Foltynie2, P. Limousin2, L. Zrinzo2,
M. Hariz2, K. Ashkan2, W. Thevathasan1, M. Bogdanovic1, A. Green1, T. Aziz1,
P. Brown1, 1Oxford, 2London, UK
3.320
212
THE RELATIONSHIP OF TAU ACETYLATION AND TAU PHOSPHORYLATION
IN ALZHEIMER´S DISEASE
L. Tan, L. Zhu, H. Tang, Z. Wang, X. Wang, Wuhan, China
3.321
213
TOXICITY OF ALUMINUM AND ALZHEIMER DISEASE
N. Djebli, Mostaganem, Algeria
3.322
214
SIMULATING MICRO ELECTRODE RECORDINGS FROM DEEP BRAIN
SURGERY FOR APPLICATIONS IN A CLINICAL FRAMEWORK
K.J. Weegink, J.J. Varghese, P.A. Bellette, T.J. Coyne, P.A. Silburn,
P.A. Meehan, Brisbane, QLD, Australia
3.323
215
POSTERIOR HYPOTHALAMIC NUCLEUS AS A NOVEL TARGET FOR DEEP
BRAIN STIMULATION: PHYSIOLOGICAL CHANGES IN THE BASAL
GANGLIA AND THALAMO-CORTICAL SYSTEMS
C.K. Young1, B.H. Bland2, 1Trondheim, Norway, 2Calgary, AB, Canada
3.324
216
COUNTERMEASURES AGAINST EMERGENCY FOR PATIENTS WITH
INTRACTABLE NEUROLOGICAL DISEASE IN SAGAMIHARA AREA
M. Saruwatari, Sagamihara, Japan
3.325
THE OXIDATIVE MODIFICATION OF CYTOSKELETAL PROTEIN IN PC12
CELL MODEL OF PD TREATED WITH PSI
Y. Zhang, T. Jin, H. Deng, Changchun, China
3.326
PHOSPHOPROTEOME STUDY REVEALS HSP27 AS A NOVEL SIGNALING
MOLECULE INVOLVED IN GDNF-INDUCED NEURITE OUTGROWTH
Z. Hong1,2, S. Chen2, 1Chengdu, 2Shanghai, China
3.327
IN VITRO AND IN VIVO EVALUATION OF COQ10 LOADED POLYMERIC
NANOPARTICLES: AN ATTEMPT TO RESCUE THE CELLS FROM
OXIDATIVE STRESS
N.K. Swarnakar, A.K. Jain, S. Jain, SAS Nagar (Mohali), India
3.328
217
218
219
114
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
220
AUTOPHAGY INVOLVED IN THE AGE RELATED SENSITIVITY OF
PARKINSON'S DISEASE
Y.-P. Yang, H.-F. Zheng, L.-D. Cao, C.-J. Mao, Y. Hong, L.-F. Hu, C.-F. Liu,
Suzhou, China
3.329
221
MTOR SIGNALING PLAY A KEY ROLE IN NEURODEGENERATIVE
DISORDERS OF SAMP8 VIA AUTOPHAGY REGULATION
Q. Ma, J. Qiang, P. Gu, M. Wang, Shijiazhuang, China
3.330
222
DYSFUNCTIONAL AUTOPHAGY CONTRIBUTES TO LPS-STIMULATED
INFLAMMATION IN MACROPHAGES
L.-D. Cao, L.-F. Hu, Y.-P. Yang, H.-F. Zheng, C.-F. Liu, Suzhou, China
3.331
223
DETERMINATION OF COPPER AS TRACE METAL IN BLOOD SERUM OF
MALARIAL PATIENTS BY ATOMIC ABSORPTION SPECTROSCOPY
S. Baloch, G.S. Gachal, S.A. Memon, M. Baloch, Chemistry, Zoology,
Biochemistry, Jamshoro, Pakistan
3.333
224
BETAHISTINE IS EFFECTIVE IN CONTROLLING SPASMS AND IMPROVES
LEARNING AND MNEMONIC ABILITY IN NMDA-INDUCING INFANTILE
SPASMS RAT MODEL
3.334
DUAL-RESONANCE GENERATED BY SK-CURRENT AND H-CURRENT AT
HYPERPOLARIZED MEMBRANE POTENTIALS AT THETA FREQUENCY IN
RAT SNC NEURONS
W.-N. Xue, Y. Wang, Z.-Q. Yan, J.-L. Zhu, S.-M. He, X.-L. Wang, G.-D. Gao,
Xi'an, China
3.335
PROTEOMIC STUDIES OF THE DIFFERENTIATED SH-SY5Y CELLS
TREATED BY PROTEASOMAL INHIBITOR
F. Jia, H. Jiang, S. Liu, H. Li, L. Hu, Changchun, China
3.336
PROTEOMIC STUDIES OF THE UNDIFFERENTIATED SH-SY5Y CELLS
TREATED BY PROTEASOMAL INHIBITOR
F. Jia, H. Jiang, S. Liu, H. Li, L. Hu, Changchun, China
3.337
225
226
227
228
OVEREXPRESSION OF HDAC2 ACTIVATED GSK-3BETA WITHOUT DIRECT
INTERACTION
X. Wang, Wuhan, China
3.339
229
HUMAN MIDBRAIN PRECURSORS DIFFERENTIATE TO MATURE
FUNCTIONAL A9 DOPAMINE NEURONS IN VITRO. SHORT AND LONGTERM ENHANCEMENT BY BCL-XL
E.G. Seiz, M. Ramos-Gómez, E.T. Courtois, I. Liste, A. Martínez-Serrano, Madrid,
Spain
3.340
230
FCΓ RECEPTORS ARE REQUIRED FOR α-SYNUCLEIN-INDUCED
PRO-INFLAMMATORY SIGNALING IN MICROGLIA
S. Cao, A. Harms, D. Standaert, Birmingham, AL, USA
115
3.341
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
THE SUPPRESSION EFFECTS OF ROPINIROLE ON NEOCORTICAL HIGHVOLTAGE SPINDLES IN THE FREELY MOVING 6-OHDA-LESIONED RATS
C. Yang, J.-L. Zhu, L. Chen, G.-D. Gao, Xi'an, China
3.342
DEREGULATED MIRNA-184 INDUCES CELL CYCLE RE-ENTRY AND
APOPTOSIS OF POSTMITOTIC DOPAMINERGIC NEURONS VIA
REGULATION OF E2F IN PARKINSON DISEASE
Z. Zhang, X. Cao, Z. Zhang, S. Sun, T. Wang, Wuhan, China
3.343
233
DOPAMINE RECEPTOR D2 MODULATES INNATE IMMUNITY AND
SUPPRESSES NEUROINFLAMMATION
J. Zhou, Shanghai, China
3.344
234
BETAHISTINE AMELIORATES BEHAVIORAL MANIFESTATION IN THE
6-OHDA-INDUCING RAT MODEL OF PARKINSON´S DISEASE
F. Jia, H. Jiang, L. Du, S. Liu, H. Li, Changchun, China
3.345
EXPERIMENTAL STUDY ON IMPLANTATION OF NOGGIN MODIFIED
RBMSCS IN A RAT MODEL OF PARKINSON'S DISEASE
X. Zhu, Y. Cheng, Tianjin, China
3.346
236
ACTIVATED MICROGLIAL FACILITATE IRON-INDUCED SELECTIVE AND
PROGRESSIVE DOPAMINERGIC NEURODEGENERATION
Z. Yan, J. Gao, L. Sun, Z. Liu, X. Huang, C. Cao, B. Li, L. Zhang, W. Zhang,
X. Wang, Beijing, China
3.347
237
LEWY PATHOLOGY IS NOT THE FIRST SIGN OF DEGENERATION IN
SELECTIVELY VULNERABLE NEURONS IN PARKINSON´S DISEASE
J.M. Milber1, J.V. Noorigan1, J.F. Morley1, H. Petrovitch2, L. White2, G.W. Ross2,
J.E. Duda1, 1Philadelphia, PA, 2Honolulu, HI, USA
3.348
MIXED LINEAGE KINASE 2 AND HIPPOCALCIN ARE LOCALIZED IN LEWY
BODIES OF PARKINSON´S DISEASE
M. Nagao, H. Hayashi, S. Matsubara, Fuchu, Japan
3.349
239
STUDIES ON THE PROTECTIVE ROLE OF URIC ACID IN 6HYDROXYDOPAMINE-INDUCED INJURY OF PC12 CELLS
W. Luo, X. Wang, Suzhou, China
3.350
240
THE EFFECTS OF INTRANIGRAL INJECTION OF GHRELIN ON
HALOPERIDOL- INDUCED CATALEPSY IN RATS
L. Shi, H. Jiang, J. Xie, Qingdao, China
3.351
241
EFFECTS OF GREEN TEA EXTRACT (GTE) ON HALOPERIDOL (HAL)
INDUCED NEUROLEPTIC ANXIETY SYNDROME (NAS) AND PARKINSONISM
IN RATS
T. Malik, D.J. Haleem, Karachi, Pakistan
3.352
231
232
235
238
116
08:00-18:00
Poster Area
Poster Session
Board No
Abstract No
ROLE OF SOMATODENDRITIC AND POSTSYNAPTIC SEROTONIN-1A
RECEPTORS IN THE ATTENUATION OF HALOPERIDOL-INDUCED
PARKINSONIAN LIKE EFFECTS
E. Shireen, D.J. Haleem, Karachi, Pakistan
3.353
243
HTRA2 IS INVOLVED IN 6-OHDA INDUCED ENDOPLASMIC RETICULUM
STRESS
F. Luo1,2, L. Wei1, C. Sun1, Y. Li1, W. Zhu1, Z. Liu1, P. Xu1, 1Guangzhou,
2
Chengdu, China
3.354
244
MICROGLIAL NOX2: A POTENTIAL TARGET OF IRON-INDUCED
DOPAMINERGIC NEURODEGENERATION
J. Gao1, Z. Yan1, Z. Liu1, L. Sun1, C. Cao1, X. Huang1, L. Zhang1, B. Li1,
W. Zhang1, X. Wang1, J.-S. Hong2, 1Beijing, China, 2Research Triangle Park,
NC, USA
3.355
STAGE-DEPENDENT DOPAMINERGIC CELL LOSS IN THE SUBSTANTIA
NIGRA DURING PARKINSON'S DISEASE
A. Dijkstra, P. Voorn, H.J. Groenewegen, P. Heutink, A.J. Rozemuller,
W.D.J. van de Berg, Amsterdam, The Netherlands
3.356
REGULATION ROLE OF OVEREXPRESSION OF δFOSB TO THE SIGNAL
PATHWAYS IN THE STRIATUM OF LEVODOPA-INDUCED DYSKINESIA OF
HEMIPARKINSONIAN RATS
X. Cao, Wuhan, China
3.357
247
ESTABLISHMENT OF 2-DE OF CEREBROSPINAL FLUID AND PRIMARY
STUDY OF CSF PROTEOME OF PARKINSON'S DISEASE
H. Li1, M. Shao2, 1Guangzhou, 2Guanghzou, China
3.358
248
A GAMMA BAND SPECIFIC INVOLVEMENT OF THE SUBTHALAMIC
NUCLEUS IN SWITCHING IN VERBAL FLUENCY IN PARKINSON'S DISEASE
A. Anzak1,2, L. Gaynor1, M. Beigi1, P. Limousin1, M. Hariz1, L. Zrinzo1, T. Foltynie1,
P. Brown2, M. Jahanshahi1, 1London, 2Oxford, UK
3.359
249
THE CONTRIBUTION OF THE SELF POLYQ LOAD [SOMATIC MOSAICISM]
IN THE CNS TO THE ONSET, DURATION AND PROGRESSION OF SCA2
J. Laffita, D.A. Coello Almarales, Y. Vázquez Mojena, L.C. Velázquez Pérez,
Holguin, Cuba
242
245
246
117
3.360
Author Index
NOTES
NOTES
NOTES
NOTES
NOTES
NOTES

Untitled - Kenes Group

Transcription

Similar documents